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Pathogenic viruses have a huge impact on human health and have caused numerous major 
epidemics both in the past and during the 21st century. The innate immune system is the 
body’s first line of defence against viruses, with pattern recognition receptors recognising 
molecules unique to viruses and triggering the expression of interferons and other anti-viral 
cytokines, leading to the formation of an anti-viral state. The Tripartite Motif Containing 25 
(TRIM25) is an E3 ubiquitin ligase thought to be a key component in the activation of 
signalling by the pattern recognition receptor Retinoic Acid-Inducible Gene I Protein (RIG-I), 
which recognises viral RNAs with a 5’-triphosphate moiety. TRIM25 has recently been 
identified as an RNA-binding protein, raising the question of whether its RNA-binding 
activity is important for its role in innate immunity. In this thesis, I demonstrated that 
TRIM25’s RNA-binding activity is mediated by its C-terminal PRY/SPRY domain and is 
required for its E3 ligase activity. I also generated TRIM25 knockout cells using a 
CRISPR/Cas9 strategy in HeLa and HEK293 cell lines and showed that deletion of TRIM25 
does not generally affect levels of the mRNA binding partners of TRIM25 identified by a 
genome-wide Cross-Linking Immunoprecipitation (CLIP) screen. Finally, I showed that 
although deletion of TRIM25 in HEK293 cells reduced their ability to restrict Influenza A 
virus infection, it did not affect activation of RIG-I signalling pathway in response to 5’-
triphosphate RNA. This suggests that TRIM25 is redundant for RIG-I signalling in HEK293 
cells and its role in restricting Influenza A virus infection is unrelated to its role in the RIG-I 
pathway. These findings have opened new lines of investigations into functional and 
molecular roles of TRIM25 in cell biology and control of pathogenic infections and I have 







Infections by pathogens such as viruses or bacteria have a huge impact on global health. 
Viruses are an enormous class of pathogens, and millions die every year from a variety of 
viral infections. Some of the worst epidemics in recent years have been caused by viruses 
such as Ebola and Influenza. The body has developed many ways of protecting itself from 
viruses and other pathogens and together these are known as the immune system, which is 
further divided into adaptive and innate immunity. This project focused on innate 
immunity. This consists of a group of specialist ‘receptor’ proteins that can recognise 
molecules that are present in pathogens but not in humans. One of these molecules is 
called 5 prime triphosphate ribonucleic acid (5’ppp-RNA). RNA is present and plays an 
important role in the body’s processes, but human RNA does not have the 5 prime 
triphosphate that is present on RNA from many viruses including Influenza virus. The 
receptor protein for 5’ppp-RNA is called RIG-I, when RIG-I recognises 5’ppp-RNA it sends a 
multi-step signal that tells the cell that it has been infected with a virus and to turn on its 
defences to protect against the virus.  
A key step in the RIG-I signalling process is thought to require a protein called TRIM25. 
TRIM25 is known to bind to RNAs so we wanted to find out if this was important for its role 
in RIG-I signalling. In addition to this, we wanted to find out how TRIM25 binds to RNA as it 
does not contain any parts similar to other proteins that can bind to RNA. By deleting parts 
of the TRIM25 protein, we determined which part was necessary for binding to RNA. We 
also found that when TRIM25 is not bound to RNA it cannot function properly. Finally, by 
deleting TRIM25 from cells we discovered that it is not required for RIG-I signalling but it 
may still play a role in inhibiting replication of Influenza virus. This implies that there is 
another role for TRIM25 in innate immunity that is as yet unknown. This work increases our 
understanding of how the body defends against viruses and may lead to development of 




Glossary of Abbreviations 
 
5’-ppp  5’-triphosphate 
aa  amino acid 
ActD  Actinomycin D 
AIDS  Acquired Immune Deficiency Syndrome 
APOBEC  Apolipoprotein B mRNA Editing enzyme Catalytic polypeptide 
ATBF1  AT-Binding Transcription Factor 1 
ATP  Adenosine Triphosphate 
CARD  Caspase Recruitment Domain 
CCD  Coiled-coil Domain 
cDNA  complementary Deoxyribonucleic Acid 
CLIP-seq  Cross-linking Immunoprecipitation and Sequencing 
CLR  C-type Lectin Receptor 
Co-IP  Co-immunoprecipitation 
CRISPR  Clustered Regularly Interspaced Short Palindromic Repeats 
CTD  C-Terminal Domain 
DHX9  DExH-Box Helicase 9 
DMEM  Dulbecco’s Modified Eagle Medium 
DNA  Deoxyribonucleic Acid 
ds  double-stranded 
ED  Effector Domain 
EMCV  Encephalomyocarditis Virus 
EMSA  Electromobility Shift Assay 
ERα  Oestrogen Receptor α 
FBS  Fetal Bovine Serum 
FRT  Flippase Recognition Target 
G3BP2  GTPase-Activating Protein-Binding Protein 2 
GST  Glutathione S Transferase 
GTP  Guanosine Triphosphate 
HA  Haemaggutinin 
HEK  Human Embryonic Kidney 
HIV  Human Immunodeficiency Virus 
HnRNP  Heterogeneous Nuclear Ribonucleoprotein 
HRP  Horseradish Peroxidase 
IAV  Influenza A Virus 
IBV  Influenza B Virus 
iE-DAP  γ-D-glutamyl-meso-diaminopimelic acid 
IFIT  Interferon Induced protein with Tetratricopeptide repeats 
IFN  Interferon 
IFNAR  Interferon-alpha/beta Receptor 
Ig  Immunoglobulin 
IKK  Inhibitor of κB Kinase 
IL  Interleukin 




IPTG  Isopropyl β-D-1-thiogalactopyranoside 
IRF  Interferon Regulatory Factor 
ISG  Interferon-Stimulated Gene 
ISGF3  Interferon-Stimulated Gene Factor 3 
ISRE  Interferon-Sensitive Response Element 
IκB  Inhibitor of κB 
JAK1  Janus Kinase 1 
KLF5  Kruppel-Like Factor 5 
KO  Knockout 
LGP2  Laboratory of Genetics and Physiology 2 
lncRNA  long non-coding Ribonucleic Acid 
LPS  Lipopolysaccharide 
LUBAC  Linear Ubiquitin Assembly Complex 
M1  Matrix 1 protein 
M2  Matrix 2 protein 
MAPK  Mitogen-Activated Protein Kinase 
MAVS  Mitochondrial Antiviral Signalling protein 
MDA5  Melanoma Differentiation-Associated gene 5 
MDCK  Madin-Darby Canine Kidney 
MDP  Muramyl Dipeptide 
MEF  Mouse Embryonic Fibroblast 
MEX3C  Mex-3 RNA Binding Family Member C 
MHC  Major Histocompatibility Complex 
miRNA  micro Ribonucleic Acid 
MOI  Multiplicity of Infection 
mRNA  messenger Ribonucleic Acid 
MS  Mass Spectroscopy 
NA  Neuraminidase 
NEP  Nuclear Export Protein 
NF-κB  Nuclear Factor kappa-light-chain-enhancer of activated B cells 
NLR  Nod-Like Receptor 
NLS  Nuclear Localisation Sequence 
NP  Nucleoprotein 
NS1  Non-structural protein 1 
NS2  Non-structural protein 2 
nts  nucleotides 
OAS  2’-5’-Oligoadenylate Synthetases 
OD  Optical Density 
PA  Polymerase Acidic protein 
PAMP  Pathogen-Associated Molecular Pattern 
PB1  Polymerase Basic protein 1 
PB2  Polymerase Basic protein 2 
PBS  Phosphate-Buffered Saline 
PCR  Polymerase Chain Reaction 
PCR  Polymerase Chain Reaction 




PLB  Passive Lysis Buffer 
PP1  Protein Phosphatase 1 
PR8  Influenza A/Puerto Rico/8/1934(H1N1) 
PRR  Pattern Recognition Receptor 
qRT-PCR  quantitative Real Time Polymerase Chain Reaction 
RBD  RNA-Binding Domain 
RBP  RNA-Binding Protein 
RIG-I  Retinoic Acid-Inducible Gene I 
RING  Really Interesting New Gene 
RIP  RNA Immunoprecipitation 
RLR  RIG-I-Like Receptor 
RNA  Ribonucleic Acid 
RNAi  RNA interference 
rRNA  ribosomal Ribonucleic Acid 
RSV  Respiratory Syncytial Virus 
SARS-CoV  Severe Acute Respiratory Syndrome Coronavirus 
SDS  Sodium Dodecyl Sulfate 
SEAP  Secreted Alkaline Phosphatase 
SEC-MALS  Size Exclusion Chromatography Multi-Angle Light Scattering 
sgRNA  short guide Ribonucleic Acid 
SILAC  Stable Isotope Labelling by Amino Acids in Cell Culture 
siRNA  small interfering Ribonucleic Acid 
ss  singe-stranded 
STAT  Signal Transducer and Activator of Transcription 
TANK  TRAF Family Member Associated NF-κB Activator 
TBK  TRAF Family Member Associated NF-κB Activator Binding Kinase  
TBS-T  Tris-Buffered Saline with Tween 
TDA  Thermal Denaturation Assay 
TIP60  Tat Interacting Protein, 60kDa 
TK  Thymidine Kinase 
TYK2  Tyrosine Kinase 2 
TLR  Toll-Like Receptor 
TNFα  Tumour Necrosis Factor α 
TPCK  Tosyl Phenylamyl Chloromethyl Ketone 
TRAF  Tumour Necrosis Factor Repector Associated Factor 
TRIM  Tri-partite Motif 
Ub  Ubiquitin 
UV  Ultraviolet 
VGM  Virus Growth Medium 
vRNA  viral Ribonucleic Acid 
vRNP  viral Ribonuclear Protein 
VSV  Vesicular Stomatitis Virus 
WB  Western Blot 
XPO1  Exportin 1 







The innate immune system is the first line of defence against 
viral infection 
 
Viruses have a large impact on human health and society 
 
Viruses are an incredibly diverse and abundant class of obligate intracellular parasites that 
are the causes of a myriad of diseases or defects in every cellular organism. At their most 
basic, they are composed of a nucleic acid genome (either ribonucleic acid (RNA) or 
deoxyribonucleic acid (DNA)) surrounded by a protein coat (capsid) and can range in size 
from 20 nm (parvovirus) to just under 1 µm (Ebola virus). Some viruses can infect all types 
of cellular organisms including bacteria, archaea, fungi, plants and metazoans, although 
they cannot replicate autonomously. Viral infections of cells often have deleterious effects 
on the host organism as normal cellular processes are disrupted by the virus, which hijacks 
the host cell machinery in order to propagate. 
Viral human pathogens have an enormous impact on human health around the globe and 
have been the cause of the deadliest pandemics in the last 100 years. These include the 
‘Spanish flu’ outbreak of 1918 that killed an estimated 50,000,000 people1 and the Human 
Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) pandemic of 
the 1980s and 1990s that resulted in over 30,000,000 people living with HIV/AIDS 
worldwide by 19992. Viral pathogens have also caused more recent epidemics such as the 
West African Ebola virus outbreak of 2014-2016 that killed more than 11,000 in Guinea, 
Liberia and Sierra Leone3. In addition to mortality, viral infections cause a massive 
socioeconomic burden, with viral infections being a major cause of loss in agricultural 




Viruses can be classified according to their morphology, genetic material, replication 
strategy and host organism. Viruses exist in four main general forms; icosahedral (or 
isometric), filamentous, ‘head and tail’ and enveloped. The complexity of viral morphology 
bears no relation to the complexity of their hosts, with bacteriophages, some of the most 
complex viruses, infecting the simplest cellular organisms, bacteria. Viral genomes can 
consist of single-stranded (ss) or double-stranded (ds), linear or circular DNA or RNA. Most 
viruses have genomes that consist of a single DNA or RNA molecule encoding all the 
proteins the virus needs to survive and replicate although some viruses, for example 
Influenza virus, have a genome consisting of several separate nucleic acid molecules termed 
segments. Some RNA viruses, for example HIV, must reverse transcribe their genome to 
DNA so that it can be replicated by the host machinery and these are termed retroviruses. 
Since the early 1970s, viruses have been most commonly classified using the Baltimore 
classification system which distinguishes viruses based on how messenger RNAs (mRNAs) 
are produced during their life cycle4. The different classes of the Baltimore system are 
described in Table 1. The rise of genetic sequencing has led to challenges in the 
classification of viruses, particularly in the absence of information about host organisms 





Table 1 – The Baltimore Classification of virus groups. 
 
Influenza A is an RNA virus with a large impact on human health 
 
Influenza viruses are negative sense RNA viruses with both protein and lipid envelopes that 
belong to the Orthomyxoviridae family, a schematic of the virus is shown in Figure 1. The 
primary disease-causing influenza viruses in humans, Influenza A and B viruses (IAV and 
IBV), have a genome comprised of 8 segments that encodes for 9 primary proteins, as well 
as several accessory proteins. In IAV, these include the three subunits of the influenza RNA 
polymerase, polymerase basic protein 2 (PB2), polymerase basic protein 1 (PB1) and 
polymerase acidic protein (PA) encoded by segments 1, 2 and 3, respectively6. In addition to 
this the nucleoprotein (NP) is encoded by segment 5 and associates with virus genomic RNA 
and the influenza RNA polymerase to form viral ribonuclear proteins (vRNPs)7. The viral 
entry factor haemagglutinin (HA) is encoded by segment 48 and neuraminidase (NA), 
required for virus release from non-functional host cell receptors, is encoded by segment 
69. Segment 7 encodes the matrix 1 protein (M1) and matrix 2 protein (M2) which can both 
be produced from the same transcript due to alternative splicing. M1 aids in maintaining 
the structure of the virion and regulating membrane trafficking of virus components in the 







(Y or N) 
Example Family 
I DNA ds N/A N Herpesviruses 
II DNA ss + N Parvoviruses 
III RNA ds N/A N Reoviruses  
IV RNA ss + N Picornaviruses 
V RNA ss - N Orthomyxoviruses 
VI RNA ss +  Y – DNA 
intermediate 
Retroviruses (e.g. HIV) 













Segment 8 encodes non-structural protein 1 (NS1), which inhibits host cell immune 
defences and non-structural protein 2 (NS2) also known as nuclear export protein (NEP) 
which allows viral RNA to leave the host cell nucleus12,13.  
Influenza virions enter cells through receptor-mediated endocytosis, triggered by HA 
binding to sialic acid on the surface of host cells8. Virions enter the cell in endosomes, the 
membranes of which fuse with the virion lipid membrane. The acidic environment of the 
endosome triggers opening of the M2 ion channel, leading to acidification of the viral core 
and allowing the release of vRNPs from M1 and entry into the host cell cytoplasm11. The 
protein components of the vRNP (PA, PB1, PB2 and NP) each have nuclear localisation 
sequences (NLSs) which allow their import into the host cell nucleus14. Once in the nucleus, 
transcription and replication of the viral genome can occur. The viral genome must first be 
transcribed from negative sense RNA to positive sense RNA (known as complementary 
RNA, cRNA) by the viral polymerase to provide a template for replication. 5’ methylated 
caps from host cell mRNAs are ‘snatched’ and added to the viral negative sense RNA. PB2 
cleaves host mRNAs 10-15 nucleotides (nts) 3’ of the 5’ cap and this fragment is used to 
prime the viral RNA for transcription to positive sense RNA15,16. At this stage capped and 
polyadenylated positive sense viral mRNAs are also generated and are exported to the 
cytoplasm for translation into viral proteins. Once negative sense viral genomic RNA has 
been replicated, vRNPs are exported from the nucleus via the exportin 1 (XPO1) dependent 
pathway in a process mediated by NS213,14,17. The exported vRNPs contain packaging signals 
to allow them to be packaged into newly synthesised virions18. Complete virions can 
subsequently leave the host cell by budding from the lipid membrane, using the host lipid 
membrane to form the new virion lipid membrane19. This process is dependent on cleavage 




IAV strains capable of infecting humans are further classified by which of the 16 subtypes of 
HA and 9 subtypes of NA that they contain21. For example, a strain of H1N1 (containing HA1 
and NA1) is currently endemic in humans and is the cause of seasonal flu, which causes 
around 500,000 deaths worldwide each year, with very young children and the elderly 
being most at risk22,23. HA and NA are the most antigenically variable proteins of influenza 
and are the main targets of protective antibodies produced by the body21. Mutations 
accumulated by HA and NA through genetic drift help the virus to escape immune 
surveillance24. IAV has the capability to swap genome segments between different strains 
co-infecting the same cell (reassortment). Unlike other influenza viruses, IAV is capable of 
circulating in domestic animals such as pigs and chickens in addition to humans. This 
provides a ‘reservoir’ of antigenically diverse IAV strains that can reassort with strains 
circulating in humans, generating new IAV strains that may not be covered by seasonal 
influenza vaccines21,24. An example of this occurring is the 2009 ‘swine flu’ pandemic in 
which a new IAV H1N1 strain emerged from pigs25. 
Infections with IAV or IBV can cause a variety of symptoms in humans. Most IAV infections 
in humans target the epithelial cells of the respiratory tract and result in a mild respiratory 
disease with symptoms such as fever, fatigue, sore throat and muscle pain that passes in 1-
2 weeks. However, infections with influenza viruses can lead to complications, especially in 
immunocompromised individuals, including potentially fatal respiratory diseases such as 
pneumonia as well as a range of non-respiratory complications that can vary in severity21,26. 
Between 2010 and 2017, influenza virus infections resulted in up to 35,000,000 illnesses 
and 700,000 hospitalisations in the USA and each year 3-5,000,000 cases of severe disease 
due to influenza are reported worldwide, exemplifying the ubiquity of influenza as a hazard 




Vaccines are available that attempt to protect against seasonal influenza, however they are 
narrow and strain specific and have to be updated each year to protect against circulating 
influenza strains which will be antigenically diverged from the previous year due to 
antigenic drift27. In addition to this, the vaccine will not cover newly arising pandemic 
strains of influenza and it is extremely difficult to produce, distribute and administer a 
vaccine against the new strain within a timeframe in which it can make an impact. This 
occurred during the 2009 swine flu pandemic, with the vaccine being distributed after new 
infections had already peaked. Due to these issues, work is ongoing to develop a universal 
influenza vaccine that can protect against all strains of influenza A and B viruses27. In 
addition to vaccines, antiviral drugs are also used to treat influenza infections. Currently 
there are four recommended treatments for influenza infection, three of which are 
inhibitors of NA activity and one that is an endonuclease inhibitor that blocks viral 
replication28. Development of resistance to antiviral drugs is prevalent and a challenge in 
treating the disease. For example, adamantanes, a class of drugs targeting the M2 ion 
channel, are now resisted by the vast majority of circulating influenza strains28,29. 
 
The innate immune system defends against viral pathogens 
 
Humans, as well as other organisms, must protect themselves from infection by viruses and 
other pathogens. To do this, they developed a robust means of distinguishing self from non-
self and responding accordingly. Their primary means of doing so is through the immune 
system. The immune system is divided into two parts, the adaptive and innate immune 
systems. Adaptive immunity consists of antigen-specific receptor-mediated responses to 




common to many pathogens as well as physical barriers such as the skin. In general, the 
innate immune system is fast-acting, involving elements that are ubiquitously expressed in 
somatic cells and acts in early infection. In contrast, the adaptive immune response is 
slower, acting in late infection, as there are only small numbers of each antigen-specific 
receptor and the cells expressing these must undergo clonal expansion before an effective 
response can be mounted30. 
Of the two, adaptive immunity is more complex. It involves the recognition of antigens by 
antigen-specific receptors on the surface of B (immunoglobulins, Igs31) and T (T cell 
receptors32) lymphocytes. The antigen-specific receptors are generated by a process known 
as somatic rearrangement: rearrangement of the antigen-specific receptor genes to form 
complete receptors with a very high affinity for their antigen33. This process can potentially 
generate millions of antigen-specific receptors, each with a different specificity. Upon 
infection, cells will present antigens on their surface. These are then recognised by a 
complementary antigen-specific receptor, triggering a cytokine response that leads to the 
propagation of the cell encoding the receptor30. T cells that have undergone this process 
can propagate and can differentiate into other cell types including T-helper cells and T-killer 
cells. T-killer cells proceed to kill infected host cells by inducing apoptosis, helping to 
prevent the spread of the pathogen. T-helper cells perform a variety of roles, including 
recruiting other immune cells such as macrophages and neutrophils as well as presenting 
antigen to B lymphocytes. B lymphocytes are generally activated after binding to antigen 
present by T-helper cells, however they are capable of being activated without this30. 
Activated B lymphocytes secrete antibodies, which can induce neutralisation of infected 
cells or the pathogen itself, for example by opsonisation leading to recruitment of 




both types of lymphocytes also leads to the propagation of memory cells, which allow a 
rapid adaptive immune response to a second infection by the pathogen34. 
The innate immune system involves non-antigen-specific pattern recognition receptors 
(PRRs) that recognise pathogen associated molecular patterns (PAMPs) that are common to 
many pathogens, but not found in host cells. An overview of PRR pathways in human cells is 
shown in Figure 2. Upon detection of PAMPs by PRRs, a signalling cascade is initiated that 
results in the expression of various anti-pathogenic molecules such as interferons (IFNs) 
and other cytokines, resulting in activation of host defences such as inflammation and 
recruitment of the adaptive immune system. Importantly, no single pathogen is recognised 
by a single PRR and biologically unrelated pathogens can be recognised by the same PRR, 
allowing for a fast and efficient response to any pathogen35. Different classes of pathogens 
are recognised by different PAMPs, for example viruses are recognised through 
glycoproteins and various DNA and RNA species36. Bacteria through lipoproteins37, 
peptidoglycan and derivatives38, CpG DNA39, lipopolysaccharides (LPS)40 and proteins such 
as flagellin41. Fungi are generally recognised through cell wall or cell surface components 
such as phospholipomannan42 or β-glycan43. 
There are a wide variety of PRRs found in humans that recognise different classes of 
PAMPs. PRRs are generally classed into the membrane-bound Toll-like receptors (TLRs) and 
C-type lectin receptors (CLRs) as well as the cytoplasmic RIG-I like receptors (RLRs), Nod-like 
receptors (NLRs) and cytosolic DNA sensors such as cGAS. There are 10 distinct TLRs in 
humans, recognising a diverse range of PAMPs. Cell surface TLRs mainly recognise microbial 
membrane components such as LPS (TLR4)40, flagellin (TLR5)41, peptidoglycans and 
glycoproteins (TLR2 in complex with TLR1 or TLR6)44. Intracellular TLRs are often found on 





Figure 2 - Overview of PRRs in human cells. Upon detection of their PAMP, PRRs initiate 
signal transduction pathways that converge on the activation of various transcription 
factors including IRF-3, IRF-7 and NF-κB. The transcription factors enter the nucleus where 






dsRNA (TLR3)45, ssRNA (TLR7/8)46 or CpG DNA (TLR9)47. The ligand for TLR10 is not yet 
known, however it has been shown to induce cytokine production in response to Listeria 
monocytogenes48 and influenza49 infection. TLRs signal downstream through MyD88 and 
TRIF, resulting in activation of the transcription factors Interferon Regulatory Factor 3 (IRF-
3) and Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) which enter 
the nucleus and induce expression of type I IFNs and other pro-inflammatory cytokines44.  
CLRs are a large family of PRRs that primarily function in immunity against fungal 
pathogens, however some family members have roles in immunity against other 
organisms50,51.  NLRs are divided into four subfamilies based on their structure; NLRA, NLRB, 
NLRC and NLRP. The best characterised NLRs are NOD1 and NOD2, both caspase 
recruitment domain (CARD)-containing NLRCs. NOD1 recognises γ-D-glutamyl-meso-
diaminopimelic acid (iE-DAP) which is a component of peptidoglycans from Gram negative 
bacteria52 while NOD2 recognises muramyl dipeptide (MDP) found in both Gram positive 
and Gram negative bacteria53. Both of these NLRs signal through activation of NF-κB. The 
RLR family consists of three members; Retinoic Acid-Inducible Gene I (RIG-I), Melanoma 
Differentiation-Associated gene 5 (MDA5) and Laboratory of Genetics and Physiology 2 
(LGP2). The RLRs primarily recognise viral RNAs, with RIG-I recognising RNAs with a 5’-
triphosphate (5’ppp) moiety and MDA5 recognising long dsRNAs. LGP2 is less well 
characterised, with studies suggesting it is capable of both positive and negative regulation 
of RIG-I54,55. The mechanisms of RLR activation will be explained in more detail later in this 
introduction. 
Signalling through PRR pathways generally results in the activation of transcriptional 
activators such as IRF-3, IRF-7 and NF-κB in the cytoplasm. These transcription factors 




to the establishment of an anti-pathogenic state such as IFNs and pro-inflammatory 
cytokines. The IRF proteins primarily activate expression of type I IFNs, consisting of 13 
subtypes of IFNα and a single IFNβ as well as the poorly characterised IFNε, IFNω and 
IFNκ56. IFNα/β secreted from cells and are recognised by the Interferon-alpha/beta 
Receptor alpha/beta chain heterodimer (IFNAR1/2), which is present on the cell 
membranes of all nucleated cells57. IFNα/β bind to IFNAR2 with a much higher affinity than 
IFNAR1 (0.2-200nm compared to 1-5µm)58,59. Upon IFNAR2 binding to IFNα/β, the receptor 
homodimer undergoes phosphorylation on its cytoplasmic domain and the associated Janus 
family kinases Janus Kinase 1 (JAK1) and Tyrosine Kinase 2 (TYK2) are also activated by 
reciprocal trans-phosphorylation60. JAK1 and TYK2 phosphorylate Signal Transducer and 
Activator of Transcription 1 and 2 (STAT1 and STAT2) which in turn form a complex with 
IRF-9 called Interferon-Stimulated Gene Factor 3 (ISGF3)61. ISGF3 enters the nucleus and 
activates transcription of thousands of target ISGs by binding to the Interferon-Sensitive 
Response Element (ISRE)62. In addition to this canonical pathway of IFNα/β action, IFNAR 
can also activate other STAT proteins as well as other signal transduction proteins such as 
the Mitogen-Activated Protein Kinases (MAPKs). This means an even greater variety of ISGs 
can be induced and the cellular response to IFNα/β can vary by cell type as well as other 
context-dependent factors. Among the best characterised ISGs are the 2’-5’-Oligoadenylate 
Synthetases (OAS), which synthesise 2’,5’-oligoadenylates that activate RNase L63, and 
Protein Kinase R (PKR), which performs many roles including inhibition of mRNA translation 
and activation of NF-κB64. Others include the Interferon Induced proteins with 
Tetratricopeptide repeats (IFIT proteins), which inhibit translation and bind to viral RNAs65, 
the Apolipoprotein B mRNA Editing enzyme Catalytic polypeptide proteins (APOBECs), 
which edit viral mRNAs66 and MX1, which specifically inhibits assembly of the influenza 




inflammatory and pro-apoptotic cytokines and can help to activate the adaptive immune 
response, particularly through dendritic cells and CD8+ T cells68,69. 
The other primary transcription factor activated by PRR pathways is NF-κB, which 
represents 5 closely related proteins which act as homo- or heterodimers to activate 
transcription of a number of target genes70. Induction of gene expression by NF-κB varies by 
cell type but induced genes include many pro-inflammatory cytokines such as Tumour 
Necrosis Factor α (TNFα) and interleukins (ILs) as well as other immunoregulatory proteins 
such as Major Histocompatibility Complex (MHC) proteins and complement cascade 
proteins71.   
Overall, innate immune responses triggered by PRR recognition of PAMPs are a key part of 
the initial host defences against virus infection, resulting in large-scale gene expression 
changes and the formation of an antiviral state. Genes stimulated by these pathways 
perform a variety of roles from the direct inhibition of viral replication to the initiation of 
inflammation and the priming of the adaptive immune system. Further underlining the 
importance of these processes, most pathogenic viruses have evolved strategies to evade 
or dampen host innate immune responses and these can be key for viral proliferation. 
Therefore, further understanding of the mechanisms of activation of PRR pathways and 
their inhibition by viruses is key for protecting human health. 
 
RIG-I is a key PRR in the recognition of RNA viruses 
 
RIG-I and MDA5 are cytosolic PRRs that recognise viral RNA 
 
The RIG-I-like receptor family consists of three members; RIG-I, MDA5 and LGP2. Each has a 




both have N-terminal tandem Caspase Recruitment Domains (2CARD)72. RIG-I recognises 
RNAs with a 5’- di- or triphosphate (5’pp/5’ppp) moiety while MDA5 recognises long, 
double-stranded RNA (dsRNA)73–77. Upon binding to their substrates, both RIG-I and MDA5 
trigger downstream signalling pathways via the adaptor Mitochondrial Antiviral Signalling 
protein (MAVS, also known as Interferon Beta Promoter Stimulator Protein 1 (IPS1), CARD 
Adapter Inducing Interferon Beta (CARDIF) or Virus-Induced-Signalling Adapter (VISA)), 
leading to activation of IRF-3, IRF-7 and NF-κB72. The role of LGP2 is less well characterised 
but as it does not have the N-terminal CARDs needed for interaction with MAVS, it does not 
seem to act as a PRR75. It has been shown to both positively and negatively regulate RIG-I 
and MDA5 signalling in mice in response to infection by different viruses54,78. More recent 
work has elucidated the mechanism of LGP2 enhancement of MDA5 signalling. LGP2 
increases the rate of MDA5 binding to RNA and induces the formation of more numerous, 
shorter MDA5 filaments that exhibit an increased signalling activity compared to the 
filaments produced in the absence of LGP279. 
Both RIG-I and MDA5 recognise RNA from a multitude of RNA viruses, as well as RNA 
intermediates produced by some DNA viruses80. There are several viruses that have been 
shown to trigger innate immune signalling via both RLRs. For example, negative sense 
ssRNA paramyxoviridae such as Sendai virus75,81,82, Newcastle disease virus82 and 
Respiratory Syncytical virus83. In addition to this positive sense ssRNA flaviviridae such as 
Dengue and West Nile viruses83 as well as Hepatitis C virus84 are recognised by both MDA5 
and RIG-I. Double stranded RNA replicative intermediates from positive sense ssRNA 
picornaviridae are generally recognised by MDA5 rather than RIG-I85. RIG-I, but not MDA5, 
generally recognises RNA from other negative sense ssRNA viruses that are not 




Vesicular Stomatitis Virus (VSV)76,82 and negative sense RNA viruses with a segmented 
genome such as Rift Valley fever virus and Lassa virus87. 
RNA from IAV and IBV is recognised by RIG-I but not MDA584,88,89. RIG-I-/- mice showed 
reduced production of IFNβ compared to WT mice in response to infection with IAV lacking 
NS1, while MDA5-/- mice showed no change84. In addition to this, IAV NS1 was shown to 
interact with human RIG-I, but not MDA5 in co-immunoprecipitation experiments. Also, 
Transfection of IAV vRNA in human cell lines was shown to induce innate immune activity in 
a RIG-I dependent manner89. Further work found that activation of RIG-I signalling in IAV 
infection was dependent on replication of the IAV genome with the agonist for RIG-I being 
full-length IAV genome segments. After infection with IAV, RNA associated with RIG-I was 
isolated and IAV genome segments, but no smaller RNAs, were identified88. More recent 
work has suggested that replication of IAV is not necessary and rather RIG-I can recognise 
and bind to vRNA upon nucleocapsid entry into the cell. This work also identified the 
‘panhandle’ RNA structure as possibly being important for RIG-I recognition of 
nucleocapsid-associated RNA90. Further studies using synthetic viral RNAs determined that 
5’ppp-ssRNA was not on its own sufficient for activation of RIG-I signalling and a stretch of 
dsRNA, as found in the panhandle structure of negative sense RNA virus genomes, was 
required for efficient signalling91,92. 
RIG-I recognises 5’ppp-RNA through its DExD/H-box RNA helicase domain and its CTD. The 
CTD of RIG-I contains a basic stretch that binds 5’ppp and this interaction is enhanced by 
the presence of a blunt ended dsRNA stretch compared to ssRNA93. Crystallisation of the 
RIG-I CTD with short 5’ppp-dsRNA indicated that the side chain of Phe853 in the CTD stacks 
over both bases at the terminal end of the RNA duplex, explaining this increase in affinity93. 




the CTD loop spanning residues 847-888, with multiple lysine and histidine residues forming 
hydrogen bonds with the phosphate groups93. MDA5 does not have this basic stretch in its 
CTD and as such does not interact with the 5’ phosphate groups, explaining its lower affinity 
for 5’ppp-RNAs94,95. The DExD/H-box RNA helicase domain of RIG-I is made up of three sub-
domains; Hel1, Hel2i and Hel2. Crystal structures of the helicase domain and CTD in 
complex with dsRNA indicated that all thee helicase sub-domains, as well as the CTD, 
surround dsRNA in a ring-like structure with the 5’ end of the RNA covered and the 
opposite end exposed96. The RIG-I helicase/CTD encircles roughly 8 base pairs of RNA, with 
interactions primarily with the RNA phosphate backbone. 
 
RIG-I signalling is activated upon binding to 5’ppp-RNA 
 
To prevent inappropriate activation of innate immune responses, RIG-I signalling must be 
repressed in the absence of 5’ppp-RNA. This is achieved by several auto-repression 
mechanisms. For example, crystal structures of ligand-free RIG-I indicated that RIG-I is kept 
in an inactive conformation through interactions between the helicase 2i and the second 
CARD97. Mutational analysis of RIG-I also identified the linker between the helicase and C-
terminal domains as necessary for auto-repression as transfection of a RIG-I construct 
lacking this linker induced type I IFN signalling even in the absence of RIG-I agonists98. In 
addition to this, phosphorylation of the RIG-I 2CARD by Protein Kinase C-α and β (PKC-α and 
PKC-β) has been shown to significantly inhibit RIG-I signalling and dephosphorylation of the 
2CARD by Protein Phosphatase 1-α (PP1α) and PP1γ is required for efficient activation of 
signalling99,100. Upon binding to 5’ppp-RNA, RIG-I undergoes an ATP-dependent 




RNA and the 2CARD being released from auto-repression97,101. It has been suggested that 
K63-linked polyubiquitination of the RIG-I CTD and helicase-CTD linker by the E3 ubiquitin 
ligase Riplet is also necessary for release of the 2CARD102,103.  
 
Upon binding to 5’ppp-RNA, RIG-I translocates down the dsRNA stem, allowing multiple 
RIG-I molecules to form a ‘beads-on-a-string’ complex on the RNA104,105. This 
oligomerisation activity is ATP hydrolysis-dependent and increases the strength of the 
resulting type I IFN response106. Oligomerisation of RIG-I is also important for the formation 
of tetramers of the 2CARD, which is required for activation of downstream signalling via 
MAVS through interaction with MAVS’ own CARD107. A critical process in the formation of 
the 2CARD tetramer and the activation of MAVS is the K63-linked polyubiquitination of the 
2CARD, which has been shown to stabilise the 2CARD tetramer and enhance the formation 
of MAVS filaments that are required for signalling108,109. Upon filament formation, MAVS 
can act as a scaffold for the recruitment of downstream signalling factors including Tumour 
Necrosis Factor Receptor Associated Factor proteins (TRAFs) such as TRAF3 and TRAF5 
through a TRAF binding motif110–112. TRAFs in turn recruit and activate the Inhibitor of κB 
(IκB) Kinases (IKKs) IKKα/β/γ that phosphorylate IκB, causing it to dissociate from NF-κB and 
allowing NF-κB to translocate to the nucleus and induce expression of pro-inflammatory 
cytokines. TRAFs also recruit and activate IKKε and TRAF Family Member Associated NF-κB 
Activator (TANK) Binding Kinase 1 (TBK1) that can phosphorylate and activate the 
transcription factors IRF-3 and IRF-7 which enter the nucleus and induce expression of type 





K63-linked polyubiquitination of the RIG-I 2CARD may be performed by 
multiple E3 ubiquitin ligases 
 
Initially, Tri-partite Motif 25 (TRIM25) was identified as the key E3 ubiquitin ligase for the 
ubiquitination of the RIG-I 2CARD in both mice and humans by Gack et al.113. In this report, 
6 lysine residues on the RIG-I 2CARD that underwent K63-linked polyubiquitination were 
identified by mass spectrometry (MS); K99, K169, K172, K181, K190 and K193. Of these, 
only mutation of K172 to arginine resulted in a reduction in polyubiquitination of the 
2CARD and a concomitant reduction in activation of the NF-κB and IFNβ promoters when 
the 2CARD was transfected into HEK293 cells. This suggested that polyubiquitination of this 
residue is key for RIG-I 2CARD-mediated signalling. However, later work suggested that a 
RIG-I K172R mutant was fully functional and could efficiently trigger innate immune 
signalling in response to Sendai virus infection, suggesting that K172 may not be required 
for signalling114. Gack et al. also identified TRIM25 as a binding partner of the 2CARD in co-
immunoprecipitation (Co-IP) experiments and demonstrated that this interaction was 
mediated by the C-terminal SPRY domain of TRIM25. Furthermore, knockdown of TRIM25 
using RNA interference (RNAi) resulted in a reduction of RIG-I 2CARD polyubiquitination 
and IFNβ promoter activity in response to 2CARD transfection. Finally, production of IFNβ in 
TRIM25 knockout (KO) mouse embryonic fibroblast (MEF) cells upon Sendai virus infection 
was reduced compared to WT cells, while replication of VSV was increased in the TRIM25 
KO cells compared to WT113.  
Further work has underlined the role that TRIM25 plays in ubiquitination of the RIG-I 
2CARD. Mutation of T55 in the first RIG-I CARD was found to abolish the TRIM25-2CARD 
interaction and this was required for TRIM25-mediated polyubiquitination of the 2CARD115. 




K63-linked polyubiquitin chains to the 2CARD was not necessary for activation of signalling 
as unanchored K63-linked chains generated by TRIM25 can be bound by the 2CARD and this 
is sufficient for activation of signalling116. Transfection of TRIM25 into HEK293T KO cells 
enhanced IFNβ promoter activity by about 2-fold compared to TRIM25 KO cells alone in 
response to transfection of the RIG-I 2CARD. However, a roughly 20-fold induction of IFNβ 
promoter activity when compared to cells not transfected with the RIG-I 2CARD was seen in 
the TRIM25 KO HEK293T cells, suggesting that there may be some redundancy in the role of 
TRIM25 in RIG-I signalling117. The same work reported that IAV replication was restricted 
upon TRIM25 transfection in the TRIM25 KO cells when compared to the TRIM25 KO cells 
alone. 
Importantly, other E3 ubiquitin ligases have also been implicated in the ubiquitination of 
the RIG-I 2CARD. In addition to its role in ubiquitinating the RIG-I helicase-CTD linker, Riplet 
(also known as RIG-I E3 Ubiquitin Ligase (REUL)) was found to polyubiquitinate the RIG-I 
2CARD at lysines 154, 164 and 172. Knockdown of Riplet was shown to inhibit IFNβ 
expression in response to Sendai virus infection and resulted in increased replication of 
VSV118. Knockdown of TRIM4 was found to inhibit activation of the IFNβ promoter in 
response to overexpression of RIG-I or infection with Sendai virus119. This study also found 
that TRIM4 primarily targeted K164 and K172 of the RIG-I 2CARD for polyubiquitination. A 
systems biology approach combined with experimental validation identified the 
ubiquitination of K164 and K172 by TRIM25 and TRIM4 as being key for RIG-I signalling 
activation, with TRIM25 and TRIM4 working synergistically to optimise activation120. 
Another E3 ubiquitin ligase, Mex-3 RNA Binding Family Member C (MEX3C), was found to 
co-localise with RIG-I in antiviral stress granules and ubiquitinate the RIG-I 2CARD at K48, 
K99 and K169. Cells derived from MEX3C KO mice were shown to have impaired activation 




while activation after infection with Encephalomyocarditis Virus (EMCV, recognised by 
MDA5) was unaffected121. Shi et al. showed that in a HEK293T cell-free system knockout of 
Riplet abrogates RIG-I mediated aggregation of MAVS in response to VSV genomic RNA 
while knockout of TRIM25, MEX3C or TRIM4 did not abrogate aggregation. However, MAVS 
aggregation could still be triggered in response to addition of the RIG-I 2CARD even in the 
absence of Riplet122. This may suggest that activation of full-length RIG-I signalling in 
response to viral RNA requires Riplet activity, but Riplet is redundant with the other E3 
ubiquitin ligases in the ubiquitination of the RIG-I 2CARD alone.  
More recent work has underlined the importance of Riplet in RIG-I signalling and indicated 
that TRIM25 is dispensable for activation of signalling by full-length RIG-I. TRIM25, Riplet 
and RIG-I were knocked out of HEK293T cells before the cells were stimulated with a 42bp 
5’ppp-dsRNA or Sendai virus (SeV). Riplet and RIG-I KO cells, but not TRIM25 KO, showed a 
reduction in expression of ISGs or luciferase under the IFNβ promoter upon stimulation123. 
Expression of exogenous Riplet in the Riplet KO cells restored IFN activity, confirming that 
Riplet is required for efficient RIG-I signalling. These findings were repeated with an 
expanded range of stimulants (5’ppp-dsRNA, SeV, Rift Valley fever virus and IAV) and in 
other cell lines from independent sources including mouse embryonic fibroblasts (MEFs) 
and A549 lung carcinoma cells123. Interestingly, stimulation of TRIM25 KO cells with GST-
2CARD resulted in a 50% reduction in signalling activity compared to WT cells, while Riplet 
KO had no effect. This further suggests a difference in the activation mechanisms of full-
length RIG-I and isolated 2CARD and helps to explain the earlier findings of Gack et al. This 
study also looked at the abilities of Riplet and TRIM25 to ubiquitinate RIG-I in vitro by 
performing ubiquitination assays with purified RIG-I, ubiquitin and E1 and E2 ubiquitin 
ligases in the presence or absence of 42bp 5’ppp-dsRNA. This showed that Riplet, but not 




study, by Hayman et al., similarly showed that Riplet, and not TRIM25, was essential for 
RIG-I signalling124. As shown by Cadena et al., knock-out of TRIM25 in A549 cell lines was 
shown to have no effect on RIG-I signalling in response to several RIG-I-stimulating viruses 
or ligands while Riplet knock-out abolished RIG-I signalling. Interestingly, deletion of 
TRIM25 in mice resulted in higher virus titres after infection with IAV, with levels of IFNγ in 
the lungs being unaffected124. This implies that TRIM25 may be playing a RIG-I-independent 
role in the restriction of IAV in mice. 
Okamoto et al. proposed a ‘sequential ubiquitination’ mechanism to explain the activation 
of RIG-I by polyubiquitination by different E3 ubiquitin ligases (Figure 3)125. In this model, 
Riplet first ubiquitinates the helicase-CTD linker at K788 upon RIG-I RNA binding to release 
the 2CARD from auto-repression and this step is required for the E3 ligases to access the 
2CARD. This is followed by ubiquitination at various sites on the 2CARD by Riplet, TRIM25, 
TRIM4 and MEX3C. This would fit with the observations of Shi et al., Cadena et al. and 
Hayman et al. that Riplet is absolutely required for efficient RIG-I signalling activation, as 
well as explaining why there is seemingly redundancy between the other E3 ligases.  
 
RIG-I signalling is targeted for inhibition by many viruses 
 
In order to be able to replicate efficiently, most human viruses have evolved mechanisms 
for avoiding the triggering of innate immune signalling. Many RNA viruses that can be 
recognised by RIG-I have developed mechanisms of inhibiting RIG-I signalling at different 
stages of the pathway. In addition to this, RIG-I signalling must be tightly controlled by host 





Figure 3 - Model of activation of RIG-I based on the sequential ubiquitination model 
proposed by Okamoto et al. Upon recognition of 5’ppp-dsRNA, RIG-I undergoes a 
conformational change and the Helicase-CTD linker can be ubiquitinated by Riplet. This 
releases the 2CARDs from auto-repression and allows their dephosphorylation by PP1α/γ. 
Ubiquitination of the linker also promotes the assembly of other RIG-I molecules along the 
dsRNA, although the CTD of only one molecule can bind the 5’ppp moiety. The 2CARDs 
from RIG-I molecules assembled along the dsRNA can form ‘tetramer’ structures that are 
stabilised by K63-linked polyubiquitination of the 2CARD. This tetramer structure interacts 








expression. Examples of this include the mechanisms for RIG-I auto-repression as explained 
previously. RIG-I must also avoid signalling upon recognition of self RNA. This is reliant on 
hydrolysis of ATP, which leads to displacement of RIG-I from self RNA which is bound less 
stably than non-self RNA126. A mutant of RIG-I that could bind to, but not hydrolyse, ATP 
was found to stably associate with 60S rRNA, triggering innate immune signalling while WT 
RIG-I rapidly dissociated127. 
A common viral strategy for avoiding recognition by RIG-I is by post-transcriptionally 
removing or sequestering the 5’ppp moiety on genomic RNAs. For example, the Crimean-
Congo hemorrhagic fever, Hanta and Borna disease viruses all remove 5’ppp from their 
genomic RNA87 and Polioviruses cap the 5’ end of their RNAs128. Arenavirus has an unpaired 
5’ppp nucleotide overhang that prevents recognition by RIG-I129. The VP35 proteins from 
both Ebola and Marburg viruses sequester vRNA from RIG-I and mask the 5’ppp by end-
capping130,131. IAV NS1 also prevents RIG-I binding to its RNA through its dsRNA binding 
activity132. Another strategy used by several viruses is the targeting of RIG-I or MAVS for 
degradation or mislocalisation. Proteins encoded by Hepatitis A virus cleave MAVS while 
Hepatitis B virus targets it for degradation133,134. EMCV and Respiratory Syncytial virus (RSV) 
both target RIG-I for degradation via the proteasome135,136, while RSV, as well as Dengue 
virus, cause mislocalisation of MAVS and RIG-I respectively133,137. In addition to strategies 
targeting upstream factors in RIG-I signalling, viruses also target downstream factors. For 
example, Dengue virus inhibits the phosphorylation of TBK1 and IRF-3138, Severe Acute 
Respiratory Syndrome Coronavirus (SARS-CoV) disrupts the TANK-TBK1/IKKε complex139 
and Herpes Simplex virus type 1 (HSV-1) targets IRF-3140. 
As ubiquitination of the RIG-I 2CARD is a key process in RIG-I signalling activation it is also 




deubiquitinases that remove polyubiquitin chains from the RIG-I 2CARD including SARS-
CoV, arterivirus, nairovirus, foot-and-mouth disease virus (FMDV) and herpesvirus141–143. 
Hepatitis C virus (HCV) NS3-4A targets Riplet to prevent it from ubiquitinating RIG-I by 
disrupting their association102. The NS1 protein of IAV is known to block ubiquitination of 
RIG-I through interactions with TRIM25, Riplet and RIG-I itself144–146. 
IAV NS1 binds to the coiled-coil domain of TRIM25, preventing its multimerisation which it 
requires for its catalytic activity145. The interaction between NS1 and TRIM25 requires the 
E96 and E97 residues in the NS1 effector domain (ED) as well as R38 and K41 in the RNA 
binding domain (RBD) and recombinant IAVs with the mutant NS1 E96E97A or R38K41A 
lose their ability to block type I IFN expression as well as their virulence in mice145. A later 
study indicated that NS1s from IAV strains adapted to multiple organisms including 
humans, mouse, swine and birds efficiently interacted with and blocked the activity of 
human, but not mouse, TRIM25146. In mouse cells, IAV NS1 interacted with and blocked the 
activity of Riplet and this was sufficient to inhibit RIG-I signalling146. In human cells, NS1 
from a human adapted IAV strain was also capable of inhibiting Riplet activity and this is 
likely important for the overall inhibitory effect of NS1 on RIG-I signalling146. A crystal 
structure of the TRIM25 coiled-coil and PRY/SPRY domains in complex with IAV NS1 
indicated that E96 and E97 of NS1 are likely needed for overall structural integrity of the 
NS1 protein rather than direct interactions with the TRIM25 coiled-coil and instead critical 
interactions were formed with NS1 L95 and S99147. This study also showed that only the ED 
of NS1 was necessary for the interaction with TRIM25 and the RBD was not required as had 
been previously reported. In addition, the inhibitory effect of NS1 on TRIM25 activity was 
shown to be due to disruption of interactions between the TRIM25 PRY/SPRY and coiled-





Other viruses also target TRIM25-mediated RIG-I ubiquitination for inhibition in order to 
dampen the innate immune response. The V proteins of several paramyxoviruses (Nipah, 
measles, Sendai and parainfluenza viruses) were found to interact with both the RIG-I 
2CARD and the SPRY domain of TRIM25, preventing TRIM25-mediated ubiquitination of 
RIG-I148. Similarly, RSV NS1 and N protein from SARS-CoV were also found to interfere with 
TRIM25 activity149,150. Inhibition of TRIM25 was also found to be a factor in the replacement 
of an endemic clade of Dengue virus by a new clade151. The new clade showed increased 
expression of a subgenomic flavivirus RNA (sfRNA) that bound to and inhibited TRIM25, 
increasing the epidemiological fitness of the new clade compared to the previous one151. 
TRIM25 can be targeted for inhibition by the host cell in order to downregulate RIG-I 
signalling to prevent excessive inflammation and IFN responses. The Linear Ubiquitin 
Assembly Complex (LUBAC), composed of Heme-Oxidized IRP2 Ubiquitin Ligase 1 (HOIL-1) 
and HOIL-1 Interacting Protein (HOIP), competes with TRIM25 for binding to RIG-I and also 
targets TRIM25 for degradation via the proteasome152.  
The wide variety of viruses and mechanisms that target RIG-I signalling for inhibition 
underlines the importance of RIG-I signalling as a means of restricting virus infection. As 
RIG-I 2CARD ubiquitination is a commonly targeted step of this pathway, this suggests that 
it is critical for efficient RIG-I signalling. Due to the large amount of similarity between 
TRIM25 and Riplet (around 60% sequence homology), it is possible that some of the 
mechanisms mentioned will also inhibit Riplet activity, as is the case with IAV NS1. 
However, despite its seeming importance in the activation of RIG-I signalling, Riplet remains 
less studied than TRIM25 so more work is needed to further elucidate the extent of Riplet 





The E3 ubiquitin ligase TRIM25 has many different roles 
 
TRIM family proteins are E3 ubiquitin ligases 
 
The Tri-partite Motif (TRIM) family is a large (>80 members in humans) group of E3 
ubiquitin ligase proteins that share a common domain structure. Almost all TRIM family 
proteins consist of an N-terminal Really Interesting New Gene (RING) domain, responsible 
for their E3 ubiquitin ligase activity, 1 or 2 B-box domains and a coiled-coil domain (CCD), 
responsible for homo and heterodimerisation117,153–155. Most TRIM family proteins have one 
or a combination of several types of C-terminal domain generally responsible for protein-
protein interactions. C-terminal domains include the PRY (~61aa) and SPRY (~140aa) 
domains, that can be found individually or combined as a single unit, known as a PRY/SPRY 
or B30.2 domain. Other C-terminal domains include the plant homeodomains (PHDs), 
fibronectin type 3 domains (FN3s) and COS boxes153,154,156,157. 
The primary role of TRIM E3 ubiquitin ligases is to catalyse the addition of polyubiquitin 
chains or single ubiquitin monomers (monoubiquitination) to lysine residues on their target 
proteins. Ubiquitin is a 76 aa, 8.5 kDa protein and poyubiquitin chains are made by the 
formation of isopeptide bonds between the ubiquitin C-terminal glycine and one of the 7 
lysine residues present in the protein158,159. It has also been shown that polyubiquitin chains 
can form in a ‘head-to-tail’ manner via the N-terminal methionine residue160. The addition 
of ubiquitin monomers to a target protein or extension of a polyubiquitin chain involves 
three types of proteins; E1, E2 and E3. The E1 activating enzyme forms a thioester bond 
with the ubiquitin C-terminal glycine and the ubiquitin is transferred to the E2 conjugating 
enzyme via a trans-thiolation reaction so that it is bound to a cysteine in the active site of 




catalyse the transfer of the ubiquitin from the former to the latter. The E2 is the main 
determinant of the type of ubiquitin chain formed (i.e. which lysine residue the new 
monomer is added to) while the E3 determines the target protein and the target residue on 
that protein161. 
The multiple lysines present in ubiquitin allow the formation of several different types of 
polyubiquitin chains, each of which has different functionality. Chains can vary significantly 
in length and can be homogenous or mixed (a chain of different ubiquitin linkages) and 
straight or branched. The most well studied are straight, homogenous K48-linked 
polyubiquitination, which leads to targeting of proteins for degradation via the proteasome, 
and K63-linked polyubiquitination which is used in many intracellular signalling pathways162. 
The proteasome recognises I44 of K48-linked polyubiquitin163 and ubiquitin-mediated 
degradation of an inhibitor is a common mechanism for the activation of proteins, for 
example the NF-κB inhibitor IκBα is degraded following K48-linked polyubiquitination in 
order to allow NF-κB activation164. K63-linked polyubiquitination can have many different 
functions on the target protein including modulating protein:protein interactions, common 
in the DNA damage response, and regulation of protein activity as is seen in innate immune 
signalling162. 
 
Many TRIM family proteins are involved in innate immune responses 
 
As discussed previously, TRIM25 and TRIM4 have both been shown to be able to activate 
downstream signalling from RIG-I by ubiquitinating the RIG-I 2CARD. Many other TRIM 
family proteins have been shown to play a role in host immune defences, particularly in the 




closely related to each other, are often clustered together in the genome, suggesting they 
may have arisen from gene duplications and several TRIMs are ISGs, underlining their 
importance in innate immune responses165,166. Around half of human TRIMs were found to 
enhance innate immune responses to RIG-I 2CARD expression when overexpressed167. 
Some TRIM proteins in addition to TRIM25 and TRIM4 directly regulate RIG-I signalling 
through interactions with RIG-I or MAVS. TRIM40 targets both RIG-I and MDA5 for 
degradation, while TRIM38 stabilises both through addition of the ubiquitin-like protein 
SUMO, suppressing their K48-linked polyubiquitination168,169. TRIM14 promotes the 
translocation of RIG-I to the mitochondria and its interaction with MAVS by recruiting 
Werner Helicase Interacting Protein (WHIP) and Protein Phosphatase 6 Catalytic Subunit 
(PPP6C) which aid the MAVS/RIG-I interaction and dephosphorylation of RIG-I 
respectively170. TRIM14 also recruits IKKγ and NF-κB Essential Modulator (NEMO) to MAVS 
to aid downstream signalling171. TRIM31 was found to promote the aggregation of MAVS in 
response to RIG-I stimulation, required for efficient downstream signalling, through K63-
linked polyubiquitination172. TRIM44 interacts with MAVS through its B-box domains and 
stabilises it by preventing its K48-linked polyubiquitination173. In addition to these proteins, 
several more TRIMs act downstream of MAVS to positively regulate innate immune 
responses including TRIM9174, TRIM26175 and TRIM23176, while some negatively regulate 
these responses including TRIM11177. TRIM proteins are also involved in innate immune 
signalling through cGAS-STING, TLRs and in IFN signalling through IFNAR154. 
Apart from their roles in PRR signalling, TRIM proteins are also known to directly restrict 
viruses. TRIM5α from monkeys is able to efficiently restrict HIV-1, however human TRIM5α 
is less efficient in this178,179. TRIM5α binds directly to the virus capsid proteins and TRIM5α-




is ubiquitinating the capsid protein and targeting it for degradation180,181. TRIM11 promotes 
premature uncoating of HIV-1 and restricts the virus in a proteasome-independent 
manner182,183. TRIM19, TRIM22 and TRIM37 have also been shown to restrict HIV-1, 
although the mechanisms for this are poorly understood153. Two TRIMs have also been 
shown to restrict IAV by targeting components of the virus for degradation via the 
proteasome. TRIM22 targets NP184 and TRIM32185 targets PB1 for K48-linked 
polyubiquitination. In addition to this, TRIM56 has been shown to restrict IAV and IBV in a 
ubiquitination-independent manner, possibly through blocking transcription by binding to 
vRNAs186. TRIM56 expression was found to restrict IAV and IBV, but not Sendai virus or 
Monkeypox virus, and this restriction was not dependent on the presence of the RING, B-
box or CCD but rather a 63 amino acid stretch in the CTD. This region of the CTD was also 
shown to be sufficient to inhibit transcription of a luciferase reporter construct by the IAV 
RNA polymerase, implying that transcription by the polymerase is being blocked186. Similar 
ubiquitination-independent blocking of IAV RNA polymerase transcription was also seen for 
TRIM25 and this will be discussed in further detail later187. 
 
TRIM25 has other cellular roles and has been implicated in some cancers 
 
Human TRIM25 is a 630 amino acid, 71 kDa E3 ubiquitin ligase that is widely expressed 
across human cell types and is conserved among vertebrates including fish, birds and 
mammals188–192. Like other TRIM family proteins, it consists of a zinc-finger RING domain, 
two B-box domains and a CCD with a linker domain leading to a C-terminal PRY/SPRY 
(B30.2) domain. TRIM25 forms an antiparallel dimer mediated by its CCD, with the RING 




positioned at the centre via the CCD-PRY/SPRY linker193. Further work indicated that the 
RING domain of TRIM25 must dimerise in order to catalyse polyubiquitin chain formation, 
implying that higher-order assembly of TRIM25 dimers is required for its activity117. Two 
separate mechanisms of higher-order assembly were proposed. Firstly, an ‘end-to-end’ 
model in which RING domains on each end of the dimer interact with RING domains from 
separate dimers. Secondly, a ‘tetramer’ model in which TRIM25 dimers effectively stack on 
top of each other with RING domains on either end of one dimer interacting with both RING 
domains from another dimer (Figure 4)117. When human TRIM25 RING domain was 
crystallised with an ubiquitin-charged E2 conjugating enzyme, UBE2D1, it was shown to 
form a dimer with both RING monomers contacting the ubiquitin molecule194. Crystal 
structures have also been generated for the PRY/SPRY domain of mouse TRIM25, showing 
that its overall structure is that of two anti-parallel β-sheets in a sandwich type 
conformation, similarly to PRY/SPRY domains found in other proteins195. By comparing the 
TRIM25 PRY/SPRY structure to other PRY/SPRY domains, a putative binding site was 
identified. Three solvent-exposed phenylalanine residues (F528, F559 and F623) and a 
‘ladder’ of arginine and tryptophan residues in close proximity, all of which are conserved 
across species, form a pocket of hydrophobic and hydrogen bonding-capable residues and 
were identified as one potential binding site. Conserved residues in loop regions that do not 
contribute to overall domain architecture were also tested. Mutational analysis revealed 
that D488 and W621 were key residues for the binding of the PRY/SPRY domain to the RIG-I 
2CARD195. A recent study identified a second putative 2CARD binding site in the TRIM25 
PRY/SPRY on the opposite surface of the domain to the previously identified one196. This 
study also showed that the linker between the CCD and the PRY/SPRY is flexible, allowing 






Figure 4 – Possible models of dimerization of the RING domains of TRIM25 dimers as 
proposed by Sanchez et al. Due to the anti-parallel structure of the TRIM25 dimer, RING 
domains from TRIM25 molecules found in the same dimer cannot dimerise themselves. This 






Apart from its role in the ubiquitination of the RIG-I 2CARD, TRIM25 has been found to 
perform other roles in the cell and has been implicated in several cancers. TRIM25 was 
initially identified as a protein responsive to oestrogen in a screen for regions of DNA bound 
by the oestrogen receptor and was shown to be upregulated in oestrogen receptor-positive 
mammary cells197.  Mice with TRIM25 knocked out were shown to be viable and fertile but 
with a significantly underdeveloped uterus and a dampened response to oestrogen198. 
TRIM25 has subsequently been shown to interact with and ubiquitinate with components 
of the oestrogen response. In the presence of oestrogen, TRIM25 ubiquitinates oestrogen 
receptor α (ERα), stimulating interactions with co-factors such as Tat Interacting Protein, 60 
kDa (TIP60) and increasing ERα activity199. However, a mutant TRIM25 lacking the RING 
domain increased the half-life of ERα, suggesting that this ubiquitination also targets ERα 
for degradation199. TRIM25 can also positively regulate ERα activity by targeting AT-binding 
transcription factor 1 (ATBF1), which competes with ERα for co-activators, for 
degradation200. TRIM25 also targets another negative regulator of ERα, Kruppel-like factor 5 
(KLF5), for degradation201.  
TRIM25 has been implicated as being important in the progression of several cancers. In 
breast cancer, TRIM25 targets the scaffold protein 14-3-3σ for degradation202. 14-3-3σ is a 
negative cell cycle regulator and loss of TRIM25 in MEF cells was shown to lead to an 
accumulation of 14-3-3 and reduced cell growth. In addition, growth of Michigan Cancer 
Foundation-7 (MCF7) breast cancer cells implanted in athymic mice was attenuated by the 
targeting of TRIM25 by RNAi202,203. Overexpression of TRIM25 in these cells can overcome 
the cells oestrogen dependency for tumour growth202. A systems biology approach 
identified TRIM25 as a key regulator at both transcriptional and post-transcriptional levels 
of a network of genes that promote metastasis of breast cancer and it was linked with 




suppressor that helps to initiate apoptosis in response to DNA damage, among other anti-
proliferative activities, and as such is mutated or downregulated in many cancers205. 
TRIM25 has been shown to regulate p53 in both a negative and positive manner. Upon 
TRIM25 knockdown in lung cancer cells, p53 levels increased and proliferation, 
tumorigenesis and migration of the cells was inhibited206. However another study showed 
that p53 levels were upregulated in the presence of TRIM25 but p53 transcriptional activity 
was lowered, dampening the p53-dependent DNA damage response207. In prostate cancer, 
TRIM25 was shown to stimulate p53 translocation to the cytoplasm through interaction 
with GTPase-activating protein-binding protein 2 (G3BP2) and TRIM25 knockdown resulted 
in reduced prostate tumour growth in mouse models208. TRIM25 was also shown to play a 
role in the invasion and migration of both colorectal and gastric cancer cells through the 
stimulation of Transforming Growth Factor β signalling209,210. 
Apart from its role in ubiquitination of the RIG-I 2CARD, TRIM25 has been shown to play 
other roles in innate immunity. TRIM25 has been shown to enhance the activity of Zinc-
finger Antiviral Protein (ZAP), which binds to and inhibits translation of viral mRNAs211,212. 
TRIM25 was shown to mediate K63-linked polyubiquitination of ZAP which enhanced its 
antiviral activity and was also shown to be required for efficient binding of ZAP to its target 
mRNA211. However another study showed that although TRIM25 E3 ligase activity was 
needed to enhance ZAP-mediated inhibition of Sindbis virus RNA translation and TRIM25 
mediated ZAP ubiquitination, ubiquitination of ZAP itself did not directly affect antiviral 
activity212. It is possible that TRIM25 also targets other factors for ubiquitination in a ZAP-
dependent manner and these factors aid ZAP-mediated inhibition of translation. TRIM25 
can also be involved in the dampening of RIG-I signalling. The ubiquitin-like FAT10 (also 
known as Ubiquitin D) forms a complex with TRIM25/RIG-I that sequesters RIG-I away from 




transduction213. TRIM25 stabilises FAT10, which is usually unstable, by preventing its 
proteasome-mediated degradation213. 
 
TRIM25 is an RNA-binding protein 
 
TRIM25 was initially discovered to be an RNA-binding protein (RBP) in a screen of mRNA 
binding proteins in HeLa cells214. Proteins were cross-linked to RNA via UV irradiation and 
mRNAs were isolated from the cell lysate with oligo(dT) probes before bound proteins were 
analysed by mass spectroscopy214. A similar strategy also identified mouse Trim25 as an RBP 
in mouse embryonic stem cells215. Binding of human TRIM25 to RNA was further validated 
by immunoprecipitation (IP) of TRIM25 followed by radiolabelling of RNA. Signal from 
radiolabelled RNA after TRIM25 IP was reduced in cells in which TRIM25 had been knocked-
down by RNAi, indicating that TRIM25 was binding to RNA215. This study also tested several 
truncation mutants of TRIM25 for their RNA binding activity. Truncations in which the N-
terminal RING and B-box domains, or the C-terminal PRY/SPRY domain, were deleted were 
capable of binding RNA in this assay as seen by signal from radiolabelled RNA 
corresponding to the size of the constructs as visualised by western blot. Conversely, any 
mutants in which the CCD was deleted were incapable of binding RNA, suggesting that the 
CCD could play a role in TRIM25 RNA binding activity215. 
Previous work in this lab uncovered a potential RNA binding-dependent function for 
TRIM25 in the Lin28-mediated degradation of pre-let-7a-1216. Two pre-let-7a-1 mutants 
with minimal loops required for Lin28a binding (pre-let-7a-1@2 and @3) showed 
differential uridylation when incubated with P19 cell extracts despite equal binding to 
Lin28a. Uridylation by TuT4 leads to exonuclease-mediated degradation of pre-let-7a-1, an 




This discrepancy led to the hypothesis that additional Lin28a cofactors were needed for 
efficient uridylation, which was tested by the use of RNA pulldown coupled to SILAC mass 
spectroscopy to search for proteins binding differentially to the two pre-let-7a-1 
mutants216,218. It was found that TRIM25 bound more to pre-let-7a-1@2, which was 
efficiently uridylated, than two pre-let-7a-1@3 which wasn’t and this was confirmed by 
RNA pulldown followed by western blot216. Further to this, knock-down of TRIM25 resulted 
in decreased uridylation and therefore increased levels of pre-let-7a-1, although the 
mechanism of this remains unknown216. In terms of sequence, pre-let-7a-1@2 and @3 
varied by the change of the GGAGAU motif found in the WT pre-let-7a-1 terminal loop and 
mutant @2 to GGAGUA in mutant @3, suggesting that the GGAGAU motif may be 
important for TRIM25 binding to pre-let-7a-1216. 
Further work performed in the lab has suggested that TRIM25 has a broad specificity with a 
preference for GC-rich regions of RNA219. This was determined through cross-linking 
immunoprecipitation followed by sequencing (CLIP-seq). T7-tagged TRIM25 was transiently 
expressed in cells that were subsequently exposed to UV radiation in order to induce cross-
linking between proteins and RNAs. T7-TRIM25 was then precipitated and subjected to 
stringent washes to remove non-cross-linked proteins and RNAs before the bound RNAs 
were isolated and sequenced. This identified a total of 2611 distinct transcripts, with no 
correlation seen between the abundance of the transcript in the cell and the abundance 
that associated with TRIM25 in this experiment, suggesting a level of specificity in the 
interactions. The majority (56%) of the transcripts identified were mRNAs, with most 
binding sites being in the exons (56%) or 3’-UTR (23%) of these. Comparison of the 
sequences identified in the experiment showed that there was no single consensus 
sequence required for TRIM25 binding, although GC-rich sequences were enriched 




does not discriminate between RNAs that are bound directly to TRIM25 and those that 
associate indirectly, for example via binding by other proteins that interact with TRIM25. As 
such, care must be taken when interpreting these results as they do not necessarily 
represent TRIM25’s direct RNA-binding activity.  
Recent work has identified a role for the RNA binding of TRIM25 in the restriction of IAV220. 
TRIM25s from human and gibbon were overexpressed in Crandell Reese Feline Kidney 
(CRFK) cells that were subsequently infected with IAV. Levels of viral proteins were reduced 
in cells overexpressing TRIM25, with gibbon TRIM25 having a greater effect than human 
TRIM25, and this was rescued by expression of WT NS1 protein. Virus titres and levels of 
viral RNAs were also reduced upon overexpression of TRIM25, again with gibbon TRIM25 
showing a larger effect and this was also seen for TRIM25 mutants lacking ubiquitin ligase 
activity (TRIM25 C13A/C16A)220. Deletion of RIG-I and TRIM25 from human A549 lung cells 
resulted in increased viral titres, viral protein, and vRNA levels, which could be rescued by 
expression of human or gibbon TRIM25. Interestingly, deletion of RIG-I alone had no effect, 
suggesting this function of TRIM25 is RIG-I-independent220. Further evidence that RIG-I is 
not required for this activity was shown by the use of a viral minigenome assay in HEK293T 
ΔRIG-I cells. Overexpression of both human and gibbon TRIM25 in these cells reduced 
expression of a luciferase reporter that could only be expressed in the context of IAV RNA 
polymerase activity, indicating that TRIM25 was inhibiting the activity of the IAV 
polymerase220. TRIM25 was subsequently shown to bind to IAV vRNPs in an RNA-dependent 
manner and that gibbon TRIM25 binds to vRNPs more efficiently than human TRIM25. In 
addition to this, purified human or gibbon TRIM25 was able to inhibit viral mRNA chain 
elongation in vitro, again with gibbon TRIM25 doing this more efficiently, reflecting its 
higher ability to restrict viral replication and protein production as well as its stronger 




blocks the IAV RNA polymerase from moving down the vRNA template and prevents the 







Figure 5 – A possible mechanism for inhibition of IAV transcription by TRIM25 proposed by 
Meyerson et al187. TRIM25 interacts with IAV vRNPs in an RNA-dependent manner, blocking 
the onset of RNA chain elongation by the viral polymerase and therefore inhibiting IAV 








The overall aims of this project were to elucidate the mechanism and functions of TRIM25 
RNA-binding activity. TRIM25’s roles in important disease-related processes such as innate 
immunity and cancer make it an intriguing and physiologically relevant target to study. It 
has been shown to bind to RNA despite the lack of a canonical RBD so uncovering the 
mechanism of this binding may provide insights into a novel method of protein-RNA 
binding. In addition to this, as TRIM25 is a member of a large family of proteins with similar 
domain structures, it is possible that this mechanism could be conserved in other members 
of the same family, many of which have important roles in innate immunity. As TRIM25 is 
known to function in an innate immune pathway that detects viral RNAs, the obvious 
question is whether its RNA-binding activity is important for its role in this pathway. It is 
possible that TRIM25 RNA binding could positively regulate its activity, either through 
bringing it into close contact with RNA-bound RIG-I or by promoting its E3 ligase activity. 
Conversely, RNA binding could negatively regulate TRIM25 activity in this pathway, for 
example through sequestration of TRIM25 away from RIG-I, as has been shown with 
Dengue virus151. The recently uncovered direct restriction of IAV transcription by TRIM25 
also underlines the importance of determining the mechanism of TRIM25 RNA binding as 
TRIM25 interacts with vRNPs in an RNA-dependent manner220. 
Previous results from our lab have shown that TRIM25 binding to pre-let-7a-1 can influence 
the stability of the RNA216. This raises the question of whether TRIM25 is capable of 
influencing the stability, or any other properties, of other RNAs. This could prove important 
in many situations. For example, changes to gene expression are the root of many cancers 
and if TRIM25 is found to be a possible cause of these changes through its RNA binding 




TRIM25 RNA-binding is that it aids in the targeting of proteins to be ubiquitinated. For 
example, TRIM25 could use RNA as a scaffold to target other proteins that bind to the same 
RNA. As TRIM25 is capable of both K48 and K63-linked polyubiquitination, this could be 
important for targeting proteins for degradation or in modulating protein activity in 
signalling pathways. 
As such, this project had the following aims: 
• Elucidating the mechanism of TRIM25 RNA binding – This included determining any 
sequence specificity of the RNAs TRIM25 binds to and identifying the amino acids 
that are important for binding to RNA. 
• Identifying RNAs and proteins affected by loss of TRIM25 – This included generating 
TRIM25 knock-out cell lines and analysing the levels of RNAs or proteins that had 
changed in response to loss of TRIM25. 
• Determining if TRIM25 RNA binding has a function in its role in innate immunity – 
This included analysis of TRIM25s roles in both the RIG-I pathway and direct 









Templates for In Vitro Transcription 
 
Primers used for generation of templates for in vitro transcription of RNAs are shown in 
Table 2. 
Template F or R Sequence 
Pre-let-7a-1 F 5’-TAATAGGACTCACTATAGGTGAGGTAGTAGGTTCTATA-3’ 
Pre-let-7a-1 R 5’-GAAAGACAGTAGATTGTATA-3’ 
5’ppp-79 F 5’-TAATAGGACTCACTATAGGGAGACCATCTGCTACTCGA 
TCGATATCCTAGCATATTCGT-3’ 
5’ppp- R 5’-GATTATGCTAGGTACCAGTCAGAAGTGACCTCGAGCG 
TACGATATGCTAGGATATCG-3’ 
5’ppp-UA F 5’-TAATACGACTCACTATAGGGAGACCATCTGCTAC 
CGATATATAGTTTAAAAGGA-3’ 
5’ppp-UA R 5’-GATTATGCTAGGTACCAGTCAGAAGTGTATAGTTTA 
CTCCTTTTAAACTATATATCG-3’ 
5’ppp-AU F 5’-TAATACGACTCACTATAGGGAGACCATCTGCTAC 
CGATATATAGTTTAAAAGGA-3’ 
5’ppp-AU R 5’-GATTATGCTAGGTACCAGTCAGAAGTGTATAGTTAT 
CTCCTTTTAAACTATATATCG-3’ 
Table 2 – Primers used for generation of templates for in vitro transcription of RNAs. All PCR 
products contained a promoter for T7 RNA polymerase. Pre-let-7a-1 primers were used for 
pre-let-7a-1 WT and all mutants. 
 
Sequencing 
Primers used for amplifying regions of genes to be sequenced or for sequencing reactions 






Name F or R Sequence 
CMV F 5’-CGCAAATGGGCGGTAGGCGTG-3’ 
TRIM25 genomic F 5’-TCCTCTCGAGCTAGGTTTCG-3’ 
TRIM25 genomic R 5’-ATTGTGCTGGGAACATTTGC-3’ 





Primers used for quantification of RNAs by qRT-PCR are shown in Table 4. 
Name F or R Sequence 
GAPDH F 5’-GAGTCAACGGATTTGGTCGT-3’ 
GAPDH R 5’-TTGATTTTGGAGGCATCTCG-3’ 
18S F 5’-GTAACCCGTTGAACCCCATT-3’ 
18S R 5’-CCATCCAATCGGTAGTAGCG-3’ 
TRIM25 F 5’-CCAAGAGGGATGAGTTCGAG-3’ 
TRIM25 R 5’-GCTTCAGCTCGTTTTTGAGG-3’ 
cMyc F 5’-TCGGATTCTCTGCTCTCCTC-3’ 
cMyc R 5’-CCTGCCTCTTTTCCACAGAA-3’ 
MKNK2 F 5’-GCCAAAGACCTCATCTCCAA-3’ 
MKNK2 R 5’-CAGCTGTTCCTCTGCAGGAC-3’ 
MALAT1 F 5’-CCCACCCCCTTAATCAGACT-3’ 
MALAT1 R 5’-CAACAGCACAGCGGTACACT-3’ 
LINC00324 F 5’-TGTCAGCACGCAGAGTGTAA-3’ 
LINC00324 R 5’-AGGAAGGCCAAACTCTCCTC-3’ 
SLC7A5 F 5’-GAAGGCACCAAACTGGATGT-3’ 
SLC7A5 R 5’-GGGTCACCTGCCACTCTTTA-3’ 
ZAP F 5’-TGCGATAACCTGCATCTCTG-3’ 
ZAP R 5’-ATCACTTTGGAGGAGGAGCA-3’ 
SUB1 F 5’-TCAAGCTCTTCTGGCAGTGA-3’ 
SUB1 R 5’-AAGATGACAGGGCTCTCGAA-3’ 
HERC2 F 5’-AAAAATTGCTGCCCATTCTG-3’ 
HERC2 R 5’-TCACCTTAGGCTCCTCCAAA-3’ 
WDR91 F 5’-GAACACCGTGTACAGCATCG-3’ 
WDR91 R 5’-CCGAGTCAAAAGCGAAGAGT-3’ 
SYBU F 5’-CTCCTGGACAGCGCGATG-3’ 
SYBU R 5’-TCAAGAGTCAAATGGGCTGTGGC-3’ 
PCDH11X F 5’-GAAACAACCTCAGCGACTCC-3’ 
PCDH11X R 5’-CTCCGGTATGTGATCTGTGGA-3’ 
SERPINB5 F 5’-ACTAATCAAGCGGCTCTACG-3’ 
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Antibodies used in this project are shown in Table 6. 
 




Composition of buffers used in this project are shown in Table 7. 
 
Table 7 – Compositions of buffers and solutions used in this project. All concentrations 
shown are final concentrations in 1x solution. 
 
Target Dilution Species Source 
TRIM25 1:2000 Rabbit Monoclonal Abcam 
hnRNPA1 1:1000 Mouse Monoclonal Millipore 
hnRNPI 1:1000 Mouse Monoclonal Santa Cruz 
DHX9 1:2000 Rabbit Polyclonal Protein Tech 
T7 (HRP conjugated) 1:10000 Mouse Monoclonal Millipore 
Tubulin 1:40000 Mouse Monoclonal Sigma-Aldrich 
SERPINB5 1:1000 Rabbit Polyclonal GeneTex 
IRF-3 1:1000 Rabbit Polyclonal Cell Signalling 
Technologies 
Phospho-IRF-3 1:1000 Rabbit Polyclonal Cell Signalling 
Technologies 
Buffer Composition 
Buffer G 20 mM Tris-HCl pH7.5, 137 mM NaCl, 1 mM EDTA, 1% TritonX-
100, 10% glycerol, 1.5 mM MgCl2, X mM DTT, 1 mM PMSF 
BWB 1xPBS with 0.02% v/v Tween 20 
PXL 1xPBS with 1%v/v Igepal, 0.5%wt/v Sodium Deoxycholate, 0.1% 
wt/v SDS 
RNA Elution Buffer 0.3 M Sodium Acetate pH 5.2, 0.5 mM EDTA, 0.1%SDS 
Roeder D 100 mM Tris pH8, 100 mM KCl, 200 µM EDTA, 20% Glycerol, X 
mM DTT, 1 mM PMSF 
TBE  100 mM Tris, 100 mM Boric Acid, 2 mM EDTA, NaOH to pH 
TBS-T (pH7.5) 20 mM Tris, 150 mM NaCl, 0.1% Tween 20, HCl to pH 
Transfer Buffer 200 mM Glycine, 25 mM Tris, 10% Methanol 




In Vitro Transcription and RNA Purification 
 
DNA templates of pre-let-7a-1 and mutants or sgRNAs with a T7 promoter sequence were 
generated by PCR through amplification of the sequence of interest from a plasmid using 
Phusion polymerase (New England Biosciences, NEB). Reagents used for PCR amplification 
are shown in Table 8. Reactions were run initially at 98°C for 30 seconds before 35 cycles of: 
10 seconds at 98°C, 30 seconds at 55°C and 15 seconds at 72°C. Following these cycles 





Table 8 – Reagents used for generation of templates for in vitro transcription by PCR. 
 
Templates for 5’ppp-79 and mutants were generated by Klenow extension of two 
overlapping oligonucleotides using Klenow fragment polymerase. 5 µL of each of the 
forward and reverse oligonucleotides (100 mM) were mixed with 2 µL Klenow Buffer (New 
England Bioscience) in a total volume of 20 µL. These were heated to 100°C for 2 minutes 
before being allowed to cool slowly for 30 minutes to allow annealing. 1 µL 10 µM dNTPs 
and 1 µL Klenow Polymerase (New England Bioscience) were added and reactions were 
incubated for a further hour at 37°C. 
In vitro transcription reactions were set up as follows:  2.5 µL 10x T7 RNA Polymerase buffer 
(Lucigen), 1.25 µL 20 µM rNTPs, 1 µL NxGen T7 RNA polymerase (Lucigen), 0.5 µL RNase Out 
Component Volume (µL) 
Phusion Buffer 10 
10 µM dNTPs 1 
F Primer (10 mM) 2.5 
R Primer (10 mM) 2.5 
Plasmid 2 






(Invitrogen) and 2 µL template DNA in a total volume of 25 µL. Reactions were incubated 
for 90 minutes at 37°C. Subsequently, 10 in vitro transcription reactions were pooled and 2 
µL Turbo DNase (Invitrogen) was added and reactions incubated at 37°C for a further 10 
minutes. After this, 25 µL 3 M sodium acetate and 800 µL ice cold 100% ethanol were 
added before the mixture was precipitated for approximately 1 hour on dry ice. The 
precipitated mixtures were centrifuged for 15 minutes at 13,000rpm, 4°C , washed with 
1mL ice cold 70% ethanol and centrifuged for 2 minutes at 13,000rpm, 4°C. Ethanol was 
removed and the pellet resuspended in 40 µL H2O and 40 µL 2xUEO buffer before being 
loaded onto a pre-warmed 10% polyacrylamide, 7.5M Urea gel with TBE running buffer. 
The gel was then run for approximately 90 minutes at 50mA. After running, gels were 
stained with RNA staining solution to visualise RNA before RNA bands were excised. Excised 
RNA bands were incubated overnight in 300 µL RNA elution buffer before buffer was 
removed from the gel pieces and added to 700 µL 100% ethanol. Samples were precipitated 
either overnight at -20°C or for 1-2 hours on dry ice. Samples were then centrifuged for 15 
minutes at 13,000rpm, 4°C, washed with 1mL ice cold 70% ethanol and centrifuged again 
for 2 minutes at 13,000rpm, 4°C. Ethanol was removed and pellets were allowed to dry to 
remove residual ethanol before being resuspended in 22 µL H2O. RNA concentration was 
determined using a nanodrop spectrophotometer. 
 
Cell culture and transfections 
 
Cells were grown in Dulbecco’s Modified Eagle Media (DMEM) supplemented with 10% 




6-well or p100 plates 24 hours before transfection such that they reached a confluency of 
70% by the time transfection occurred. 
For transfections, DNA or RNA to be transfected was added to 250 µL (6-well) or 1.5mL 
(p100) Optimem serum-free media. 5 µL (6-well) or 30 µL (p100) Lipofectamine 2000 was 
also added to a separate tube containing 250 µL or 1.5mL Optimem. Both mixtures were 
incubated for 5 minutes at room temperature before the Lipofectamine mixture was added 
dropwise to the DNA/RNA mixture. This mixture was then incubated for 30 minutes at 
room temperature. Meanwhile, cells were washed with Optimem and fresh DMEM was 




Cells were washed twice in PBS and scraped in Roeder D buffer. Cells were lysed by 
sonication before being centrifuged for 5 minutes at 10,000rpm and 4°C to remove cell 
debris. Supernatant was removed to a fresh tube and protein concentration was 




Cells were washed twice in PBS before being resuspended in 1mL Tri-Reagent (Invitrogen). 
200 µL chloroform was added and samples were mixed vigorously by hand for 15 seconds, 
followed by being allowed to settle for 2-3 minutes at room temperature. Samples were 
centrifuged for 15 minutes at 12,000  rcf, 4°C and the aqueous phase (approximately 500 




by inversion before being incubated 10 minutes at room temperature. Following this 
samples were centrifuged for 10 minutes at 12,000 rcf, 4°C before being washed with ice 
cold 70% ethanol. Samples were further centrifuged for 5 minutes at 7500 rcf before 
ethanol was removed and pellets were allowed to dry to remove residual ethanol. Pellets 





Volumes of protein extract corresponding to 80µg protein were mixed with 5 µL 4x NuPage 
LDS Sample Buffer (Invitrogen), 2 µL 10x NuPage Sample Reducing Agent (Invitrogen) and 
Roeder D buffer to a final volume of 20 µL. Samples were boiled for 10 minutes at 70°C 
before being loaded on a NuPage 4-12% Bis Tris Protein Gel (Invitrogen) with NuPage MOPS 
SDS Running Buffer (Invitrogen). 10 µL protein ladder was also loaded. Gels were run for 1 
hour at 180V and subsequently transferred to a nitrocellulose membrane using Tris-Glycine 
transfer buffer. Membranes were blocked overnight in a 1 in 20 dilution of Western 
Blocking Reagent (Roche) in TBS-T. 
After blocking, primary antibodies were diluted as described in Table 6 in TBS-T with a 1 in 
20 dilution of Western Blocking Reagent and added to membranes. Membranes were 
incubated, rocking for one hour at room temperature before being washed with TBS-T 3 
times for ten minutes. Corresponding HRP-linked secondary antibodies were diluted as 
described and incubated, rocking with membranes for 1 hour at room temperature. 
Membranes were again washed 3 times with TBS-T for ten minutes before addition of 
SuperSignal West Pico Plus western blotting substrate (ThermoFisher). Membranes were 




To re-blot membranes for a different protein of interest, they were first stripped for 10 
minutes in a 1 in 10 dilution of ReBlot Plus Strong Antibody Stripping Solution (Chemicon) in 
TBS-T. Following this, blots were blocked for 30 minutes and re-probed with a new antibody 
as described previously. 
 
quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
 
The SuperScript II Platinum One-Step qRT-PCR Kit (Invitrogen) was used for qRT-PCR assays 
according to manufacturer’s instructions. Each reaction was performed with 500ng RNA in a 
total reaction volume of 25 µL with the primers indicated in Table 4. Reactions ran for 40 




In principle, RNA pulldowns seek to identify proteins that associate with a particular RNA by 
attaching the RNA of interest to agarose beads and incubating with whole cell extract. After 
washing out unbound proteins, bound proteins can be analysed by western blot or mass 
spectrometry221. Identified proteins do not necessarily bind directly to the RNA in question 
as they may interact with the RNA via interactions with another protein or RNA molecule. 
RNAs were covalently attached to adipic-acid coated agarose beads using sodium 
periodate222. A mixture was prepared containing 500 pmol RNA of interest, 100 mM sodium 
acetate and 5 mM sodium periodate in a total volume of 200 µL. A sample without RNA was 
also prepared at this stage for use as a beads-only control. Samples were wrapped in foil to 
protect from light and were incubated 1 hour at room temperature while rocking. 




RNA was precipitated on dry ice for 30 minutes. Samples were then centrifuged for 15 
minutes at 13,000rpm, 4°C, washed with 1mL ice cold 70% ethanol and centrifuged again 
for 2 minutes at 13,000rpm, 4°C. Ethanol was removed and pellets were allowed to dry to 
remove residual ethanol before being resuspended in 500 µL 100 mM sodium acetate pH 5. 
Adipic acid-coated beads were prepared by adding 250 µL resin to a fresh falcon tube per 
reaction and washing 3 times with 100 mM sodium acetate (spins of 3 minutes at 300rpm). 
Beads were resuspended in 100 mM sodium acetate such that there was 200 µL total 
volume per prepared RNA. 200 µL prepared beads were added to each tube of periodate-
treated RNA and incubated rocking at 4°C overnight, again wrapped in foil to protect from 
light. 
After incubation, 700 µL 4 M KCl was added to each tube and these were incubated, rocking 
for 30 minutes at room temperature. Subsequently non-bound RNA was washed out by two 
washes with 2 M KCl followed by three washes with Buffer G (spins of 2 minutes at 
3000rpm, 4°C). To the RNA-coupled beads was added 1mg protein extract, 1.5 mM MgCL2, 
25 mM Creatine-phosphate, 0.5 mM ATP and 5 µL RNase OUT in a total volume of 650 µL. 
Samples were incubated, rocking at 37°C for 30 minutes before beads were pelleted by 
centrifuging 3 minutes at 1000rpm, 4°C. Supernatant at this stage from beads-only controls 
was kept for use as a loading control (input). Samples were then washed 3 times in Buffer G 
(spins of 2 minutes at 1000rpm, 4°C). After the last wash, supernatant was removed and 
beads resuspended in 39 µL H2O, 15 µL 4x NuPage LDS Sample Buffer and 6 µL 10x NuPage 
Sample Reducing Agent. 13 µL Loading control samples were added to 5 µL NuPage LDS 
Sample Buffer and 2 µL 10x NuPage Sample Reducing Agent. Samples were boiled for 10 
minutes at 70°C before 30 µL of pulldown samples and 20 µL loading control was loaded 









A list of the buffers used in purification of proteins is found in Table 9. All buffers were 
passed through a 0.22nm filter before use. 




The full-length human 6xHis-tagged TRIM25 WT and TRIM25ΔRBD mutant were cloned into 
the pET30a plasmid, which was transformed into BL21 gold E. coli cells. 5mL overnight 
cultures were grown before expression cultures were set up in 250mL Superbroth with 50 
µg/mL kanamycin and 1mL of overnight culture. Cultures were grown to an OD of 0.6-0.8 
before 0.5 mM IPTG was added and cultures were incubated 22 hours at 30°C shaking at 
180rpm. After incubation, cultures were centrifuged for 15 minutes at 8000 rpm, 4°C and 
pellets were divided into 5g and snap frozen in liquid nitrogen. 5g pellets were resuspended 




20 mM Sodium Pyrophosphate pH7.4, 500 mM NaCl, 5 
mM MgCl2 
Binding Buffer 20 mM Sodium Pyrophosphate pH7.4, 500 mM NaCl, 10 
mM Imidazole 




10 mM Tris pH8, 300 mM NaCl, 2 mM DTT 
Cell Lysis Buffer 50mL Resuspension Buffer, 200 µL lysozyme (100mg/mL), 
50 µL DNase, 5 µL RNase (100mg/mL), 2 Complete 




a 0.6 x 30 mm needle. Samples were then passed through a cell disruptor at 25 kPsi, 
followed by 30mL lysis buffer and the resulting sample was centrifuged for 1 hour at 50,000 
rcf, 4°C. The supernatant was passed through a 5 µm filter, followed by a 0.45 µm filter. 
Samples were loaded onto an IMAC HiTrap 1 mL FF NiCl2 column (GE Life Sciences) and 
passed through with binding buffer before elution with elution buffer. 
Samples were concentrated to below 500 µL using a Vivaspin 6 30kD centrifugal 
concentrator (Sartorius Stedim) before being further purified by size exclusion 
chromatography. Size exclusion chromatography was performed using a Superdex 200 
10/300 GL column (Sigma-Aldrich). The column was primed and run with gel exclusion 
buffer. Subsequently, samples were further concentrated using a Vivaspin 5 30,000 MWCO 
centrifugal concentrator (Sartorius Stedim). 
 
RNA Footprinting/Structure Probing 
 
In vitro transcribed and purified pre-let-7a-1 was 5’ end-labelled with γ-ATP-32P using T4 
polynucleotide kinase (Roche) for 15 minutes at 37°C. End-labelled RNA was purified by gel 
electrophoresis as previously described. Structure probing reactions took place in a total 
volume of 8 µL with 1 µL RNA (~100,000 c.p.m) and 7 µL structure probing buffer containing 
0.2 mM Pb2+ or dilutions of 0.5, 0.25 or 0.125 units/ µL T1 RNase in H2O. 200ng purified His-
TRIM25 WT was added to the indicated reactions. T1 ladder was generated in the same 
manner with 1 unit/mL T1 RNase. Reactions proceeded for 10 minutes at 37°C before being 
stopped with 8 µL 2xUEO buffer. Samples were run on a 10% denaturing polyacrylamide-
urea gel as previously described before the gel was dried and exposed to a phosphoscreen 







EMSAs were performed with end-labelled pre-let-7a-1 probe and 0-2000 ng purified 
TRIM25 WT or TRIM25ΔRBD. 0.1 pmol probe and the indicated amount of purified protein 
in gel exclusion buffer were supplemented with 3 mM MgCl2, 0.5 mM ATP and 37.5 mM 
creatine phosphate in a total volume of 16 µL. Reactions were incubated for 1 hour at 4°C 
before addition of 16 µL 2x native loading buffer. Samples were loaded on a non-
denaturing 6% w/v polyacrylamide gel and run in 0.5x TBE buffer at 8 W. The gel was 
subsequently dried and exposed to a radiographic film that was scanned using a Fujifilm 
FLA 5000 scanner. 
 
Thermal Denaturation Assays 
 
Around 4 µM purified His-TRIM25 WT or His-TRIM25ΔRBD were mixed with 10 µL 5x Sypro 
Orange (ThermoFisher) to a total volume of 50 µL. Thermal denaturation assays were then 
performed on a Bio-Rad iQ5 iCycler, with readings taken at 30 second time points as 
temperature increased from 20°C to 70°C. The melting temperature was determined from 
the maximum of the first derivative of the melting curve. The mean melting temperature 
was determined from the average of three independent replicates. 
 
RNA-binding Protein Immunoprecipitation (RIP) 
 
HeLa cells were cultured in P100 plates and transfected with a plasmid encoding T7-tagged 




resuspended in 1mL PXL buffer and incubated ten minutes on ice before being centrifuged 
for 20 minutes at 13,000rpm, 4°C to remove cell debris. 50 µL Dynabeads (ThermoFisher) 
were washed 3 times in BWB buffer before resuspension in 50 µL BWB and addition of 1 µL 
anti-T7 antibody. Beads were incubated, shaking 30 minutes at room temperature before 
being washed 3 times in PXL buffer and resuspended in 20 µL PXL. Protein extracts were 
added to antibody-coupled beads and incubated, rocking 1 hour at 4°C before being 
washed 3 times with PXL. RNA was isolated by adding 1mL Tri-Reagent to beads and 
proceeding with RNA extraction as previously described. Levels of bound RNAs were 




Purified His-TRIM25 WT or His-TRIM25ΔRBD were run ar 0.75 mg/mL, 1 mL/min on a 
Superdex200 Increase 10/300 GL column in gel exclusion buffer (Table 9). This was attached 




30 µL Protein A beads were washed in Buffer G and resuspended in 500 µL Buffer G before 
1 µL anti-T7 antibody was added. Beads were incubated, rocking 30 minutes at room 
temperature and subsequently washed twice with Buffer G. 20 µL Protein A beads were 
washed in Roeder D buffer before 500 µg protein extract in a total volume of 500 µL Roeder 
D was added. Samples were incubated, rocking 30 minutes at room temperature before 
beads were pelleted by centrifugation for 3 minutes at 4000 rpm, 4°C. Supernatant from 




temperature. Beads were washed 3 times in Buffer G before addition of 26 µL H2O, 10 µL 4x 
NuPage LDS Sample Buffer and 4 µL 10x NuPage Sample Reducing Agent and boiled for 10 
minutes at 70°C. 20 µL of this was run on a gel with 40 µg of the original extract used as a 
loading control. Gels and western blotting were run as previously described. 
 
In Vitro Ubiquitination 
 
Initially, IP of T7- tagged TRIM25 or mutants was performed as previously described. After 
the last wash with Buffer G, the components required for ubiquitination, purified Ube1, His-
Ube2D3 and ubiquitin (all from UBP-Bio) were added. For TRIM25 auto-ubiquitination, 1 
mg/mL Ube1, 2 mg/mL His-Ube2D3 and 50 mg/mL ubiquitin were added. For ZAP 
ubiquitination 5 mg Ube1, 10 mg/mL His-Ube2D3 and 250 mg/mL ubiquitin were used. 
Samples were incubated, shaking for 1 hour at 37°C before being prepared for running on a 
protein gel and western blot as previously described for IPs. 
For RNase experiments, 5 µL RNase A/T1 Mix (ThermoFisher) was added to the sample 
during the initial pre-clearing phase of the IP. 
 
Generation of Knockout Cell Lines  
 
Two short guide RNAs (sgRNAs) targeting exon 1 of TRIM25 were designed by Nila Roy 
Choudhury (TRIM25 Left sgRNA – CCACGTTGCACAGCACCGTGTTC and TRIM25 Right sgRNA 
CTGCGGTCGCGCCTGGTAGACGG). Purified sgRNAs were produced by in vitro transcription 
as previously described. HeLa or HEK293 Cells were transfected with 50ng of each sgRNA in 
addition to 200 ng of GeneArt CRISPR Nuclease mRNA (ThermoFisher). Cells were incubated 




present in each well. Cells were grown until colonies were visible with the naked eye before 
cells were split into two more 96-well plates. Once cells had grown, one plate was used for 
immunoblot (dot-blot) analysis. 
Cells were washed twice in PBS before addition of 30 μL of Passive Lysis Buffer (Promega). 
Cells were incubated, rocking for 15 minutes at room temperature. 2 µL of protein extract 
from each well was spotted directly onto a nitrocellulose membrane. Membranes were 
blocked in Western Blocking Reagent at a 1 in 10 dilution in TBS-T for 1 hour before 
western blotting proceeded as previously described. Selected clones were picked from 
corresponding wells of the second 96-well plate and grown in 6-well plates before levels of 




Genomic DNA was isolated from cell lines using the GenElute Mammalian Genomic DNA 
Miniprep Kit (Sigma-Aldrich) according to manufacturer’s instructions. The region 
surrounding the target sequences of the sgRNAs was amplified by PCR using the primers 
described in Table 3. The PCR product was gel purified then cloned into a pJET vector using 
the CloneJET PCR Cloning Kit (ThermoFisher) according to manufacturer’s instructions and 
sequenced using the primer included in the kit. 
 
RNA Stability Assays 
 
Cells were grown in 6-well plates to 90-95% confluency before addition of 10 µg/mL 
Actinomycin D (Sigma-Aldrich). Total RNA was extracted from cells at the indicated time 




to levels of 18S rRNA. The SuperScript II Platinum One-Step qRT-PCR Kit (Invitrogen) was 
used for qRT-PCR assays according to manufacturer’s instructions. Each reaction was 
performed with 500ng RNA in a total reaction volume of 25 µL with the primers indicated in 
Table 4. Reactions ran for 40 cycles and were performed on a Roche 480 LightCycler. 
Reactions for 18S rRNA were first diluted 1 in 100 from the original samples such that 5ng 




RNA was extracted from HeLa WT or TRIM25 KO cells using Tri-Reagent as previously 
described. To ensure purity, RNA samples were subjected to a second round of purification 
using Phenol:Chloroform:Isoamyl Alcohol 25:24:1 (Sigma-Aldrich). Equal parts phenol-
chloroform reagent and RNA samples were mixed and subsequently centrifuged for 5 
minutes at 12,000 rcf, room temperature. The aqueous phase containing purified RNA was 
transferred to a fresh tube and this process was repeated two more times. 
RNA purity and integrity was analysed on an Agilent 2100 Bioanalyzer to ensure that total 
quantity of RNA, OD260/280 ratio and 28S:18S rRNA ratios met minimum standards for 
RNAseq analysis. Samples were subsequently sent to BGI Tech Solutions for library 
preparation, sequencing and analysis. Additional analysis was performed by Shaun Webb 
(University of Edinburgh). 
 





IAV A/PR/8/34 (PR8) virions were generated using an 8 plasmid reverse genetics system as 
described by de Wit et al. 223. In short, this strategy uses pDUAL plasmids encoding each of 
the 8 segments of the PR8 genome under both a positive sense RNA Polymerase II 
promoter and a negative sense RNA polymerase I promoter. This results in the transcription 
of positive sense mRNA encoding the viral proteins as well as negative sense vRNA. Once 
translated, the viral proteins and vRNA assemble into vRNPs that transcribe more mRNA 
and replicate vRNA. Viral proteins and vRNA can assemble into mature IAV virions that are 
released from cells into the supernatant and can then be harvested and used to infect 
Madin-Darby Canine Kidney (MDCK) cells, allowing the virus to multiply and generate a 
working virus stock. 
250 ng of each pDUAL plasmid was transfected into HEK293T cells. To create a negative 
control for use in future experiments this was repeated minus the plasmid encoding 
segment 1, resulting in no mature virions being produced. Also, PR8 NS1 R38K41A mutant 
virus was generated in the same way but the plasmid encoding segment 8 of the genome 
was replaced with one encoding the indicated mutation. After 24 hours, media was 
replaced by virus growth medium (VGM, DMEM supplemented with 0.14% BSA and 1 
µg/mL TPCK-treated trypsin). After a further 48 hours, P0 virus stock was harvested by 
removing VGM from cells and centrifuging this at 13,000 rpm for 1 minute to pellet any 
detached cells. P0 stock was used to infect MDCK cells in a T25 flask. MDCK cells were first 
washed 2 times with serum-free DMEM before addition of 1 mL VGM and 100 µL P0 stock. 
Cells were incubated 1 hour at 37°C before the addition of a further 5 mL VGM. After 48 
hours P1 stock was harvested, media was removed from cells and cells were pelleted as 
before. Supernatant was then aliquoted into 100 µL portions and viral titre was calculated 







MCDK cells were seeded at 1.5x106 cells per well in 6-well plates in standard growth media. 
After 24 hours, serial 10-fold dilutions of the virus samples to be titred were made up to a 
dilution of 1x10-8 in serum-free DMEM. MDCK cells were washed with DMEM before 
addition of 800 µL virus dilutions (from 10-3 to 10-8 in the same 6-well plate). Cells were 
incubated for 1 hour at 37°C before overlaying with Avicell overlay media (50% DMEM, 50% 
2.4% Avicell, supplemented with 0.14% BSA and 1 µg/mL TPCK-treated trypsin). Cells were 
incubated for 48 hours at 37°C before 1 mL 10% formaldehyde was added per well. Cells 
were incubated 1 hour at room temperature before media/formaldehyde were removed 
and 0.1% crystal violet (in methanol) was added to stain. After 30 minutes, plates were 
washed with water and plaques were counted to calculate titre in plaque forming units 
(pfu)/mL of the original virus stock. 
 
Infection of Cells with IAV 
 
HEK293 cell lines were infected with PR8 WT or PR8 NS1 R38K41A at the indicated 
multiplicity of infection (MOI). Cells were grown such that there were 1x107 cells per well 
before growth media was removed and 400 µL serum-free DMEM was added. Virus stocks 
were diluted in DMEM such that the correct number of virus particles were present in 100 
µL for the desired MOI. 100 µL virus dilution was added per well and cells were incubated 
for 1 hour at 37°C. Media was removed and 1 mL VGM was added before cells were 
incubated for the indicated times. Virus titre in supernatant was determined by plaque 







Western Blot and HEKBlue Assays 
 
Cells at 70% confluency were transfected with 100 ng/mL 3p-hpRNA (Invivogen) as 
previously described and incubated for 6 hours. Protein extracts and western blotting 
proceeded as previously described but supernatants from cell media were taken for 
analysis using the HEKBlue system. 20 µL of the supernatant or an IFNα/β standard 
containing indicated units of purified IFNα and IFNβ were added to 50,000 HEK-Blue cells 
(Invivogen) in a total volume of 200 µL and incubated for 24 hours. 5 µL of the resulting 
supernatant was added to 180 µL QUANTI-Blue (Invivogen) in a 96-well plate and incubated 




For luciferase assays, cells were transfected with 100 ng/mL 3p-hpRNA along with a Firefly 
luciferase reporter under the IFNβ promoter and Renilla luciferase under a constitutive 
Thymidine Kinase (TK) reporter. The cells were incubated for 24 hours post-transfection 
before extraction with passive lysis buffer (PLB, Promega). Cells were washed twice in PBS 
before addition of 500 μL of PLB and were incubated, rocking for 15 minutes at room 
temperature.  Protein extracts were moved to fresh tubes and centrifuged for 5 minutes at 
10,000 rpm, 4°C to pellet cell debris. Activity levels were measured for Firefly and Renilla 
luciferase using the Dual-Luciferase Reporter Assay System (Promega) according to 
manufacturer’s instructions. In short, 50 µL Luciferase assay buffer was added to 5 µL 




Stop and Glo buffer was added and a reading taken for Renilla luciferase activity. Activity of 




HEK293 cell lines were transfected with 250 ng each of pDUAL plasmids encoding segments 
1, 2, 3 and 5 of the IAV genome (PA, PB1, PB2, NP) along with a Firefly luciferase reporter 
plasmid under the control of an RNA polymerase I promoter. The luciferase construct is in 
the negative sense and flanked by the untranslated regions of IAV segment 8. As such, it 
will resemble a vRNA to the vRNP and must be transcribed to positive sense mRNA to be 
able to be translated into luciferase protein. A negative control in which segment 5 of the 
IAV genome (NP) had been omitted was also performed. After incubation for 48 hours, a 













TRIM25 has been shown to bind to RNA previously, but little is known about the 
mechanism of how this occurs or any functions this activity might have. The aim of this 
section of the project was to determine how TRIM25 binds to RNA, as well as to design 
mutants of either TRIM25 or its RNA binding partners that do not bind to each other and 
could thus be used in experiments to uncover the function of TRIM25 RNA binding.  
TRIM25 does not have a canonical RNA-binding domain (RBD) but there is evidence that 
removing its coiled-coil domain impairs RNA binding215. Previous work in the lab has shown 
that TRIM25 binding to pre-let-7a-1 can affect the stability of the RNA by recruitment of the 
terminal uridylase TUT4, which adds a poly(U) chain to the 3’ end of the pre-miRNA, leading 
to degradation by the exonuclease Dis3L2216. The mechanism of TRIM25’s involvement in 
this process, as well as its ubiquitination target(s), are not yet known. In order to determine 
the effects of TRIM25 RNA binding on any of its functions it was first important to 
understand how TRIM25 binds to RNA. This would allow the design of mutants of TRIM25 
that do not bind to RNA or RNAs that do not bind to TRIM25. These mutants could then be 
used in experiments to elucidate the functions of TRIM25 RNA binding by comparing them 
to wild-type (WT) TRIM25 or RNAs. Two strategies were used in this project to further 
understand the mechanisms underpinning TRIM25 RNA binding. Firstly, I attempted to 
identify any sequence motifs required for TRIM25 RNA binding. This would enable the 




TRIM25 binding to be induced in previously non-binding RNAs by addition of the identified 
motif. Secondly, identifying the amino acids of TRIM25 that are important for RNA binding 
would allow the design of a non-RNA binding TRIM25 mutant by mutagenizing or deleting 
these residues. In addition, this would provide insights into how a protein with no canonical 
RBD can bind to RNA, which may also apply to other non-canonical RBPs. 
 
The GGAGAU motif of pre-let-7a is not necessary for TRIM25 RNA-
binding 
 
TRIM25 has been shown to bind to RNA on multiple occasions. Previous work in this lab 
identified the GGAGAU motif in the terminal loop of pre-let-7a-1 as being important for 
TRIM25 binding to pre-let-7a-1 with a minimal terminal loop216. This was shown through 
RNA pull-down assays with a mutant of pre-let-7a-1 where GGAGAU of a minimal pre-let-
7a-1 terminal loop has been mutated to GGAGUA216. In this experiment, the RNA with an 
intact GGAGAU motif in the minimal terminal loop (pre-let-7a-1@2) showed increased 
binding to TRIM25 compared to the GGAGUA mutant (pre-let-7a-1@3). To further 
determine the importance of the GGAGAU motif to TRIM25 RNA-binding activity two more 
mutants of pre-let-7a-1 were designed; a full-length pre-let-7a-1 with just the switch from 
GGAGAU to GGAGUA (pre-let-7a-1/4.2) and a mutant where the terminal loop of pre-let-
7a-1 had been replaced with that of pre-miR-16 (pre-let-7a-1/16)(FIG. 6A). In addition to 
this a 79nt synthetic viral RNA (5’ppp-79) with unknown TRIM25 binding potential was 
used. This RNA had previously been shown to activate RIG-I signalling in a cell-free 
system116. It was hoped that modulating its ability to be bound by TRIM25 would allow it to 
be used to test whether TRIM25 binding to an RNA might have an effect on whether it can 




with either the GGAGAU motif (5’ppp-AU) or GGAGUA (5’ppp-UA) in an effort to increase 
binding to TRIM25 (FIG. 6A). TRIM25 binding to these RNAs was assayed by RNA pull-down. 
In vitro transcribed and gel-purified RNAs were covalently linked to adipic acid-coated 
agarose beads that were subsequently incubated with HeLa whole cell extract (WCE). After 
washing, proteins left bound to the RNAs were analysed by western blot (FIG. 6B). 5’ppp-
79, 5’ppp-AU and 5’ppp-UA all showed substantial binding to TRIM25 compared to a beads-
only control with TRIM25 binding to 5’ppp-UA being slightly more efficient. Pre-let-7a-1 
also showed binding to TRIM25 as expected, however both pre-let-7a-1/16 and pre-let-7a-
1/4.2 also bound, although at a lower level. DHX9, a double-stranded RNA binding protein, 
was used as a positive control and hnRNPA1 was used as a specificity control as it should 
only bind to the RNAs containing the pre-let-7a-1 terminal loop224. HnRNPI was also used as 
a specificity control as it should not bind to pre-let-7a-1 but should to 5’ppp-79 due to its 
sequence specificity. This was indeed observed in the pull-down results. Taken together, 
these results suggest that although the GGAGAU motif may increase the efficiency of pre-
let-7a-1 binding to TRIM25, it is not required for binding and does not seem to make a 
difference in binding efficiency when added to another, unrelated, RNA. It is possible that 
the GGAGAU motif in the pre-let-7a-1 terminal loop helps to stabilise the structure of the 
loop and it is this structure that TRIM25 is recognising, not the GGAGAU motif itself. 
 
Mutating a potential TRIM25 binding site on pre-let-7a-1 does not reduce 
binding 
 
One method for determining the RNA nucleotides directly bound by a protein is through a 
technique called RNA foot printing225. This involves incubating purified protein of interest 













Figure 6 - The GGAGAU motif is not required for TRIM25 RNA binding. (A) Secondary 
structures of RNAs tested for TRIM25 binding. Secondary structures are those with 
minimum free energy and were predicted by RNAfold (http://rna.tbi.univie.ac.at/cgi-
bin/RNAWebSuite/RNAfold.cgi) and visualised using forna 
(http://rna.tbi.univie.ac.at/forna). (B) WB analysis of RNA pulldown assay of selected RNAs 
coupled to beads and incubated with HeLa WCE. Input lane represents 4% (40 µg) of 





at the 5’ end (pre-let-7a-1) and subjecting the RNA to partial RNase T1 or lead ions (Pb2+) 
cleavage. As the purified protein binds on the RNA, it should protect the nucleotides it is 
bound to (and potentially some of the surrounding area) from digestion and as such this 
binding site can be visualised by running the RNA on a gel after digestion then developing 
on radioactivity-sensitive film. The protein-bound area of the RNA is identified by the 
absence of bands in the protein-bound sample compared to a protein free control. Purified 
TRIM25 used in this experiment was expressed in E. coli cells with a 6xHis tag at the N-
terminal of the protein. It was subjected to affinity chromatography on a Nickel column 
(IMAC HiTrap 1 mL FF) followed by size exclusion chromatography. This experiment was 
performed with lead ions (Pb2+), which cleave phosphodiester bonds after any nucleotide, 
and T1 RNase, which cleaves after guanosine (G) nucleotides (FIG. 7A). A small sequence 
protected by purified TRIM25 was identified in the Pb2+ treated sample, corresponding to a 
repeated 5’-CACCCACC-3’ sequence in the terminal loop of pre-let-7a-1 (nucleotides 37-44). 
These nucleotides were mutated to either G or U to generate the mutants pre-let-7a-1/GG 
and pre-let-7a-1/UU (FIG. 7B). To determine if these mutants could still bind TRIM25 with 
the identified binding motif removed an RNA pull-down assay was performed (FIG. 7C). 
Neither of the two mutants lost any binding affinity for TRIM25, suggesting that the 5’-
CACCCACC-3’ sequence is not the only place that TRIM25 can bind to pre-let-7a-1. 
A subsequent cross-linking immunoprecipitation and sequencing (CLIP-seq) experiment 
performed in the lab showed that TRIM25 does not have a strong consensus sequence for 
RNA binding, instead showing a preference for G-rich areas219. CLIP involves cross-linking 
the target protein (in this case T7-TRIM25) to RNA by UV irradiation followed by 
immunoprecipitation of the target. RNAs cross-linked to the target protein are digested 
such that only the sequence in close contact with the protein of interest remains and these 






Figure 7 – Mutagenizing TRIM25-binding residues on pre-let-7a-1 does not result in less 
binding to TRIM25. (A) RNA footprinting assay. Pre-let-7a-1 end-labelled with γ-ATP-32P 
was partially digested with T1 RNase or Pb2+ in the presence or absence of 200ng purified 
His-TRIM25. (B) Predicted secondary structures of pre-let-7a-1 WT, /GG and /UU. The 
mutated region is marked in green for pre-let-7a-1 WT and red for pre-let-7a-1/GG and 
/UU. (C) WB analysis of RNA pulldown of pre-let-7a-1 WT, /GG or /UU coupled beads with 





 G-rich sequences, with GC-rich content of RNAs also being slightly higher than would be 
expected if it had no preference. However, the finding that TRIM25 does not have a strong 
consensus motif may explain why mutagenizing the putative TRIM25-binding sequences of 
pre-let-7a-1 does not reduce TRIM25 binding to the RNA. 
 
Amino acids 470-508 in the PRY/SPRY domain of TRIM25 contribute to 
RNA binding 
 
As it proved difficult to identify any RNA motif required for RNA binding, another strategy 
for elucidating how TRIM25 binds to RNA was required. Using a technique called ‘mRNA 
interactome capture’ our collaborator, Alfredo Castello (University of Oxford), identified 
residues which are in close contact with RNA for a number of RNA-binding proteins226. The 
technique involves cross-linking proteins to RNAs using UV irradiation followed by the 
capture of mRNAs with an oligo (dT) probe attached to beads. Proteins are subsequently 
cleaved by protease digestion (LysC/ArgC), leaving just the residues close to the RNA still 
attached by the crosslink, before another round of oligo (dT) capture. A final round of 
RNase digestion and protein digestion by trypsin occurs before the peptides are identified 
by mass spectroscopy (MS). Peptides released at the earlier digestion step are also 
separately treated with trypsin and identified by MS. One of the peptides identified by this 
screen as being in close proximity to RNA was residues 470-508 of human TRIM25, located 
in the PRY/SPRY domain. Peptides from the other TRIM25 domains were identified in the 
fraction released following the first digestion step (FIG. 8A). To test if residues 470-508 
were important for RNA binding a TRIM25 mutant was generated with these residues 
deleted, called TRIM25ΔRBD (delta RNA Binding Domain) (FIG. 8B). T7-tagged TRIM25ΔRBD 






Figure 8 – Deleting a putative RNA-binding peptide abolishes TRIM25 binding to pre-let-7a-
1. (A) mRNA capture assay result for TRIM25. Blue lines indicate peptides from TRIM25 that 
were identified in the fraction of peptides released after one digestion step. Red line 
indicates TRIM25 peptide identified in the RNA-bound fraction. (B) Schematic 
representation of TRIM25 WT and TRIM25ΔRBD. Residues 470-508 of TRIM25 WT were 
deleted to generate TRIM25ΔRBD. (C) WB analysis of RNA pulldown assay of pre-let-7a-1 
with WCE of HeLa cells transfected with T7-TRIM25 WT or TRIM25ΔRBD or untransfected. 
Input lanes represent 4% (40 µg) of extracts used for pulldowns. Note should be taken of a 
non-specific band that appears in the pre-let-7a-1 pulldown lanes for untransfected extract 
and T7-TRIM25ΔRBD transfected extract when probed with anti-T7 antibody. (D) & (E) 
Electromobility shift assay (EMSA) with radiolabelled pre-let-7a-1 and purified 6His-TRIM25 
WT (D) or 6His-TRIM25ΔRBD (E). Lanes 2-11 in these figures represent increasing amounts 
of TRIM25 protein from 200-2000 ng rising in increments of 200 ng. (F) Thermal 




and 70°C with 30 seconds at each step. Approximately 4 µM of each protein was used. 
Figure A courtesy of Alfredo Castello. The experiments shown in figures D, E and F were 




RNA-binding activity by RNA pull-down with pre-let-7a-1 (FIG. 8C). T7-TRIM25 WT showed 
strong binding to pre-let-7a-1 as expected, however T7- TRIM25ΔRBD binding was 
substantially reduced, even though endogenous TRIM25 was present in the HeLa WCE. This 
is interesting as TRIM25 is known to dimerise through its coiled-coil domain, suggesting 
that having one copy of TRIM25ΔRBD in the dimer is sufficient to disrupt RNA binding. Due 
to the presence of other proteins and RNAs in the WCE, RNA pull-down assays do not 
confirm if the protein is binding directly to RNA. To further confirm that TRIM25ΔRBD 
cannot bind pre-let-7a-1 directly as efficiently as TRIM25 WT an electro-mobility shift assay 
(EMSA) was performed. This involves incubating purified protein with radiolabelled RNA 
and running them on a polyacrylamide gel before visualising on radioactivity-sensitive film 
to detect the RNA. Free RNA will run further on the gel than RNA that is bound to protein, 
resulting in a characteristic ‘shift’ in the visualised band if a complex is formed. This assay 
was performed with 5’-end-radiolabeled pre-let-7a-1 and purified 6His-tagged TRIM25 WT 
or TRIM25ΔRBD (FIG. 8D and 8E). With TRIM25 WT a shift was seen, indicating complex 
formation, and at higher concentrations of TRIM25 WT almost all RNA present was bound, 
however with TRIM25ΔRBD no shift was seen, even at high concentrations of protein, 
indicating no complex formation. This suggests that at least in these conditions 
TRIM25ΔRBD cannot directly bind to pre-let-7a-1. To ensure that TRIM25ΔRBD did not 
undergo large-scale changes in protein folding compared to TRIM25 WT due to the 39 
amino acid deletion, it was subjected to a thermal denaturation assay (FIG. 8F). This 
showed that both proteins have Tms of around 43.5°C, suggesting that overall TRIM25ΔRBD 
folding was not affected. This does not, however, ensure that folding of the PRY/SPRY 
domain alone is not affected by the deletion. 
In order to test whether TRIM25ΔRBD could bind to other RNAs apart from pre-let-7a-1 an 




TRIM25ΔRBD were transfected into HeLa cells and immunoprecipitated with anti-T7 
antibody. Bound RNAs were subsequently analysed by quantitative real-time polymerase 
chain reaction (qRT-PCR). The RNAs analysed were chosen from those identified as binding 
to TRIM25 in the CLIP-seq experiment previously performed in the lab. All of the RNAs 
tested showed markedly reduced binding to T7-TRIM25ΔRBD compared to T7-TRIM25 WT, 
with most having binding at the same level as the mock (no T7-tagged TRIM25 present) 
(FIG. 9A and 9B). For Trim25 mRNA, there was an increase in binding to T7-TRIM25ΔRBD 
compared to mock, however this is likely due to the antibody picking up nascent T7-
TRIM25ΔRBD that was still associated with the ribosome. The lack of binding to T7-
TRIM25ΔRBD was seen for mRNAs and non-coding RNAs (FIG. 9A) and miRNAs (FIG. 9B). 
These results suggest that TRIM25ΔRBD’s lack of binding to RNA is not limited to pre-let-7a-
1 and encompasses the majority of tested endogenous RNAs. It should, however be noted 
that this experiment does not contain a negative control as every RNA tested showed 
binding to TRIM25. It would be interesting to test abundant RNAs that were not identified 
as TRIM25 binding partners in the CLIP assay as these may provide a suitable negative 
control for TRIM25 RNA binding. 
 
Two intact TRIM25-PRY/SPRY domains in a dimer are likely important for 
TRIM25 RNA binding 
 
As deletion of the 39 amino acid ‘RBD’ from the PRY/SPRY domain of TRIM25 is sufficient to 
disrupt TRIM25 RNA binding, knowing whether the PRY/SPRY domain alone is sufficient for 
RNA binding would help to elucidate the mechanism of TRIM25 RNA binding. As such, a 
construct encoding T7-tagged TRIM25-PRY/SPRY was generated and tested for its ability to 





Figure 9 – TRIM25ΔRBD shows reduced binding to every RNA tested in an RNA 
immunoprecipitation (RIP) assay. (A & B) qRT-PCR analysis of RNAs (A) or miRNAs (B) bound 
to TRIM25 WT or TRIM25ΔRBD in RIP assay. HeLa cells were transfected with T7-TRIM25, 
T7-TRIM25ΔRBD or mock transfected and extracts were subjected to immunoprecipitation 
with an anti-T7 antibody before bound RNAs were isolated. Values are shown relative to 
mock which is set at 1. Figures represent mean and standard deviation of three 
independent experiments. The experiments shown in this figure were performed by Nila 


























Figure 10 – TRIM25-SPRY and TRIM25ΔCC do not bind to pre-let-7a-1. (A) WB analysis of 
RNA pulldown of pre-let-7a-1 with WCE of HeLa cells transfected with either T7-TRIM25 WT 
or T7-TRIM25-SPRY. (B) WB analysis of RNA pulldown of pre-let-7a-1 with WCE of HeLa cells 





to pre-let-7a-1 compared to a beads only control, implying that it is not sufficient for RNA 
binding. One reason for this could be that the PRY/SPRY domain must be part of a dimer, as 
it is in full-length TRIM25, to be able to bind RNA. This would also explain why TRIM25ΔRBD 
does not bind RNA even in the presence of endogenous TRIM25 WT. Previous work has  
suggested that TRIM25 lacking the coiled-coil domain, which mediates dimerization, cannot 
bind to RNA215. This was tested with pre-let-7a-1 in an RNA pull-down after generating a T7-
tagged TRIM25 mutant in which the coiled-coil domain had been deleted (T7-TRIM25ΔCC) 
(FIG. 10B). As expected, T7-TRIM25ΔCC did not bind to pre-let-7a-1 in the RNA pull-down. 
In order to ensure that TRIM25ΔRBD was capable of dimerizing in the same way as TRIM25 
WT it was subjected to analysis by Size Exclusion Chromatography followed by Multi-Angle 
Light Scattering (SEC-MALS). This experiment consists of separating purified proteins by size 
exclusion chromatography so that oligomers of the same order are grouped together 
followed by detecting the molecular weight and radius of the particles present by 
measuring the extent of light scattering by the protein sample. In short, this technique 
determines the molecular weight of protein complexes formed in solution, which can be 
used to determine if a protein exists as a monomer, dimer or higher order oligomer. SEC-
MALS was performed with either purified His-TRIM25 WT or His-TRIM25ΔRBD (FIG. 11A). 
TRIM25 was present with a molecular weight of 263 ± 5.3 kDa and TRIM25ΔRBD was 
present with a molecular weight of 258 ± 5 kDa. This suggests that both purified proteins 
are forming tetramers in solution. This agrees with the work of others that found that 
TRIM25 often forms tetramers composed of two TRIM25 dimers. Overall this suggests that 
TRIM25ΔRBD oligomerisation activity does not deviate from that found in TRIM25 WT. 
Although SEC-MALS can determine if TRIM25ΔRBD homo-oligomerises it cannot determine 





Figure 11 – TRIM25ΔRBD maintains the dimerization ability of TRIM25 WT. (A) SEC-MALS 
trace of TRIM25 WT and TRIM25ΔRBD. Samples were run at approximately 0.75mg/mL. (B) 
WB analysis of T7 Co-IP of HeLa TRIM25 KO cells transfected with T7 or eGFP-tagged 
TRIM25 WT and TRIM25ΔRBD. Input lanes represent 10% (50 µg) of WCEs used for Co-IP. 
Beads lanes represent Co-IP performed with uncoupled Protein A beads. (C) WB analysis of 
control Co-IPs showing eGFP-tagged proteins are not pulled down in the absence of T7-
tagged proteins. The experiments shown in these figures were performed by Nila Roy 




heterodimerise with TRIM25 WT as this would help elucidate whether an intact PRY/SPRY 
domain is needed in both copies of TRIM25 in a dimer to enable RNA binding. In order to 
find this out HeLa TRIM25 knockout (KO) cells (further information in chapter 2) were co-
transfected with different combinations of T7 or eGFP-tagged TRIM25 WT and 
TRIM25ΔRBD before co-immunoprecipitation (Co-IP) with an anti-T7 antibody (FIG. 11B). 
The eGFP-TRIM25 fusion proteins were used as these could be distinguished by size from 
T7-TRIM25 constructs. This showed that eGFP-TRIM25ΔRBD can Co-IP with T7-TRIM25 WT 
and conversely eGFP-TRIM25 WT and Co-IP with T7-TRIM25ΔRBD. In addition, eGFP-
TRIM25 WT co-Co-IPs with T7-TRIM25 WT and eGFP-TRIM25ΔRBD Co-IPs with T7-
TRIM25ΔRBD. Neither eGFP-tagged protein precipitates in the absence of a T7-tagged 
protein in the anti-T7 Co-IP (FIG. 11C). These results provide further confirmation that 
TRIM25ΔRBD can homodimerise and suggest that TRIM25ΔRBD can heterodimerise with 
TRIM25 WT. Following on from this, these data suggest that TRIM25ΔRBD can probably 
heterodimerise with endogenous TRIM25 WT and the lack of RNA binding of TRIM25ΔRBD 
in the presence of endogenous TRIM25 WT, coupled with TRIM25-PRY/SPRY being 
insufficient for RNA binding, suggests that at least two intact PRY/SPRY domains in a dimer 
are required for TRIM25 RNA binding. 
 
TRIM25 requires RNA binding for efficient auto-ubiquitination 
 
TRIM25 is an E3 ubiquitin ligase and undergoes auto-ubiquitination on Lysine 117 (K117), 
which is present in the B-box domain of the protein152. Ubiquitination activity is dependent 
on the RING domain of TRIM25, as it is for all TRIM family proteins. To determine if auto-




assays were performed. T7-tagged TRIM25 WT or TRIM25ΔRBD were immunoprecipitated 
with an anti-T7 antibody before the addition of purified ubiquitin, the E2 Ube2D3 and the 
E1 UBE1 which comprise all the components required for TRIM25 ubiquitination activity. 
The samples were incubated for an hour at 37°C with time points taken at 5, 30 and 60 
minutes before being analysed by WB. Under these conditions T7-TRIM25 WT was 
efficiently ubiquitinated while T7-TRIM25ΔRBD was not (FIG. 12A). A negative control 
where Ube2D3 was excluded abrogated auto-ubiquitination by T7-TRIM25 WT showing that 
the E2 conjugating enzyme did not Co-IP with T7-TRIM25 WT in this experiment. The 
experiment was repeated with T7-TRIM25K117R and T7-TRIM25ΔRING, which should not 
be auto-ubiquitinated due to the absence of the auto-ubiquitinated residue and the RING 
domain, respectively. As expected, both of these proteins are not ubiquitinated efficiently 
after 60 minutes of incubation with the ubiquitination components (FIG. 12B). This confirms 
the specificity of this assay by showing that TRIM25 is not being ubiquitinated by another 
protein or on a different residue. To confirm that loss of RNA binding is responsible for the 
loss of TRIM25ΔRBD auto-ubiquitination, the in vitro ubiquitination assay was repeated 
with T7-TRIM25 WT in the presence of RNases A and T1 (FIG. 12C). Addition of the RNases 
after immunoprecipitation (at the same time as the ubiquitination components) greatly 
reduced polyubiquitination of T7-TRIM25 WT while monoubiquitination was mostly 
unaffected. This could be because of direct transfer of ubiquitin between the E2 Ube2D3 
and TRIM25 as monoubiquitination is abrogated in the absence of Ube2D3. Taken together, 
these results strongly suggest that binding to RNA greatly increases the efficiency of 
TRIM25 auto-ubiquitination. This could be because TRIM25 RNA binding elicits a change in 
the protein, for example in the protein structure, that allows efficient ubiquitination activity 





Further in vitro ubiquitination experiments in the lab identified ZC3HAV1 (zinc-finger 
antiviral protein, ZAP) as another target of TRIM25 for which loss of TRIM25 RNA binding 
reduces ubiquitination219. This was shown by the failure of TRIM25ΔRBD, or TRIM25 WT in 
the presence of RNase, to ubiquitinate ZAP while TRIM25 WT could in the absence of 
RNase219. This further implies the reliance of TRIM25 ubiquitination activity on RNA binding 
and gives an example of this occurring for aTRIM25 ubiquitination target. There are 
currently conflicting reports as to whether ubiquitination enhances the anti-viral role of 
ZAP, with reports indicating that the E3 ligase activity of TRIM25 is required for activation 






























Figure 12 – RNA binding is necessary for TRIM25 auto-ubiquitination activity. (A) In vitro 
ubiquitination of T7-TRIM25 WT and T7-TRIM25ΔRBD. T7-tagged proteins were 
immunoprecipitated from extracts with an anti-T7 antibody before the addition of 
recombinant, purified components 6His-Ube2D3, UBE1 and Ubiquitin which are required 
for ubiquitination. Samples were taken at 5, 30 and 60 minutes. A negative control was also 




immunoprecipitated T7-tagged proteins prior to the addition of ubiquitination components. 
(B) In vitro ubiquitination of TRIM25ΔRING and TRIM25K117R performed in the same way. 
(C) In vitro ubiquitination of T7-TRIM25 in the presence or absence of RNases. Purified 
RNases A and T1 were added subsequently to immunoprecipitation at the same time as 
ubiquitination components. The experiments shown in these figures were performed by 






The data presented here, as well as other work performed in the lab, suggest that TRIM25 
has a broad specificity of RNA binding, although it shows a preference for GC-rich 
sequences219. A mutant of TRIM25, TRIM25ΔRBD, which shows substantially reduced 
binding to RNA has been designed based on deletion of a peptide in the TRIM25 PRY/SPRY 
domain identified by mRNA interactome capture. This helped to validate this technique as a 
method of identifying RNA-binding peptides and provided a non-RNA binding mutant of 
TRIM25 that can be used in experiments to determine the functions of TRIM25 RNA 
binding. TRIM25ΔRBD was also shown to maintain the ability to dimerize with either itself 
or TRIM25 WT; however, its inability to bind RNA is maintained even in the presence of 
endogenous TRIM25 WT. This, along with the inability of TRIM25-PRY/SPRY alone or 
TRIM25ΔCC to bind RNA, suggests that TRIM25 dimerization is necessary for RNA binding 
and at least two copies of the PRY/SPRY domain are required. However, the exact 
mechanism of TRIM25 RNA binding remains to be uncovered, for example the individual 
residues that contact RNA. The best way of determining this would be x-ray crystallography 
or cryogenic electron microscopy (Cryo-EM) of TRIM25 in complex with RNA, although this 
can be difficult and time-consuming and was beyond the scope of this project. Finally, it 
was shown that TRIM25 ubiquitination activity, both auto-ubiquitination and ubiquitination 
of one of its target proteins (ZAP), was impaired by the loss of RNA binding. 
Interestingly, several other TRIM family proteins (as well as a total of around 100 human 
proteins) contain a PRY/SPRY, also known as a B30.2, domain and several of these proteins 
are also involved in innate immunity154,227. This raises the question of whether these 
proteins can also bind RNA and if this is important for their functions. To this end, work in 




family proteins (TRIM5, TRIM21, TRIM27 and TRIM65) that have a PRY/SPRY domain. Some, 
but not all, of these chimeric proteins were shown to bind to pre-let-7a-1 in an RNA pull-
down assay and a positive correlation was shown between the pull-down efficiency and the 
efficiency of auto-ubiquitination of these proteins219. This suggests that other TRIM family 
proteins may have the ability to bind RNA and that the ubiquitination activity of TRIM25 is 
reliant on RNA binding, not the exact sequence of the PRY/SPRY domain. Further 
experiments will be needed to determine if RNA binding activity of other TRIM proteins is 
required for their ubiquitination activity. It is also currently not known by what mechanism 
TRIM25 RNA binding contributes to its enzymatic activity. One possible model is that 
TRIM25 uses RNA as a scaffold to bring it into close proximity to its target proteins, allowing 
ubiquitination. Another model is that RNA binding induces a conformational change in the 
protein that increases the efficiency of its E3 ligase activity. In order to determine which of 










One way to determine the effects of removing the RNA binding ability of TRIM25 on its 
functions in the cell is to compare the ability of TRIM25 WT to TRIM25ΔRBD to perform 
these functions. In cells that express TRIM25 endogenously it is almost impossible to 
perform these experiments as the endogenous protein would likely be sufficient to mask 
any difference between additional WT or mutant protein. In addition, by reducing 
endogenous TRIM25 expression and analysing the cells’ phenotype (e.g. expression levels 
of TRIM25 RNA binding partners) it would be possible to discover novel functions of 
TRIM25. 
One way to reduce endogenous expression of a protein is through the use of RNA 
interference (RNAi)228. Small interfering RNAs (siRNAs) are short, double stranded RNAs 
that can silence gene expression by specific binding to mRNA, leading to mRNA degradation 
or preventing translation. RNAi can be a powerful tool in some situations however there are 
limitations. RNAi does not silence gene expression entirely, meaning that there will always 
be some endogenous protein left in the cell. In the case of TRIM25, previous work in the lab 
has shown that it is difficult to reduce levels to less than 30-40% of endogenous levels, 
which may be sufficient to perform some of its functions. In addition, RNAi is transient; 
meaning that in experiments run over a long period of time, levels of the protein will begin 
to return to normal and it may be difficult to see effects that require extended perturbation 
from steady state expression levels.  
Another option was to knock out the protein, i.e. to modify the DNA such that the gene 




endogenous protein whatsoever which makes it easier for TRIM25 WT and TRIM25ΔRBD to 
be directly compared. CRISPR/Cas9 is a recently developed method for the editing of DNA 
that can be used to disrupt a gene and prevent its expression or to introduce a new DNA 
sequence into the genome229,230. The Cas9 protein is added to cells along with a short guide 
RNA (sgRNA) that is targeted to the gene of interest. Cas9 cleaves the DNA in the region of 
the sgRNA on both strands, causing a double strand break. The DNA repair machinery then 
attempts to repair the break, often using non-homologous end joining, simply attaching the 
two broken ends of the DNA back together. This method of DNA repair is error prone and 
can easily introduce small deletions or insertions in the DNA sequence that will disrupt the 
target gene, particularly if the mutation causes a frame shift. A frameshift occurs when an 
insertion or deletion is of a number of nucleotides not divisible by 3, ‘shifting’ the open 
reading frame and causing transcription of an mRNA that encodes a completely different 
set of amino acids. It is also possible to introduce new DNA at the break point by including a 
DNA cassette with flanking sequences homologous to the sequences on either side of the 
break. This process is known as homology directed repair and can be used, for example, to 
add a tag to the protein of interest. 
The aim for this part of the project was to generate knockout (KO) cells for TRIM25 for use 
in further experiments and as such it was decided to use CRISPR/Cas9 to simply disrupt the 
gene without introducing any new sequences. This was done in HeLa cells as these had 
been used for previous experiments in the project and are easy to work with. TRIM25 KO 
cells were also generated for HEK293 cells as HeLa cells are not very permissive to virus 
infection and as such were not ideal for use in future experiments in this area. Another 
advantage of the HEK293 cell line used was that they contained a flippase recognition 
target (FRT) site that allows stable integration of a gene of choice into the genome231. This 




genome of TRIM25 KO cells to be expressed in a constitutive manner. This would be ideal 
for confirming whether phenotypes seen in TRIM25 KO cells were due to loss of TRIM25 
(i.e. they could be rescued by reintegration of TRIM25) as opposed to any off-target effects 
from CRISPR/Cas9 targeting, as well as comparing the ability of mutants of TRIM25 to 
perform its functions compared to WT protein. The strategy used for generating the KO 
cells was based on one used by Estep et al. whereby colonies were screened for expression 
of the target protein by dot immunoblot, allowing easy and fast screening of many colonies 
at once (FIG. 13A)232.  
 
HeLa TRIM25 KO cells were generated by CRISPR 
 
The first task of this part of the project was to design sgRNAs targeting TRIM25 for use in 
the CRISPR experiment. HeLa cells have an altered karyotype and contain three copies of 
chromosome 17, on which the TRIM25 gene is located, therefore all three copies must be 
disrupted to knock out TRIM25. Two sgRNAs were designed to target exon 1 of the TRIM25 
gene (FIG. 13B). Two sgRNAs were used to increase the chances of disrupting the gene and 
exon 1 was targeted as frameshift-causing mutations in this area would affect the entire 
protein, ensuring that it would not be expressed. The two sgRNAs were transcribed using in 
vitro transcription and subsequently gel purified. They were transfected into HeLa cells 
along with purified mRNA for the Cas9 nuclease. 48 hours post-transfection, cells were split 
into a 96-well plate such that the majority of wells had a single clonal colony growing in 
them. The cells were grown up before being split into two new 96-well plates, one of these 
being harvested for use in a dot immunoblot. Protein extracts were harvested using 30 µL 






Figure 13 - Knock out of TRIM25 by CRISPR. (A) Schematic of the strategy used for knocking 
out TRIM25 by CRISPR. Cells were transfected with 2 sgRNAs targeted at exon 1 of TRIM25 
and incubated for 48 hours before being split into individual clones in a 96-well plate. 
Clones were grown up and tested for TRIM25 expression by dot immunoblot to identify 
clone in which TRIM25 expression was reduced compared to a loading control. (B) The 




membrane. Clones were then screened by immunoblot for TRIM25 expression, with DHX9 
as a loading control (FIG. 14A). Several clones were identified from this as potentially having 
reduced TRIM25 expression (red circles). These clones were transferred from the second 
96-well plate to 6-well plates and were grown up before protein was extracted to validate 
levels of TRIM25 by western blot (FIG. 14B). Clone E10 (blue circles) was used as a positive 
control for TRIM25 expression. None of the clones tested showed complete loss of TRIM25 
expression, however several (E8, E11, F9, G8) showed reduced expression. Of these clone 
E8 showed the largest reduction in TRIM25 levels, with likely two of the three copies of 
TRIM25 being disrupted.  
Clone E8 was subjected to a second round of CRISPR/Cas9 treatment that was performed in 
the same way as the first. Again, several clones from this second round were identified as 
potential KO clones (FIG. 15A) and TRIM25 levels were validated by western blot, with WT 
HeLa cells and clone E8 used as controls (FIG. 15B). Every clone tested here showed 
complete loss of TRIM25 expression, although of these only clone C3 showed a similar 
growth rate to WT HeLa cells with the others either dying or having slower growth. As such, 
clone C3 was selected for use in future experiments. It is possible that the reason that most 
clones in which TRIM25 had been deleted showed growth defects is that TRIM25 is 
essential for normal growth. If this is the case, it is possible that clone C3 contains 
mutations that compensate for the loss of TRIM25, for example the upregulation of a 
protein that can perform TRIM25’s roles. To confirm that the TRIM25 gene had been 
disrupted, genomic DNA was isolated from clone C3 and the area surrounding the sgRNA 
target sequences was sequenced. The target area was amplified by PCR and cloned into 
pJET vector before being transformed into E. coli cells. Bacterial cells were isolated as 






Figure 14 – The first round of CRISPR in HeLa cells generated a clone with substantially 
reduced TRIM25 expression. (A) Dot immunoblots for HeLa clones that had undergone 
CRISPR. 2 µL protein extract from clones was added directly to a nitrocellulose membrane 
before antibody probing. Clones that may have reduced expression of TRIM25 are marked 
by red circles and a positive control for TRIM25 expression is marked with a blue circle. 
DHX9 was used as a loading control. (B) Western blot validation of identified clones with 








Figure 15 – The second round of CRISPR in HeLa E8 cells generated several TRIM25 KO 
clones. (A) Dot immunoblots for HeLa E8 clones that had undergone CRISPR. Potential KO 
clones are marked by a red circle. DHX9 was used as a loading control. (B) Western blot 
validation of potential TRIM25 KO clones. WT HeLa cells and HeLa E8 cells were used as 





miniprep before being sequenced. This confirmed disruption of two copies of TRIM25 with 
two different mutations identified; a 234-nucleotide deletion (positions 128-362 of exon 1) 
and a 13 nucleotide deletion (169-182, causing a frameshift). Although several clones were 
sequenced, only two separate mutations were identified despite the three copies of 
TRIM25 in the HeLa genome. This may be due to mutations on two of the copies of TRIM25 
being identical or a failure to generate a PCR product in the target region on one of the 
copies of chromosome 17, for example due to a mutation in the sequence one of the 
primers binds to. As no TRIM25 protein was detectable, it was decided to proceed with this 
clone, which was called HeLa TRIM25 KO. 
 
HEK293 TRIM25 KO cells were generated by CRISPR 
 
After the successful generation of HeLa TRIM25 KO cells, generation of HEK293 TRIM25 KO 
cells was performed in the same way. In the initial screen, much fewer clones managed to 
grow in the 96-well plate, however a few possible KO clones were identified on the dot 
immunoblot (FIG. 16A). These clones were validated for TRIM25 expression by western blot 
(FIG. 16B). Of these, one clone, C8, showed complete knockout of TRIM25. This clone was 
also sequenced to confirm disruption of TRIM25 in the same manner as HeLa TRIM25 KO.  
 
TRIM25 was reintegrated into the HEK293 TRIM25 KO genome using the 
Flp-In system 
 
The HEK293 cells that were used to generate HEK293 TRIM25 KO contain an FRT site under 






Figure 16 – The first round of CRISPR for HEK293 cells generated a TRIM25 KO clone. (A) Dot 
immunoblots of HEK293 clones that had undergone CRISPR. Potential KO clones are marked 
with red circles. DHX9 was used as a loading control. (B) Western blot validation of 




and stable, constitutive expression of the protein encoded by that gene. The genes of 
interest, in this case codon optimised TRIM25 WT, TRIM25ΔRBD or TRIM25ΔRING, were 
cloned into the pcDNA5/FRT expression vector, which contains FRT flanking sequences for 
homologous recombination with the FRT site in the genome as well as a hygromycin 
resistance cassette. The pcDNA5/FRT plasmid with the gene of interest was co-transfected 
with pOG44 (encoding the Flp recombinase) into HEK293 TRIM25 KO cells. Cells in which 
the genes of interest had been successfully integrated were selected for by colony growth 
in the presence of hygromycin. These colonies were then picked to a 24-well plate and 
tested for expression of TRIM25 WT, TRIM25ΔRBD or TRIM25ΔRING. One clone of each cell 
line with integrated WT or mutant TRIM25 with similar expression levels of TRIM25 and 
growth rate to WT HEK293 cells was selected for use in future experiments to ensure 
consistency (FIG. 17A). These cell lines were called HEK293 TRIM25 KO+TRIM25 WT, 
HEK293 TRIM25 KO+TRIM25ΔRBD and HEK293 TRIM25 KO+TRIM25ΔRING. Of note, it 
proved more difficult to re-integrate TRIM25 WT into the genome than the TRIM25 
mutants, with attempts initially yielding no hygromycin-resistant colonies as opposed to 
many colonies for both TRIM25ΔRBD and TRIM25ΔRING. In order to remedy this, different 
amounts and ratios of the pcDNA5/FRT and pOG44 plasmids were used, with higher 
amounts of pcDNA5/FRT compared to pOG44 (1:5 ratio as opposed to 1:10 used initially) 
successfully generating a small number of hygromycin resistant clones. 
It was important that TRIM25 WT and its mutants maintained their RNA-binding activity 
upon re-integration into the genome. As such RNA binding for these proteins was tested by 
RNA pull-down with pre-let-7a-1 (FIG. 17B). TRIM25 WT and TRIM25ΔRING were both able 
to bind to pre-let-7a-1 while TRIM25ΔRBD showed reduced binding, as would be expected 
from previous results. This indicates that the reintegrated proteins have maintained their 





Figure 17 – TRIM25 WT and mutants maintained their respective RNA-binding ability upon 
re-integration into the HEK293 TRIM25 KO genome. (A) Western blot validation of TRIM25 
expression levels in selected HEK293 cell lines. (B) RNA pull-down of WCE of selected 
HEK293 cell lines with pre-let-7a-1. Input represents 4% (40 µg) of extracts used for pull-








TRIM25 KO cell lines were successfully generated for both HeLa and HEK293 cells. In 
addition to this, TRIM25 WT, TRIM25ΔRBD and TRIM25ΔRING were successfully 
reintegrated into the HEK293 TRIM25 KO genome with expression levels similar to WT cells 
and maintaining their respective RNA-binding capabilities.  
CLIP-seq experiments performed in the lab identified thousands of TRIM25-bound RNA 
transcripts in HeLa cells219. Creation of HeLa TRIM25 KO cells will allow analysis of the 
possible effects of TRIM25 on the levels of these transcripts, as well as any effects on RNA 
processing or stability. They also allowed experiments concerning the ability of 
TRIM25ΔRBD to function without the possible masking of any effects of loss of RNA binding 
by the presence of endogenous TRIM25. In addition, they enabled analysis of any proteins 
whose levels change upon deletion of TRIM25, for example targets of TRIM25 
ubiquitination that are no longer targeted for degradation by the proteasome. It is, 
however, possible that clone C3 contains compensatory mutations for the loss of TRIM25, 
potentially masking the effects of TRIM25 deletion when assaying the cells’ functions. 
HEK293 TRIM25 KO and the cell lines with reintegrated TRIM25 WT, TRIM25ΔRBD and 
TRIM25ΔRING provide an ideal system for determining if the RNA binding or E3 ubiquitin 
ligase activity of TRIM25 are necessary for its functions. In addition to this, the HEK293 
TRIM25 KO+TRIM25 WT cell line can be used to confirm that any differences seen between 
HEK293 WT and HEK293 TRIM25 KO are due to the loss of TRIM25. If any difference in 
phenotype in HEK293 TRIM25 KO compared to HEK293 WT is rescued in HEK293 TRIM25 
KO+TRIM25 WT cells, this would show that the difference was due to loss of TRIM25 and 




HEK293 TRIM25 KO+TRIM25ΔRING can be used in a similar way to determine if a function 




Chapter 3 – Analysis of changes in RNA and protein levels in 




Previous work in the lab has shown that TRIM25 can bind to and affect the stability of pre-
let-7a-1 by acting as a co-factor for Lin28/TuT4-mediated uridylation216. As such, it would be 
interesting to find out if TRIM25 could influence the stability of other RNAs to which it 
binds. TRIM25 could affect RNA stability in several ways. Firstly, by binding RNAs, TRIM25 
may exclude the binding of other RBPs or directly recruit other binding partners that can 
modify RNA in a way that leads to stabilisation or degradation. In addition to this, TRIM25 
could use the RNA as a scaffold to ubiquitinate other proteins that are bound to the RNA, 
either targeting them for degradation or otherwise modulating their activity. A Co-IP 
experiment to identify proteins that interact with TRIM25 identified many proteins that are 
involved in RNA metabolism, for example ribosomal proteins, helicases and proteins 
involved in RNA processing, stability or splicing219. This further underlines the potential 
roles that TRIM25 could play in RNA biology. A CLIP-seq experiment performed in the lab 
identified over 2000 RNAs that associate with TRIM25 in HeLa cells, with most of these 
being mRNAs (56%) or long non-coding RNAs (lncRNAs, 29%)219. This indicates that there is 
a large pool of RNAs that TRIM25 could potentially regulate.  
TRIM25 is an E3 ubiquitin ligase, meaning it can catalyse the formation of polyubiquitin 
chains on its target proteins. The addition of a K48-linked polyubiquitin chain to a protein 
targets it for degradation via the proteasome and is an essential aspect of the control of 
protein abundance and the targeting of damaged or improperly translated proteins for 




loss of TRIM25 as changes in protein abundance can have knock-on effects on the functions 
and proliferation of the cell. 
The aim of this part of the project was to identify RNAs or proteins whose levels or stability 
are affected by the loss of TRIM25 in HeLa TRIM25 KO cells. Initially, the stability and levels 
of individual RNAs identified in the CLIP experiment were tested. Following this, genome-
wide screening techniques were used to identify any other RNAs or proteins whose 
abundance is controlled by TRIM25. 
 
Stability of cMyc and ZAP mRNAs is not affected by loss of TRIM25 
 
One possible function for TRIM25 RNA binding was regulating the stability of its target 
RNAs, for example through recruitment or inhibition of enzymes such as endo- or 
exonucleases. To this end the stability of two physiologically relevant mRNAs that were 
identified in the previous CLIP-seq experiment as being TRIM25 binding partners, cMyc and 
ZAP, were tested in HeLa TRIM25 KO cells compared to HeLa WT cells. This was done using 
Actinomycin D (ActD), which blocks RNA Polymerase II transcription, allowing the rate of 
decay of the mRNAs to be followed without the confounding effect of de novo 
transcription. Cells were treated with ActD and total RNA samples taken at different 
intervals before RNA abundance was measured by qRT-PCR (FIG. 18). Of note, RNA levels 
were normalised to 18S rRNA as this is stable over the time periods measured. However, as 
18SrRNA is much more abundant than the RNAs tested, it required a 1 in 100 dilution to be 
measured (i.e. 5 ng RNA loaded instead of 500 ng). As such it may have been better to use a 
different RNA for normalisation such as Actin or GAPDH. Neither cMyc nor ZAP mRNA 






Figure 18 – Degradation of cMyc and ZAP mRNAs do not change upon loss of TRIM25. HeLa 
WT or HeLa TRIM25 KO cells were treated with Actinomycin D and total cellular RNA 
samples taken at the time points indicated. Levels of cMyc and ZAP mRNA were assayed by 
qRT-PCR and were normalised to levels of 18S rRNA. Figures represent means and standard 





Levels of SUB1 mRNA decrease upon loss of TRIM25 in HeLa cells 
 
As many RNAs were identified as TRIM25 binding partners in the CLIP experiments, it would 
be interesting to test some of these to determine if their abundance changes upon loss of 
TRIM25. Total cellular RNA was isolated from HeLa WT and HeLa TRIM25 KO using TRI 
Reagent and quantified by nanodrop. Levels of selected mRNAs in HeLa WT or HeLa TRIM25 
KO cells were determined by qRT-PCR and were normalised to levels of GAPDH (FIG. 19). Of 
the mRNAs tested, most showed no significant difference in expression upon deletion of 
TRIM25. However, one, SUB1, showed a modest (around 30%) but statistically significant 
decrease in abundance in HeLa TRIM25 KO cells. SUB1 encodes a transcriptional coactivator 
that mediates interactions between upstream transcriptional activators and the 
transcriptional machinery. These results suggest that loss of TRIM25 does not have 
substantial effects on mRNAs that it binds to, however this is only a very small subset of 
these RNAs so more need to be tested to draw any conclusions. 
 
RNAseq identifies changes in RNA levels in HeLa TRIM25 KO cells 
 
In order to determine the changes in mRNA abundance on a genome-wide scale, RNAseq 
was used. RNAseq is a technique that uses next generation sequencing (NGS) technologies 
to determine the presence and abundance of different mRNAs across the entire 
transcriptome233,234. Three samples of total cellular RNA for each of HeLa WT and HeLa 
TRIM25 KO were isolated at different times using TRI Reagent before further purification 
using phenol-chloroform extraction. Total RNA samples were sent to BGI who performed 
the library generation and sequencing. First RNA was tested to ensure it met the quality 






Figure 19 – Levels of selected RNAs in HeLa WT and HeLa TRIM25 KO cells. Total cellular 
RNAs were assayed for levels of selected mRNAs by qRT-PCR. All RNAs were normalised to 
levels of GAPDH. Figures represent means and standard deviations from three independent 
experiments. Statistical significance calculations were performed using Welch’s t-test (* 




the concentration, RNA integrity number (RIN) and 28S/18S ratio were measured (Table 
10). All of the samples had RNA of sufficient quality to proceed to RNAseq. 
Sample Concentration 
(ng/µL) 
Total mass (µg) RIN 28S/18S 
HeLa WT 1 390 7.8 9.9 1.8 
HeLa WT 2 266 5.32 10 1.8 
HeLa WT 3 394 7.88 9.9 1.8 
HeLa TRIM25 KO 1 408 9.38 10 1.8 
HeLa TRIM25 KO 2 280 5.6 10 1.9 
HeLa TRIM25 KO 3 512 10.24 9.9 1.9 
Table 10 – Total RNA samples were of sufficient quality to proceed to RNAseq. Samples 
were analysed on an Agilent 2100 Bioanalyser. 
 
A schematic of the RNAseq process is shown in FIG. 20. RNA samples were first enriched for 
mRNA as around 85% of the total RNA will be ribosomal RNA (rRNA). Oligo(dT) capture was 
used to select for mRNAs as the poly(A) tail of the mRNAs will bind to the oligo(dT) probe. 
Subsequently, RNAs were fragmented and reverse transcribed to generate double-stranded 
cDNAs. Adapters were ligated to both the 5’ and 3’ end of the cDNAs and primers specific 
to these adapters were used to amplify cDNAs by PCR. The amplified cDNAs were then 
circularised before the library was sequenced and analysed by aligning reads to a reference 
genome.  
On average around 24x106 reads were generated for each sample, with on average 95% of 
these being successfully mapped to the reference genome (Table 11). Biological replicates 
were highly correlated, with correlation values between samples isolated from the same 
cell lines at above 0.99, with a slight reduction in this for samples isolated from different 
cell lines, as would be expected (FIG. 21A). This suggests that the results obtained from this 
experiment were reliable. Around 19000 genes were identified in each sample, with 17369 






Figure 20 – Schematic of the process for RNAseq. After sequencing, sequenced reads 
underwent quality control to remove low quality sequences before being aligned to a 
reference genome. Quality control was performed at every step to improve quality and 










Figure 21 – 288 differentially expressed genes were identified in HeLa TRIM25 KO cells. (A) 
Correlation of gene expression values between samples. (B) Number of genes identified in 
HeLa WT or HeLa TRIM25 KO samples. (C) Scatter graph of genes identified in RNAseq. 








HeLa WT 1 24,104,504 95.68 4.32 
HeLa WT 2 24,096,601 95.44 4.56 
HeLa WT 3 24,101,277 95.43 4.57 
HeLa TRIM25 KO 1 24,098,396 95.36 4.64 
HeLa TRIM25 KO 2 24,094,450 95.55 4.45 
HeLa TRIM25 KO 3 24,103,091 95.74 4.26 




(FIG. 21B). Of these, 288 were differentially expressed by at least 2-fold in HeLa TRIM25 KO 
cells compared to HeLa WT, with abundance increasing for 124 and decreasing for 164 (FIG. 
21C). This suggests that only a small proportion of genes were affected by knock-out of 
TRIM25. Interestingly only 9 mRNAs identified in the previous CLIP-seq experiment were 
differentially expressed in HeLa cells (Table 12). 3 of these were increased (TSPAN5, OPN3 
and C14orf37) while 6 were decreased (COL5A1, PCDH11X, PPAN-P2RY11, SYBU, C16orf62 
and TRIM25 itself). This indicates that TRIM25 binding to mRNAs does not generally have a 
substantial effect on their abundance in steady state cells.  
 
Table 12 – mRNAs identified as binding to TRIM25 in the previous CLIP experiment that 
were found to be differentially expressed in HeLa TRIM25 KO cells compared to WT cells. 
 
Differentially expressed genes were analysed in an attempt to find any commonalities 
between them. This could give insights into the mechanism by which these RNAs are 
regulated by TRIM25. Firstly, the base composition of differentially expressed genes was 
analysed (FIG. 22A). This showed that nucleotide content does not change between 
upregulated, downregulated and non-regulated genes. This was also analysed for the 
promoter regions of differentially expressed genes as TRIM25 has previously been shown to 
function as a regulator of transcription and as such may be regulating genes on the  















Figure 22 - No difference in base composition for genes or promoters was seen in genes 
differentially expressed in HeLa TRIM25 KO cells. (A) Base composition of upregulated, 
downregulated and non-regulated genes identified in RNAseq. (B) Base composition of 





transcriptional level. Again no difference was seen between differentially expressed genes 
and genes that do not change (FIG. 22B). It was also discovered that there are no common 
motifs found in multiple differentially expressed genes, either in the coding sequence itself 
or the promoter regions. Taken together, these data suggest nucleotide content is not a 
common factor for genes that are differentially regulated upon TRIM25 deletion in HeLa 
cells. 
 
Abundance of very few proteins is changed by loss of TRIM25 
 
TRIM25 is known to target some proteins for degradation via the proteasome by using its 
E3 ubiquitin ligase activity to catalyse the addition of K48-linked polyubiquitin chains to its 
targets202. As such it was important to determine whether loss of TRIM25 leads to changes 
in levels of particular proteins. In addition, this would determine whether changes in mRNA 
levels upon loss of TRIM25 are followed by corresponding changes in protein levels. To 
determine changes in protein levels at a whole proteome level, Stable Isotope Labelling 
with Amino acids in Cell culture (SILAC) coupled with Mass Spectrometry (MS) was used. 
SILAC-MS involves growing two different populations of cells in either ‘heavy’ media 
supplemented with amino acids labelled with heavy isotopes (for example arginine labelled 
with six 13C atoms) or ‘light’ media with unlabelled amino acids (for example arginine 
incorporating regular 12C atoms)235. Proteins from either cell population can be 
distinguished by trypsin digestion followed by MS due to the difference in mass of the 
resulting peptides for each labelled amino acid. Expression levels of proteins can then be 
compared between populations.  
HeLa WT and HeLa TRIM25 KO were grown in both light and heavy media before proteins 




and the proteins present analysed by MS. This was also done reciprocally for ‘heavy’ HeLa 
TRIM25 KO extract and ‘light’ HeLa WT extract in an attempt to negate any bias for 
detection of particular peptides in either ‘light’ or ‘heavy’ extracts. Only 8 proteins were 
identified as being differentially expressed at a greater than 2-fold level in HeLa TRIM25 KO 
cells compared to HeLa WT cells in both experiments (Table 13). Excluding TRIM25 itself, of 
these, only SERPINB5 was also identified as being differentially expressed in the RNAseq 
experiment, indicating that it is downregulated at both the mRNA and the protein level. In 
addition, two genes identified in the previous CLIP experiment were also identified here, 
TMX2 and ERLIN1 and one protein identified as being a TRIM25 binding partner in a 
previous Co-IP experiment performed in the lab, ZC3HAV1, was also identified. Taken 
together, these results suggest that TRIM25 is not exerting an effect on the levels of a large 
number of proteins but may be acting on some individual proteins either through its E3 
ligase activity, its RNA-binding activity or a combination of both.  
Table 13 – Proteins identified in SILAC-MS screen as being differentially expressed in HeLa 
TRIM25 KO cells compared to WT cells. 
 
Expression of SERPINB5 is substantially reduced in HeLa TRIM25 KO cells 
 
To validate the RNAseq experiment, levels of selected mRNAs identified as being 









SERPINB5 5.9 0.25   X 
TMX2 3.8 0.68    
ERLIN1 2.3 0.74 X   
EPHX1 2.3 0.56 X   
RCN3 2.1 0.52    
ZC3HAV1 0.84 2.3  X  




being downregulated at the protein level), PCDHX11 and SYBU (as these had been 
identified as binding to TRIM25 in the CLIP experiment) were selected. Levels of SERPINB5, 
PCDHX11 and SYBU mRNA were assayed by qRT-PCR in total cellular RNA samples from 
HeLa WT and HeLa TRIM25 KO cells, as well as from two more TRIM25 KO HeLa cell lines 
(D11 and E10) that were generated in a separate CRISPR experiment in the lab (FIG. 23A). 
SERPINB5 was substantially downregulated in all three TRIM25 KO cell lines compared to 
HeLa WT cells, in agreement with the results from the RNAseq. PCDHX11 was slightly 
downregulated in all three cell lines, although less considerably than was suggested by 
RNAseq. Levels of SYBU mRNA were only slightly downregulated in the HeLa TRIM25 KO 
cells but were unchanged in both D11 and E10 cells, suggesting that this downregulation 
may just be due to off-target effects from CRISPR. As SERPINB5 was substantially 
downregulated in all three cell lines this was further validated by repeating the experiment 
(FIG. 23B). This showed a significant reduction in SERPINB5 mRNA levels in all three KO cell 
lines. In addition to this, levels of SERPINB5 protein in the KO cell lines were assayed by 
western blot (FIG. 23C). This also showed a large reduction in SERPINB5 expression upon 
loss of TRIM25. To determine if SERPINB5 expression could be rescued by TRIM25, T7-
TRIM25 was transfected into HeLa TRIM25 KO cells and total cellular RNA harvested before 
levels of SERPINB5 were analysed by qRT-PCR (FIG. 23D). There was no significant 
difference in SERPINB5 mRNA levels after addition of T7-TRIM25, implying that transient 
expression of TRIM25 is not sufficient to rescue the phenotype in KO cells. These data 
suggest that although SERPINB5 levels are significantly reduced upon loss of TRIM25 in 
HeLa cells, it was not possible to rescue this by expression of exogenous TRIM25. One 
possibility is that the SERPINB5 gene was disrupted as an off target effect of CRISPR. It is 
also possible that transient transfection of TRIM25 is not sufficient for rescue and stable re-




KO and reintegrated cell lines was analysed by qRT-PCR and protein level by western blot. 
However, SERPINB5 was not detectable at either the RNA or protein level in any HEK293 







Figure 23 – SERPINB5 is downregulated at the mRNA and protein levels in HeLa TRIM25 KO 
cells. (A) qRT-PCR showing abundance of selected mRNAs identified as being differentially 
expressed in HeLa TRIM25 KO cells by RNAseq. In addition to the HeLa TRIM25 KO cells 




were normalised to levels of GAPDH. (B) qRT-PCR of SERPINB5 in HeLa cell lines, normalised 
to GAPDH. Data represents means and standard deviations of three independent 
experiments. Statistical significance tests were performed using one-way ANOVA with post-
hoc Tukey HSD (* indicates p<0.05). (C) Western blot of whole cell extract from HeLa cell 
lines. (D) qRT-PCR of SERPINB5 RNA levels upon transient transfection of T7-TRIM25. A 
plasmid encoding T7-TRIM25 was transfected into cells and total cellular RNA was 
harvested after 48 hours. Data represents means and standard deviations of two 








The data presented here suggest that TRIM25 does not have a substantial effect on 
expression of the majority of the genes that it interacts with, either through mRNAs or 
proteins. Selected RNAs identified in the CLIP-seq experiment previously performed in the 
lab showed no difference in stability or abundance in HeLa TRIM25 KO cells, with the 
exception of SUB1 which showed a small reduction in expression. RNAseq identified several 
differentially expressed mRNAs in TRIM25 KO cells, however very few of these were 
identified in the CLIP-seq experiment as being bound by TRIM25. It should be noted, 
however, that CLIP cannot distinguish between RNAs that directly bind TRIM25 and those 
that may be associated with TRIM25-interacting proteins that are cross-linked to TRIM25 
during the UV cross-linking step. It is therefore possible that the CLIP experiment over-
estimated the number of TRIM25 interacting RNAs and this may be why so few are seen to 
change levels upon TRIM25 deletion. It may be useful to also identify proteins that are co-
precipitating with TRIM25 in these experiments, for example by using MS. SILAC-MS 
identified just 8 proteins that were differentially expressed in TRIM25 KO cells. One gene, 
SERPINB5, was identified as being substantially downregulated in HeLa TRIM25 KO cells at 
both the mRNA and the protein level, although this could not be rescued by transient 
expression of T7-TRIM25 and as such it could not be confirmed that this was due to loss of 
TRIM25 and not due to off-target effects of CRISPR/Cas9. 
The techniques used in this part of the project, although potentially powerful tools for 
detecting changes in gene expression across the whole transcriptome or proteome, were 
only used to look at gene expression in steady state cells. It is possible that TRIM25 can aid 
in the regulation of gene expression in response to particular stimuli, for example it has 




number of RNAs in steady state cells, as shown by the CLIP experiment. It could be that 
TRIM25 requires the presence of other proteins that interact with or modify it in particular 
conditions in order for it to have a greater effect on regulation of gene expression. It would 
be interesting in the future to test the effect of the loss of TRIM25 in response to different 
stimuli. 
It is also possible that the functions of TRIM25 do not extend to the regulation of gene 
expression and are instead more focused on the modulation of activity of its target 
proteins. Ubiquitination is often used for targeting proteins for degradation via the 
proteasome through the addition of K48-linked polyubiquitin chains. However, other types 
of polyubiquitin chains, for example K63-linked chains, are often used in signalling or for 
modifying protein function. TRIM25 may be using RNA as a scaffold to bring it into contact 
with its target proteins so that they can be ubiquitinated in this way. These functions are 
unlikely to be uncovered through the use of whole genome screening techniques. There is 
also a possibility that there is a level of redundancy whereby the loss of TRIM25 can be 
compensated for, for example by other TRIM family proteins. Further experiments on 
individual targets of TRIM25 ubiquitination would be required to determine if this 








The innate immune system provides the first line of defence for the body when fighting 
pathogens such as bacteria or viruses. Pathogens are detected non-specifically, as opposed 
to the adaptive immune system that is moderated by antibodies, resulting in the activation 
of a variety of anti-pathogenic factors. One of the most important components of the anti-
viral innate immune system are the interferons (IFNs), a group of signalling proteins that 
trigger the expression of many genes, termed IFN-stimulated genes (ISGs), that perform 
anti-pathogenic functions, such as activation of immune cells or down-regulating protein 
expression. Expression of IFNs is triggered by signalling cascades that result from the 
recognition of pathogen-specific molecules, termed pathogen associated molecular 
patterns (PAMPs), by pattern recognition receptors (PRRs) in the host cell. PRRs are 
grouped into four main types; Toll-like receptors (TLRs), Nod-like receptors (NLRs), C-type 
lectin receptors (CLRs) and RIG-I-like receptors (RLRs). Of these, TRIM25 has been shown to 
have a role in the signalling of RIG-I, a cytoplasmic PRR that recognises 5’-triposphate 
(5’ppp) moieties that are present on RNAs produced during the replication of RNA viruses 
such as Influenza virus or Dengue virus. Work has shown that upon binding to a 5’ppp-RNA, 
RIG-I undergoes a conformational change that exposes its 2 caspase recruitment domains 
(2CARD). TRIM25 then binds to and ubiquitinates the 2CARD, allowing RIG-I to recruit its 
downstream partner MAVS and triggering a signalling cascade resulting in phosphorylation 
of the transcription factor IRF-3, which translocates to the nucleus and activates expression 
of type I IFNs113. It has been suggested that the E3 ubiquitin ligases Riplet, TRIM4 and 
MEX3C can also perform this role, meaning that TRIM25 may be redundant in human 




replication of Influenza A virus (IAV) by binding to viral ribonuclear proteins (RNPs) in an 
RNA-dependent manner, blocking their transcription187.  
The aim of this section of the project was to try to confirm the functions of TRIM25 in 
restricting virus replication and in the RIG-I pathway. Due to the combination of TRIM25’s 
RNA-binding activity and its role in defence against RNA viruses, it was important to 
determine if these functions were dependent on RNA-binding activity. The development of 
HEK293 TRIM25 KO cells in which TRIM25 WT, TRIM25ΔRBD and TRIM25ΔRING had been 
reintegrated provided the perfect model in which to test the dependence of TRIM25’s anti-
viral function on its RNA-binding and ubiquitination activity. By infecting cells with IAV it 
would be possible to see which of these cell lines can restrict viral replication and therefore 
whether this is dependent on ubiquitination or RNA binding. In addition, TRIM25’s role in 
the RIG-I pathway could be assayed by transfecting these cells with isolated 5’ppp-RNAs 
and determining levels of IRF-3 phosphorylation and type I IFN expression in response to 
this.  
 
HEK293 TRIM25 KO cells are more permissive to an NS1 deficient IAV 
than HEK293 WT cells 
 
The NS1 protein of IAV, encoded by segment 8 of the genome, inhibits TRIM25 by binding 
directly to its coiled-coil domain, preventing oligomerisation and therefore enzymatic 
activity145,147. This would make it hard to determine the effects of deletion of TRIM25 from 
cells as even in WT cells TRIM25 would be antagonised by NS1. However, a mutant NS1 that 
cannot inhibit TRIM25 has previously been identified (NS1 R38K41A)146. This mutant is 
unable to bind to TRIM25, among other defects, and interestingly, unlike WT NS1, is also 




compared to WT IAV and it is also deficient in preventing expression of type I IFNs. As such, 
cells were challenged with two IAVs, a lab-adapted strain A/PR/8/34 (PR8 WT)223 and a 
mutant of this strain encoding NS1 R38K41A (PR8 NS1 R38K41A). Viruses were produced 
using a reverse genetics system. Plasmids encoding all 8 segments of the PR8 genome were 
transfected into HEK293T cells. Both positive and negative sense RNA are produced from 
the plasmids, with the positive sense RNA being translated into IAV proteins that are 
packaged with the negative sense RNAs that form the IAV genome, resulting in complete 
virus particles223. These virus particles are capable of replication and were used to infect 
Madin-Darby Canine Kidney (MDCK) cells to propagate them and generate a virus working 
stock. MDCK cells are used for this as they are highly susceptible to IAV infection and 
generally produce high virus titres due in part to a dampened response to IFNs238. The virus 
titre of the working stock was assayed by plaque assay. A series of 10-fold dilutions of the 
virus stock were used to infect a lawn of MCDK cells, overlaid with a thixotropic medium 
and incubated for 48 hours. The thixotropic overlay medium prevents virus particles 
spreading across the media by convection, meaning that viruses must propagate from cell 
to cell and plaques are formed that represent the initial infection of one plaque forming 
unit (pfu) of virus. The cells were fixed with formalin and stained with toluene blue to 
visualise plaques so that they can be counted. Virus working stocks were produced on 
average at a titre of 108-109 pfu/mL. 
To test HEK293 TRIM25 KO cells for their ability to restrict IAV replication compared to 
HEK293 WT, cells were infected with PR8 WT or PR8 NS1 R38K41A at a multiplicity of 
infection (MOI, the number of virus particles per cell) of 1. Virus titres post-infection for 
several time points were measured by plaque assay (FIG. 24). PR8 WT titres were similar at 
all time points and no differences were statistically significant. At 48 hours there was a 






Figure 24 – HEK293 TRIM25 KO cells are more permissive to PR8 NS1 R38K41A infection 
than HEK293 WT. Either HEK293 WT or TRIM25 KO cells were infected with IAV PR8 WT or 
PR8 NS1 R38K41A at an MOI of 1 and viral load was assessed by plaque assay at the time 
points indicated. Data represents the means and standard deviations of two independent 
experiments. Statistical significance calculations were performed using Welch’s t-test (* 
signifies p<0.05). The experiments shown in these figures were performed by Eleanor 




that this is an outlier the experiment would have to be repeated. PR8 NS1 R38K41A titres 
were significantly higher post-infection in HEK293 TRIM25 KO cells than HEK293 WT cells at 
the 40-hour time point, indicating that HEK293 TRIM25 KO cells are more permissive to PR8 
and suggesting that the presence of TRIM25 restricted IAV replication in the absence of 
functional NS1. As this experiment was only performed twice, statistical power of the 
results was diminished, leading to the differences seen at 48 and 60 hours not being 
statistically significant. However, these results were deemed promising enough to move on 
to a larger scale experiment. 
 
PR8 NS1 R38K41A restriction is rescued by TRIM25 WT, TRIM25ΔRBD and 
TRIM25ΔRING 
 
To ensure that the differences seen between HEK293 WT and HEK293 TRIM25 KO cells 
were due to the absence of TRIM25, not off target effects of the CRISPR process, as well as 
determine if this phenotype can be rescued by TRIM25ΔRBD or TRIM25ΔRING. HEK293 
TRIM25 KO cell lines with reintegrated TRIM25 WT, TRIM25ΔRBD or TRIM25ΔRING were 
infected with IAV PR8 WT or PR8 NS1 R38K41A at an MOI of 0.001 and virus titre was 
assessed after 48 hours (FIG. 25A & B). Differences seen in the raw titres of IAV after 
infection were found not to be significant, probably due to large variations in titres seen 
between experiments (FIG. 25A). However, when titres of PR8 NS1 R38K41A were 
expressed as a proportion of those of PR8 WT from the same experiment, HEK293 TRIM25 
KO cells were found to be significantly more permissive to growth of PR8 NS1 R38K41A 
than each of the other cell lines (FIG. 25B). HEK293 WT cells restricted growth of PR8 NS1 
R38K41A in comparison to PR8 WT. As seen previously, HEK293 TRIM25 KO cells lost the 






Figure 25 – HEK293 TRIM25 KO cells restriction of IAV replication is rescued by reintegration 
of TRIM25 WT, ΔRBD or ΔRING. HEK293 cell lines were infected with IAV PR8 WT or PR8 
NS1 R38K41A at an MOI of 0.001 and virus titres were assessed by plaque assay after 48 
hours. (A) Raw virus titres resulting from this infection. (B) PR8 NS1 R38K41A titres as a 




represent the same experiments, n=4. Statistical significance tests performed with 2 way 
ANOVA with post-hoc Tukey HSD test. * indicates p<0.05 in comparison to other cell lines 
infected with the same virus. The experiments shown in these figures were performed by 




earlier results. Restriction of PR8 NS1 R38K41A was rescued by re-integration of TRIM25 
WT, suggesting that the loss of restriction in HEK293 TRIM25 KO cells was due to the loss of 
TRIM25, not any off-target effects resulting from the CRISPR process. Surprisingly, 
restriction was also rescued by integration of TRIM25ΔRBD and TRIM25ΔRING. The ability 
of TRIM25ΔRBD to rescue IAV restriction suggests that TRIM25 RNA binding activity is not 
required for IAV restriction. TRIM25ΔRBD also shows a defect in ubiquitination activity, 
hinting that TRIM25’s ubiquitination of RIG-I is not required for IAV restriction. There is a 
possibility, however, that TRIM25ΔRBD could bind to vRNAs using a different mechanism, 
separate to that which it uses to bind to endogenous RNAs. The ability of TRIM25ΔRING to 
rescue restriction confirms that the ubiquitination activity of TRIM25 is not important for its 
role in restricting IAV and therefore TRIM25 ubiquitination of RIG-I is not required during 
IAV infection in cultured HEK293 cells. Taken together, these results suggest that there may 
be another, as yet unknown, mechanism of IAV restriction by TRIM25 that does not require 
its RNA binding or ubiquitination activities. However it was first important to ensure that 
the deletion of TRIM25 was not affecting the RIG-I pathway or the efficiency of 
transcription of vRNAs, as has been shown by other groups previously.  
 
Deletion of TRIM25 does not reduce activation of RIG-I signalling upon 
5’ppp-RNA transfection in HEK293 cells 
 
To test the ability of HEK293 TRIM25 KO to activate RIG-I signalling in response to a 5’ppp-
RNA, 3p-hpRNA, a synthetic 5’ppp panhandle RNA derived from the beginning of segment 8 
of the IAV genome (FIG. 26A), was transfected into the HEK293 cell lines used in the 
previous experiment. Cells were incubated for 6 hours post-transfection before being 






Figure 26 – Activation of the RIG-I/IFN type I pathway is not affected by loss of TRIM25 in 
HEK293 cells. (A) 3p-hpRNA, a 5’ppp-RNA derived from the IAV genome. (B) HEK293 cell 
lines were transfected with 100 ng/mL 3p-hpRNA and levels of phospho-IRF-3 were 
assessed by western blot after 6 hours. (C) The same experiment was performed but this 
time levels of IFNα/β were assessed using the HEK-Blue assay. Data represents means and 
standard deviations of three independent experiments. Statistical significance calculations 
were performed using one-way ANOVA followed by post-hoc Tukey HSD test. (D) HEK293 
cells were transfected with 100 ng/mL 3p-hpRNA along with firefly luciferase under the 
IFNβ promoter and a constitutively expressed renilla luciferase. Luciferase activity was 
assessed after 24 hours. Data represents means and standard deviations of three 
independent experiments. Statistical significance calculations were performed using one-




cell lines tested showed similar levels of IRF-3 phosphorylation, suggesting the RIG-I 
pathway was fully functional even in the absence of TRIM25 and that re-integration of 
TRIM25 into HEK293 TRIM25 KO cells does not increase RIG-I activation. This rules out the 
possibility that any off-target effects from CRISPR have masked a possible drop in RIG-I 
activation in HEK293 TRIM25 KO cells that may have resulted from the loss of TRIM25. This 
was further confirmed by analysing expression of IFNα and IFNβ (type I IFNs) in response to 
transfection of 3p-hpRNA. This was done using the HEK-Blue system. As IFNα and IFNβ are 
secreted by cells, supernatant can be taken from treated cells and added directly to HEK-
Blue cells. HEK-Blue cells contain a gene encoding a secreted alkaline phosphatase (SEAP) 
under the control of the IFNα/β-responsive ISG54 promoter, meaning the more IFNα/β they 
are treated with, the more SEAP will be secreted. Supernatant from HEK-Blue cells is added 
to the QUANTI-Blue substrate, in which SEAP catalyses a colour change from pink to blue 
that can be measured by absorbance at 680 nm. HEK293 cell lines were transfected with 
3p-hpRNA and 6 hours post-transfection the HEK-Blue assay was performed (FIG. 26C). As 
with IRF-3 phosphorylation, there were no significant differences between the HEK293 cell 
lines. Finally, RIG-I activation in response to 3p-hpRNA was measured using a dual-
luciferase assay. Cells were transfected with a plasmid encoding firefly luciferase under the 
IFNβ promoter, in addition to 3p-hpRNA with renilla luciferase under a constitutive 
promoter (thymidine kinase, TK) as a loading/transfection control. The higher the level of 
RIG-I activation in response to 3p-hpRNA, the higher the expression of firefly luciferase and 
therefore the higher the ratio of firefly/renilla. Cells were incubated for 24 hours and 
luciferase activity was measured (FIG. 26D). Cell lines containing WT TRIM25 (HEK293 WT 
and TRIM25 KO + TRIM25 WT) had slightly lower expression of firefly luciferase than the 
other cell lines but these differences were not statistically significant. Taken together these 




HEK293 cells in the absence of TRIM25 and provide further evidence that loss of PR8 NS1 
R38K41A restriction in HEK293 TRIM25 KO cells is not due to a defect in RIG-I signalling. The 
lack of defect in RIG-I signalling could be due to redundancy in the system, with other E3 
ubiquitin ligases (e.g. Riplet, MEX3C) previously having been shown to be able to perform 
the function of TRIM25 by ubiquitinating the RIG-I 2CARD. 
 
TRIM25 deletion compromises RIG-I activity in response to 5’pppRNA 
transfection in MEF, but not HeLa, cells 
 
To determine if the RIG-I pathway can still function in the absence of TRIM25 in other cell 
lines apart from HEK293, HeLa WT and TRIM25 KO cells were transfected with 3p-hpRNA 
and levels of phospho-IRF-3 were determined by western blot 6 hours post-transfection 
(FIG. 27A). Phosphorylation of IRF-3 was in fact marginally more pronounced in HeLa 
TRIM25 KO than WT cells, again indicating that loss of TRIM25 did not compromise RIG-I 
activation. Response to 3p-hpRNA in HeLa WT and HeLa TRIM25 KO was also tested by HEK-
Blue assay in HeLa WT and TRIM25 KO cells (FIG. 27B). Both HeLa WT and HeLa TRIM25 KO 
cells did not show a significant response to 3p-hpRNA compared to mock transfected cells. 
To determine if RIG-I signalling was affected by loss of TRIM25 in an organism other than 
humans, mouse embryonic fibroblast (MEF) WT and TRIM25 KO cells were used. MEF WT 
and TRIM25 KO cells were treated with 3p-hpRNA and phospho-IRF-3 levels were analysed 
6 hours post-transfection by western blot (FIG. 27C). In these cells loss of TRIM25 lead to 
lower levels of phospho-IRF-3 upon 3p-hpRNA transfection, although IRF-3 phosphorylation 
was not completely abolished. This indicates that RIG-I signalling had been compromised 
and suggests that TRIM25 is important for RIG-I signalling in mouse cells but is not 






Figure 27 – Activation of the RIG-I pathway is attenuated in MEF, but not HeLa, cells upon 
loss of TRIM25. (A) HeLa cell lines were transfected with 100 ng/mL 3p-hpRNA and levels of 
phospho-IRF-3 were assessed by western blot after 6 hours. (B) The same experiment was 
performed but this time levels of IFNα/β were assessed using the HEK-Blue assay. Data 
represents means and standard deviations of three independent experiments. Statistical 
significance calculations were performed using Welch’s t-test. (C) MEF cell lines were 
transfected with 100 ng/mL 3p-hpRNA and levels of phospho-IRF-3 were assessed by 
western blot after 6 hours. DHX9 was used as a loading control as the total IRF-3 antibody 




proteins being unable to ubiquitinate RIG-I or inefficient in this process. Taken together, 
these results confirm RIG-I/IFN type I activation dependence on TRIM25 in mouse cells, but 
provide further evidence that TRIM25 is dispensable for RIG-I/IFN type I activation in 
selected human cultured cell lines. Due to the variation in the presence of proteins and 
other factors, there is likely to be variation in the RIG-I/IFN type I response between cell 
lines. As such, more cell lines from both species, as well as different 5’ppp-RNAs, must be 
tested to draw further conclusions about the role of TRIM25 in RIG-I/IFN type I activation in 
both humans and mice. 
To ensure that the previous results were not confined to 3p-hpRNA, another 5’ppp-RNA 
was tested in HEK293 and HeLa WT and TRIM25 KO cells. Various amounts of 5’ppp-UA (see 
FIG. 6A) was transfected into cells along with Firefly luciferase under the IFNβ promoter 
and Renilla luciferase under the TK promoter. Cells were incubated for 24 hours and 
luciferase activity was assayed in HEK293 (FIG. 28A) and HeLa (FIG. 28B) cells. Levels of RIG-
I activation were slightly higher in HEK293 TRIM25 KO cells at all amounts of 5’ppp-UA, 
although these differences were only statistically significant for 0.5 µg and 0.125 µg of RNA. 
In HeLa cells, RIG-I activation showed no significant differences between WT and TRIM25 
KO cells for any amount of 5’ppp-UA. These data provide further evidence that RIG-I/IFN 
type I activation is not dependent on TRIM25 in HeLa or HEK293 cells. 
 
 
TRIM25 does not inhibit IAV RNA polymerase in HEK293 cells 
 
Previous work has shown that TRIM25 may inhibit transcription of IAV RNAs by direct 
binding to vRNPs in an RNA-dependent manner. To test whether this occurs in these cells, a 






Figure 28 – Activation of the RIG-I/IFN type I pathway is not attenuated in HEK293 or HeLa 
cells  in response to 5’ppp-UA transfection upon loss of TRIM25. (A) HEK293 WT or TRIM25 
KO cells and (B) HeLa WT and TRIM25 KO cells were transfected with the indicated amounts 
of 5’ppp-UA (see Chapter 1, FIG. 1A) along with firefly luciferase under the IFNβ promoter 
and a constitutively expressed renilla luciferase. Luciferase activity was assessed after 24 
hours. Data represents means and standard deviations of three independent experiments. 




components required for IAV to transcribe negative sense RNA (found in the IAV genome) 
into positive sense mRNA (required for translation by the host cell), along with a reporter to 
determine how efficient this transcription is. Plasmids encoding the components of the IAV 
RNA polymerase (PA, PB1, PB2) along with NP (required for formation of vRNPs) were 
transfected into HEK293 cell lines in addition to a firefly luciferase reporter. The firefly 
luciferase reporter is transcribed as a negative sense RNA with flanking regions resembling 
those found in IAV RNAs. It requires IAV RNA polymerase activity to be transcribed to 
positive sense mRNA so that it can be translated into luciferase protein by the host cell. As 
such any inhibition of IAV RNA polymerase activity by TRIM25 can be measured. A negative 
control was performed in exactly the same way but lacking the plasmid encoding NP 
(segment 5), preventing transcription by the IAV RNA polymerase. Cells were incubated for 
48 hours before luciferase activity was measured (FIG. 29A). There were no significant 
differences in luciferase activity between cell lines. This experiment was repeated by our 
collaborator Nikki Smith in the lab of Paul Digard (University of Edinburgh), showing similar 
results (FIG. 29B). This experiment was also performed in the presence of the IAV inhibitor 
protein Mx as a positive control for inhibition of IAV. No differences were seen between cell 
lines, however there was significant inhibition of luciferase expression in the presence of 
Mx. These results imply that in this case TRIM25 is not inhibiting IAV RNA polymerase 
activity. However, as luciferase is not part of the IAV genome, it does not reflect exactly 
what is happening during IAV infection, therefore this experiment needs to be repeated 









Figure 29 – Activity of the IAV RNA polymerase is not inhibited in the presence of TRIM25 in 
HEK293 cells. (A) Segments 1, 2, 3 and 5 of the IAV genome (encoding the components of 
the IAV RNA polymerase) were transfected into HEK293 cell lines along with a firefly 
luciferase reporter plasmid that requires the action of the IAV RNA polymerase for 
luciferase protein to be expressed. After 48 hours, luciferase activity was assessed. 
Negative control was performed in the absence of segment 5 of the IAV genome, 
preventing polymerase activity. Data represents means and standard deviations of three 
independent experiments. Statistical significance calculations were performed using one-
way ANOVA followed by post-hoc Tukey HSD test. (B) This experiment was repeated by our 
collaborator Nikki Smith in the lab of Paul Digard, University of Edinburgh. Negative 
controls were performed in the absence of Segment 1, encoding PB2 and positive controls 








Taken together, the data presented here suggest that TRIM25 can efficiently restrict IAV 
replication in the absence of fully functional NS1 but this restriction is not due to its role in 
RIG-I signalling or due to direct inhibition of IAV RNA polymerase. Restriction of IAV PR8 
NS1 R38K41A is lost in HEK293 cells upon deletion of TRIM25 and this restriction is 
efficiently rescued by re-integration of TRIM25 WT, TRIM25ΔRBD or TRIM25ΔRING. Rescue 
by TRIM25ΔRBD implies that TRIM25 RNA binding is not required for IAV restriction, 
however it is possible that TRIM25ΔRBD can bind to vRNAs by a different mechanism than 
that by which it binds to endogenous RNAs. Rescue by TRIM25ΔRING implies that TRIM25 
ubiquitination activity, for example the ubiquitination of RIG-I, is not required for IAV 
restriction. It is possible that there is redundancy in this pathway, with other E3 ubiquitin 
ligases able to perform the role of TRIM25.  
In both HEK293 and HeLa cells, but not MEF cells, deletion of TRIM25 did not lead to lower 
activation of the RIG-I pathway upon transfection of 5’ppp-RNAs. This further suggests that 
there may be redundancy in this pathway, with other E3 ubiquitin ligases able to fulfil the 
function of TRIM25 in humans but not in mice. Further work will be required to uncover the 
proteins performing this role but previous work has identified E3 ligases such as Riplet and 
MEX3C as candidates103,121. Further to this, recent work has shown that deletion of TRIM25 
from HEK293 or MEF cells does not decrease IFNβ expression in response to 5’ppp-RNA 
while deletion of Riplet abrogates IFNβ expression123. Knocking down these proteins by 
RNAi or knocking them out with CRISPR in HEK293 TRIM25 KO cells could uncover whether 




Viral minireplicon assays performed here have shown that TRIM25 does not block the 
transcription of firefly luciferase negative sense RNA by the IAV RNA polymerase. However, 
as viral minireplicon assays were only performed with a luciferase reporter, it would be 
worthwhile to repeat this experiment using the segments of the IAV genome as reporters 
(for example by measuring their transcription by qRT-PCR) to uncover any possible 
inhibition of transcription that is specific to any particular segment. 
Recent work in the lab of our collaborator Alfredo Castello (University of Oxford) using the 
HEK293 WT and TRIM25 KO cells generated in this project has shown that Sindbis virus 
(SINV) replication is restricted in the presence of TRIM25239. Cells were infected with 
mCherry-tagged SINV and fluorescence was measured over the course of 24 hours. More 
mCherry was produced in HEK293 TRIM25 KO than WT cells, indicating faster growth of 
SINV in the absence of TRIM25. It will be interesting to determine if this can also be rescued 
by re-integration of TRIM25 WT, TRIM25ΔRBD or TRIM25ΔRING to see if this is confined to 







The PRY/SPRY domain is the main determinant of TRIM25 RNA binding 
 
The data presented here show that the PRY/SPRY domain of TRIM25, specifically amino 
acids 470-508 of human TRIM25, is required for binding to RNA. TRIM25ΔRBD, in which 
these amino acids were deleted, was unable to bind to pre-let-7a-1 in an RNA pulldown or 
EMSA and exhibited loss of binding to target mRNAs and miRNAs in RIP experiments. 
Interestingly, TRIM25ΔRBD was capable of associating with TRIM25 WT, suggesting that 
dimerization with two intact PRY/SPRY domains is necessary for RNA binding. Aligning 
amino acids 470-508 with the crystal structure of the PRY/SPRY domain from mouse Trim25 
(the composition of which is highly similar to humans) shows that this region comprises β 
sheet 1, 2 and 3 as well as loops 2, 3 and 4 of the PRY/SPRY domain195.  
The requirement for the PRY/SPRY domain was confirmed by a recent study by Sanchez et 
al. that found a TRIM25 construct consisting of only the RING, B-box and CCD did not co-
purify with nucleic acids, while full-length TRIM25 did240. These constructs contradict the 
earlier finding by Kwon et al. that TRIM25 without the PRY/SPRY domain precipitated with 
RNA215. It is worth noting that the latter construct did include the CCD-PRY/SPRY ‘linker’, 
while the former did not. Sanchez et al. also identified a motif containing 7 lysine residues 
(amino acids 381-392, 5’-KKVSKEEKKSKK-3’, termed 7K) in the linker region that seemingly 
contributed to RNA binding240. Mutating all the lysines in 7K led to a significant decrease, 
although not a complete abolition, of RNA binding in EMSA experiments. A CCD-7K 
construct was not sufficient for RNA binding whereas a CCD-SPRY construct was (with an 
even higher affinity for RNA than full-length TRIM25) underlining the requirement for the 
PRY/SPRY domain240. In contrast with our RNA pulldown experiments, PRY/SPRY alone was 




affinity was reduced around 20-30-fold (similarly to the construct with 7K mutated) 
compared to the CCD-SPRY construct240.  
Taken together, these results indicate that the PRY/SPRY domain is essential for TRIM25’s 
RNA binding and that binding is enhanced by the 7K motif in the CCD-PRY/SPRY linker and 
by CCD-mediated dimerization. It remains unclear exactly which amino acids are involved in 
direct contact with the RNA. Lysine 469 and glutamate 483 (aspartate in mouse) are 
positively charged and well conserved between vertebrate species so would make 
intriguing candidates for amino acids that contribute to RNA binding. It may, however, be 
difficult to elucidate the contribution of individual residues to TRIM25 RNA binding if 
multiple amino acids make contacts with RNA as deletion or mutation of these residues 
may not abolish or significantly weaken RNA binding. It is also unclear if the 7K motif makes 
contacts with RNA or if it enhances RNA binding by affecting the positioning or 
conformation of the PRY/SPRY domain. In addition, it is possible that deletion of amino 
acids 470-508 as in TRIM25ΔRBD has implications on the overall structure of the PRY/SPRY 
domain and if this potential change in structure could be what is causing the loss of RNA 
binding. Likewise, the mechanism of the contribution of TRIM25 dimerization to RNA 
binding is also unknown. It is possible that both PRY/SPRY domains in a dimer contact the 
RNA in a ‘pincer’-type manner or that the PRY/SPRY domains themselves dimerise and this 
is required for RNA binding, for example by causing a conformational change. In order to 
fully elucidate the mechanism of TRIM25 RNA binding, the best method would be to 
perform x-ray crystallography on TRIM25 or a CCD-PRY/SPRY construct bound to RNA. This 
would allow visualisation of the amino acids in contact with RNA and comparison with 
unbound TRIM25 could uncover any structural or conformational changes that occur upon 
RNA binding. Alternatively, the mutagenesis of one or multiple amino acids in the PRY/SPRY 




amino acids are contacting RNA and would give further insights into the mechanism of 
TRIM25 RNA binding. 
 
Other PRY/SPRY containing proteins could bind to RNA 
 
The PRY/SPRY domain is found in many TRIM family proteins as well as some other proteins 
that are not members of the TRIM family with many more containing a SPRY domain alone 
preceded by a domain with a structure similar to that of the PRY domain227,241. The 
PRY/SPRY is by far the most common C-terminal domain of TRIM family proteins, with 39 
TRIMs and 6 TRIM-like proteins having this domain157,167. These include TRIM5α, involved in 
restriction of HIV, TRIM4, ubiquitination of the RIG-I 2CARD and other TRIMs involved in 
innate immunity including TRIM11 and TRIM22. In addition to this, non-TRIM family 
proteins that contain a PRY/SPRY include Riplet which is essential for RIG-I-mediated innate 
immune signalling102. It is possible that the PRY/SPRY domains of these proteins also 
contribute to RNA binding. The overall structure of PRY/SPRY domains is very well 
conserved between proteins for which crystal structures are available although the 
sequences are not as well conserved195. Loop 3 of the TRIM25 PRY/SPRY is part of the 470-
508 region and some of the residues found to contribute to RNA binding by Sanchez et al. 
also cluster in this area242. This loop corresponds to a region of PRY/SPRY domains that is 
particularly variable in sequence, indicating that RNA binding may not be a general 
characteristic of PRY/SPRY domains although this variation could also be involved in 
determining RNA binding specificity in different PRY/SPRY-containing proteins. Further 
studies into this would potentially open up a new family of RNA-binding proteins, along 
with an array of associated functions. This is particularly important due to the roles of 




done in this lab replaced the identified region required for RNA binding in TRIM25 (amino 
acids 470-508) with the equivalent sequences from other selected TRIM proteins219. When 
the 470-508 region was replaced with the equivalent from TRIM21 or TRIM27 the construct 
maintained efficient binding to pre-let-7a-1 in an RNA pulldown, however when replaced 
with sequences from TRIM65 and TRIM5α binding was reduced compared to WT TRIM25. 
Replacement of 470-508 with a random sequence of amino acids of equal length resulted in 
complete loss of pre-let-7a-1 binding, showing the specificity of this interaction219. Further 
work still needs to be done to identify PRY/SPRY containing proteins that bind to RNA and 
this data suggests that TRIM21 and TRIM27 would be good candidates. 
 
TRIM25 requires RNA binding for its E3 ubiquitin ligase activity 
 
Our data suggests that TRIM25 requires RNA binding to be able to auto-ubiquitinate and 
ubiquitinate ZAP, one of its targets. This was shown by the inability of TRIM25ΔRBD to 
ubiquitinate itself or ZAP in an in vitro ubiquitination experiment as well as the loss of 
ubiquitination activity of TRIM25 upon the addition of RNase in a similar experiment. These 
results are similar to those obtained by Sanchez et al. who found that TRIM25-mediated 
ubiquitination of the RIG-I 2CARD was severely reduced in the TRIM25 7K mutant compared 
to TRIM25 WT240. Overexpression of GST-2CARD in HEK293T cells resulted in robust 
ubiquitination of the 2CARD and induction of IFNβ promoter activity in cells expressing WT 
TRIM25 but not in cells expressing the 7K mutant240. These data support the hypothesis that 
TRIM25 requires RNA binding to ubiquitinate its target proteins and further suggest that 
this is a general property of TRIM25 activity that is not restricted to a single target protein. 
Another recent report has also suggested that TRIM25 RNA binding is important for its 




enhance its interaction with and ubiquitination of RIG-I upon VSV infection and the 
presence of Lnczc3h7a increased the type I IFN response to RNA virus infection243. In 
addition to this, both RIG-I and TRIM25 co-purified with Lnczc3h7a from cells that had been 
infected with VSV and Lnczc3h7a interacted with the RIG-I helicase domain and TRIM25 in 
RNA pulldowns. The authors of this study proposed a model whereby Lnczc3h7a acts as a 
scaffold, binding to both RIG-I and TRIM25 in order to bring them closer together. However, 
it is unlikely that this would be sufficient to explain the differences in type I IFN induction 
seen due to the apparent redundancy of TRIM25 in RIG-I signalling with other E3 ubiquitin 
ligases such as Riplet, TRIM4 and MEX3C125. It is possible, for example, that the action of 
Lnczc3h7a is not restricted to TRIM25 and it promotes the association of RIG-I with the 
other E3 ligases as well. 
The mechanism by which TRIM25 RNA binding facilitates its ubiquitination activity is 
unknown. It is known that the RING domain of TRIM25 is active as a dimer and it is likely 
that this requires higher order oligomerisation of TRIM25 dimers. It is therefore possible 
that RNA binding is important for this higher order organisation, for example by clustering 
the PRY/SPRY domains from separate dimers together to facilitate formation of a 
‘tetramer’-like structure as described in FIG. 4. This is rendered less likely by our data 
showing that purified His-TRIM25ΔRBD and His-TRIM25 WT both form tetramers in vitro, 
although it remains possible that the proteins behave differently in vivo. It is also possible 
that binding to RNA causes TRIM25 to undergo a conformational change that allows 
ubiquitin ligase activity. Again, the ideal method for determining the effect of RNA binding 
would be x-ray crystallography although crystallising full-length TRIM25 (to determine any 




TRIM25 binding to mRNAs at steady state does not have a general effect 
on RNA or protein stability 
 
According to CLIPseq experiments performed in the lab, TRIM25 binds to a large number of 
mRNAs in HeLa cells and can bind in the coding sequence and both the 5’ and 3’ 
untranslated regions (UTRs)219. However, as previously noted, the CLIPseq experiments 
performed may be overestimating the number of RNAs that TRIM25 interacts with due to 
the confounding effects of other proteins that may co-precipitate with TRIM25. RNAseq of 
WT and TRIM25 KO HeLa cells showed that few of the mRNAs identified as associating with 
TRIM25 were differentially expressed upon loss of TRIM25. This would suggest that TRIM25 
is not part of a general mechanism governing the stability of mRNAs in steady state cells. 
However, this does not discount the possibility that TRIM25 may affect stability of RNAs in 
response to certain stimuli. An example of this can be found in breast cancer cell lines, 
where knockdown of TRIM25 by RNAi led to changes in the levels of many RNAs that 
associated with TRIM25 in a RIPseq experiment204. This study also found that TRIM25 could 
act at the transcriptional level and that elevation of TRIM25 levels was strongly associated 
with tumour metastasis and poor prognosis, exemplifying the potential importance of 
TRIM25 in cancers204. It would be interesting to identify TRIM25 RNA binding partners and 
any post-transcriptional regulation it may exert in other cancer types in which it has been 
shown to be associated with tumour growth or metastasis such as endometrial and gastric 
cancers209,244. As RNA binding seems to be tied to TRIM25’s catalytic activity, it is plausible 
that the primary function of TRIM25 binding to RNAs is to use them as a scaffold to aid 
interaction with its target proteins, leading to their ubiquitination and either degradation or 
changes in activity.  
Similarly to its effects on RNA levels, loss of TRIM25 in HeLa cells seemingly has very little 




steady state cells and as such does not take into account any stimuli that could change 
TRIM25 activity. It has already been established that TRIM25 is an integral component of 
the oestrogen response and that it ubiquitinates ERα in the presence of oestrogen199. This 
underlines how certain stimuli can affect protein function and it is possible that the 
functions that TRIM25 may have in regulating protein levels may not be detectable in 
steady state cells. It is also likely that TRIM25 can exert different effects on protein and RNA 
levels depending on cell types as there may be co-factors or inhibitors integral to TRIM25 
function that are expressed at different levels in different cells. 
 
TRIM25 is not required for RIG-I signalling in HEK293 cells 
 
The data obtained in this project shows that TRIM25 is not necessary for RIG-I signalling in 
HEK293 cells as upon TRIM25 deletion there is no defect in RIG-I signalling in response to 
transfection of a 5’ppp-RNA, with similar results seen in HeLa TRIM25 KO cells. This goes 
against previous work that has posited that TRIM25 is essential for efficient RIG-I mediated 
innate immune signalling113,115,145,245.  However, some recent studies have suggested that 
Riplet, not TRIM25, is the essential E3 ubiquitin ligase for RIG-I signalling122,123,125. In 
particular, recent work by Cadena et al. has shown that deletion of TRIM25 from HEK293T 
and MEF cells results in an increase, not a reduction in RIG-I activation in response to 5’ppp-
RNA. In contrast, deletion of Riplet from the same cell line results in complete abolition of 
RIG-I signalling, to the same level as deletion of RIG-I itself123.  The same was found to be 
true for expression of IFNβ mRNA in response to infection with Sendai virus, with deletion 
of TRIM25 in this case resulting in a significant increase in IFNβ expression123. This supports 
our conclusion that TRIM25 is dispensable for RIG-I signalling in HEK293 cells and further 




TRIM25 was not capable of ubiquitinating RIG-I in vitro, even in the presence of 5’ppp-
dsRNA. This goes against previous work which has shown TRIM25 to be capable of 
ubiquitinating the RIG-I 2CARD in vitro, although these studies used purified 2CARD and not 
full-length RIG-I117,240. It is possible that TRIM25 is not capable of ubiquitinating full-length 
RIG-I, although it is not certain as there may be other factors in the cell that are required 
for this activity that are not present in vitro. It was also shown that deletion of TRIM25 did 
result in lower RIG-I signalling activity in response to transfection of GST-tagged 2CARD 
alone, suggesting that there may be different mechanisms of activation for isolated 2CARD 
and 2CARD in the context of full-length RIG-I. This study also further explored the 
interaction between Riplet and RIG-I. It found that Riplet only binds to RIG-I in the presence 
of RNA and that it can bind to full-length RIG-I or a mutant in which the 2CARD has been 
deleted but not to the isolated 2CARD123. Interestingly, the Riplet PRY/SPRY domain was 
required for its interaction with RIG-I and Riplet dimerization was also required for this 
interaction. This bears striking similarities to the requirements for TRIM25 binding to RNA, 
which also requires dimerization and the PRY/SPRY domain. Due to the similar domain 
structures of TRIM25 and Riplet, and the RNA-dependence of the Riplet-RIG-I interaction, 
this raises the question of whether Riplet is binding directly to RNA in this instance and, if it 
is, whether this RNA binding is necessary for the interaction with RIG-I. It was also 
demonstrated that Riplet was capable of ‘cross-bridging’ dsRNA-RIG-I filaments, resulting in 
the formation of aggregates that were visible by electron microscopy and this activity was 
independent of the RING domain of Riplet and the 2CARD of RIG-I123. Finally it was shown 
that this cross-bridging activity was sufficient to induce MAVS oligomerisation and RIG-I 
signalling in the absence of ubiquitination of RIG-I. This is likely because the clustering of 
RIG-I induced by Riplet cross-bridging allows the formation of RIG-I 2CARD tetramers. 




cells, suggesting that ubiquitination is required for optimal 2CARD tetramer formation and 
RIG-I signalling123.  
On balance, taking into account our data and that of others, it is likely that TRIM25 is 
dispensable for RIG-I activation in human cells while Riplet is essential. It is, however, still 
possible that requirements for different E3 ligases vary between different cell and tissue 
types as expression levels may be different and there could be other differences in the 
environments of different cells. As such it would be prudent to perform a large-scale screen 
of Riplet and TRIM25 (as well as TRIM4 and MEX3C) knock outs of many different cell types. 
The idea that TRIM25 was the key E3 ligase for RIG-I activation was mainly based off 
experiments in which the RIG-I 2CARD was overexpressed in cells or in vitro experiments 
using the 2CARD. The experiments performed with full length RIG-I exemplify the fact that 
full-length proteins may function differently to their domains in isolation and this can lead 
to confusion about how biological processes work. 
 
TRIM25 and direct restriction of IAV 
 
Previous work by Meyerson et al. showed that TRIM25 can associate with IAV vRNPs in an 
RNA-dependent manner and suggested that this blocked the initiation of transcription by 
the IAV RNA polymerase220. Similarly to this work, our data showed that deletion of TRIM25 
in HEK293 cells resulted in higher replication of a mutant IAV strain with NS1 that cannot 
inhibit TRIM25 (PR8 NS1 R38K41A). In addition, we found that restriction of PR8 NS1 
R38K41A was rescued by stable expression of TRIM25 WT, TRIM25ΔRBD or TRIM25ΔRING. 
However, unlike Meyerson et al. we found that a minireplicon assay using the IAV RNA 
polymerase and a luciferase reporter resulted in no significant differences in luciferase 




inhibiting IAV RNA polymerase-mediated transcription in our cells, in contrast to the 
Meyerson et al. study that found that overexpressing human or gibbon TRIM25 in HEK293T 
cells restricted luciferase expression. It is possible that the overexpression of TRIM25 
beyond endogenous levels in the Meyerson et al. study is enough to inhibit transcription 
but the endogenous or near-endogenous levels used in our experiments are not sufficient. 
It is likely that there are more copies of the RNA polymerase proteins and the negative 
sense RNA than would be found in the initial stages of infection of a cell with IAV. This could 
explain the discrepancy between the ΔRING-independent restriction of IAV by TRIM25 and 
the seeming lack of inhibition of IAV transcription in our experiments. 
Preliminary data from CLIPseq experiments conducted in our lab on cells infected with 
either IAV or Sindbis virus have indicated that TRIM25ΔRBD may be capable of binding to 
viral RNAs upon infection, as well as to endogenous snoRNAs. Interestingly, TRIM25ΔRBD 
seems to bind only some RNAs that are bound by WT TRIM25 while losing binding to 
others. This suggests the possibility that TRIM25ΔRBD does not lose its ability to bind to all 
RNAs and of a second mechanism of TRIM25 binding to viral RNAs. It is possible, for 
example, that the 7K motif in the CCD-PRY-SPRY linker region identified by Sanchez et al. is 
sufficient for binding to some RNAs but not to others. It is also possible, however, that the 
CLIP is identifying RNAs that are not bound directly to TRIM25ΔRBD and are interacting via 
the interaction of TRIM25ΔRBD with other proteins. Further experiments are needed to 
determine the mechanisms underlying this. Further CLIPseq experiments and optimisation 
of these experiments are required to ensure that these results are repeatable and 
physiologically relevant. If this is achieved, comparing the sequences of RNAs bound or not 
bound by TRIM25ΔRBD could uncover RNA motifs that can be bound in the absence of the 
470-508 region and these could be used as the basis for further experiments to uncover 




TRIM25 binds to could help elucidate whether TRIM25 binding to these RNAs is important 




This project aimed to elucidate the mechanism and functions of TRIM25 RNA binding. We 
have uncovered a region of the TRIM25 PRY/SPRY domain that is important for RNA binding 
and showed that RNA binding is necessary for TRIM25’s ubiquitination activity. In addition 
to this we have showed that TRIM25 does not seem to play a role in RNA stability in 
unperturbed cells and is not necessary for activation of the RIG-I pathway in innate 
immunity despite being required for efficient restriction of IAV infection. 
As TRIM25 is part of the larger TRIM family of proteins, many of which also contain a 
PRY/SPRY domain, our results raise the question of whether other PRY/SPRY-containing 
TRIMs can bind to RNA and whether this is important for their functions. Many TRIMs 
function in innate immunity and carcinogenesis and as such the new lines of research 
opened up by this project could aid understanding of these important and complex 
processes, possibly leading to the development of novel therapeutics in the future. For 
example, many vaccines contain adjuvants to help promote a stronger immune response. 
For example, an oil-in-water emulsion of squalene oil (MF59) is commonly used as an 
adjuvant in Influenza vaccines and works by inducing expression of pro-inflammatory 
cytokines246. It is conceivable that an adjuvant could be developed that would help prevent 
Influenza virus inhibition of innate immunity in vaccines using live attenuated Influenza 
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